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ABSTRACT 
Cough is a common symptom of respiratory disease. Assessment 
of antitussives has relied mainly on animal studies and clinical trials in 
which recording of natural cough is difficult. This thesis describes the use 
of ultrasonically nebulized distilled water (UNOW) to induce cough in man. 
Investigation of the chemosensitivity of this response identified that 
extremes of pH, a chloride concentration below 75mmol/l, but not changes 
in osmolarity induce cough which reflects afferent rapidly adapting 
recep~or sensitivity in animal studies. Inhaled beta-adrenergic and 
anticholinergic bronchodilators, which inhibit cough in asthma, markedly 
reduced UNOW-induced cough in both healthy and asthmatic volunteers. 
Bronchoconstriction with inhaled leukotriene 04, which constricts both 
asthmatic and non-asthmatic airways, also caused coughing. Inhibition of 
bronchoconstriction either specifically or non-specifically resulted in 
inhibition of cough. Nedocromil sodium and the diuretic, frusemide, but 
not the commonly prescribed opiate, codeine, exhibited antitussive 
activity. Cough was also induced by inhalation of the C-fibre stimulants, 
capsaicin and prostaglandin E2 (PGE2), which was characterised by 
studies of adaptation, cross-adaptation and antitussives. UNOW and 
PGE2, but not capsaicin, exhibited rapid adaptation of cough. Cross-
adaptation, however, did not occur suggesting distinct mechanisms of 
cough mediation. Nedocromil inhibited capsaicin-induced cough but not 
PGE2-induced cough, while fenoterol did not affect either challenge. 
Oxitropium, which inhibited UNOW-induced cough, did not reduce cough 
associated with upper respiratory tract infection. 
Cough can be induced by a variety of inhaled stimuli. These can 
identify differences in response which may signal a number of pathways 
leading to cough. Antitussive activity may also be specific to individual 
challenges. This diversity in response reflects the complex neurological 
organisation of cough and may be related to pathological causes of cough. 
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CHAPTER 1: INTRODUCTION 
1.1 AIMS 
The aims of this work were to develop a model of cough in humans 
which could be used to evaluate objectively the efficacy of proposed 
antitussives. Using a nebulizer to deliver aerosols of potential cough 
stimulants to subjects, an agent would be sought that was sufficiently 
irritant to evoke cough in the majority of individuals, be non-toxic and to 
elicit a reproducible cough response. 
Having developed a safe and reliable model of cough, identification 
of the afferent pathway would be determined by characterising the 
chemosensitivity of cough and comparing results with those in animal 
studies. Adaptation of the cough reflex would be studied to provide further 
information about the afferent nerves stimulated, while cross-adaptation of 
cough between different stimuli would allow identification of a common 
receptor. 
The model would then be used in healthy volunteers to try and 
identify antitussive activity of both prescribed and novel treatments, 
including opiates and bronchodilators. 
Patient studies would allow comparison of the effect of 
bronchodilators in healthy volunteers with that in asthmatics where cough 
is often the only symptom. 
Finally, the model would be tested against naturally occurring 
cough associated with upper respiratory tract infections. This is a 
common cause of cough for which medical treatment is frequently sought. 
This study would assess the relationship between induced cough and 
natural cough. 
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1.2 THE COUGH REFLEX ARC 
Whilst much of the human body is covered with a thick outer 
protective layer, the lungs, by their physiological nature, offer a potential 
port of entry for noxious material. They are therefore armed with a number 
of powerful, complex and interacting mechanisms which defend the lungs 
and airways from injury. Cough is one such action and constitutes the 
primary defence of the lower airways and larynx. It interacts with other 
defensive reflexes such as bronchoconstriction and mucus secretion to 
prevent entry of foreign matter into the lungs and to expel secretions and 
other debris. Like many of the other protective mechanisms, cough is a 
reflex action mediated by the vagus, confirmed by the fact that bilateral 
cervical vagotomy in animals blocks cough (Widdicombe, 1964). However, 
unlike the majority of other reflexes, cough can also be initiated voluntarily, 
bypassing the central respiratory control centre (Davis, 1974). The cough 
reflex arc can be divided into five components, namely sensory receptors, 
afferent pathway, central synapses, efferent pathways and effector end 
organs. Supra-threshold stimulation of sensory receptors located close to 
the airway lumen is transmitted via afferent fibres of the vagus and its 
branches to the central cough centre located in the medulla. The efferent 
pathway within the somatic nervous system transmits impulses to the 
skeletal respiratory muscles which carry out the act of coughing. The 
cough reflex arc is represented in Figure 1.1. 
1.2.1 Sensory Receptors and Afferent Pathway 
Involuntary cough in humans is entirely mediated by the vagus and 
can therefore only be initiated from structures it innervates. The main site 
of cough stimulation is the respiratory tract below the oropharynx, in 
particular, the larynx, trachea and main bronchi. Receptors responsible 
for cough are therefore expected to be concentrated in these regions and 
2 
to be inactive during tidal breathing (eupnoea). Three main groups of 
vagal afferent receptors have been identified. 
FIGURE 1.1 
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Rapidly adapting 'irritant' stretch receptors (RARs) run to small 
myelinated fibres with conduction velocities in the range of 4 to 26 ms-1 
(Widdicombe, 1964). The nomenclature reflects their rapid adaptation of 
firing frequency in response to maintained stimulation. Both their position 
and experimental evidence support their role as being responsible for 
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cough. They are located within the epithelium of the larynx and 
tracheobronchial tree, concentrated mainly in the carina and points of 
bronchial branching (Widdicombe, 1964; Mortola et al./ 1975). Their 
endings lose their myelin sheath as they branch between epithelial cells 
terminating close to the airway lumen beneath the 'tight junctions'. 
Epithelial axons have been observed histologically within human airways 
(Laitinen, 1985) in close proximity to the lumen of the trachea and main 
bronchi. They contain vesicles, neurotubules and mitochondria, which may 
be indicative of sensory function (King et al., 1974). Further evidence in 
support of RARs as cough receptors is that they are inactive during 
eupnoea, but fire in response to mechanical stimulation, large inflations 
and deflations of the lungs (which could maintain cough efforts), and to a 
large number of chemical stimuli, all of which can provoke cough 
(Widdicombe, 1964). In addition it has been found that by blocking vagal 
conduction in myelinated nerves only, cough is decreased, and that local 
anaesthesia of the airway wall abolishes cough (Widdicombe, 1964). 
However, RARs appear to be a mixed functional group. Those distal to the 
trachea are more sensitive to chemical than mechanical stimuli. 
Mechanical stimulation of the trachea causes a primary expiratory effort 
while chemical stimulation of the lower airways results in a greater 
inspiratory component of cough and the response is more prone to 
tachyphylaxis (Widdicombe, 1964). 
Slowly adapting stretch receptors (SARs) run to large myelinated 
fibres with conduction velocities of 14 to 59 ms- 1 (Widdicombe, 1964). 
They are found in association with airway smooth muscle particularly in 
large and small bronchi (Bartlett et al., 1976; Miserocchi & Sant'Ambrogio, 
1974) and are responsible for the Hering-Breuer inflation reflex, which 
primarily limits inspiration (Widdicombe, 1964). They are unlikely 
candidates for cough receptors because of their position within smooth 
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muscle and because they are insensitive to many cough stimuli 
(Widdicombe, 1964). However, they may modify the central integration of 
cough since inhibition of SARs by sulphur dioxide (S02) in rabbits inhibits 
RAR-mediated cough (Hanacek et al., 1984; Sant'Ambrogio et al., 1984). 
C-fibre receptors run to unmyelinated fibres with conduction 
velocities between 0.8 and 2.6 ms-1. In animal studies, they are the most 
numerous fibre in the vagus accounting for over 80% of fibres in the cat 
(Jammes et al., 1982). Two categories of C-fibres have so far been 
distinguished; pulmonary C-fibres responsive to injections of stimulants 
into the right atrium and bronchial C-fibres responsive to injections of 
stimulants into the bronchial circulation (Coleridge & Coleridge, 1984). 
Chemical stimulants of C-fibres include capsaicin, the pungent extract of 
red pepper, (Coleridge et al., 1965), prostaglandins (Coleridge et al., 
1976) and bradykinin (Kaufman et al., 1980). Observations that inhalation 
of these agents in humans results in cough (Collier & Fuller, 1984; 
Costello et al., 1985 and Simonsson et al., 1973, respectively) suggest 
that C-fibres may also mediate cough. 
The afferent pathways of the cough reflex are represented 
schematically in Figure 1.2. 
Thus all three groups of receptors may playa role in the cough 
reflex. In addition to the respiratory tract, cough can be elicited from the 
external auditory meatus and tympanic membrane, the pericardium and 
diaphragm (Korpas & Tomori, 1979). 
Impulses from supra-threshold stimulation of afferent cough 
receptors pass up the vagus and its branches including the auricular, 
pharyngeal and superior laryngeal nerves to the central nervous system 
(CNS) via the vagal nuclei. 
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FIGURE 1.2 
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A 'cough centre' separate from the respiratory centre which drives 
the basic mechanisms of respiration has been postulated. The most likely 
site for this is an area close to the solitary tract nucleus in the medulla 
oblongata (Chou & Wang, 1975). The central mechanisms are 
complicated because they are not predetermined but can be modified by 
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higher centres in the cerebellum to achieve different patterns of cough, for 
example, suppressing cough during sleep (Jamal et al., 1983; Power et 
al., 1984) and initiating voluntary cough (Davis, 1974). 
1.2.3 Efferent Pathway and Effector End Organs 
The efferent pathway of the reflex has been extensively studied 
(Korpas & Tomori, 1979; Leith, 1977; Bucher, 1958). It lies within the 
somatic nervous system and involves all the muscles of respiration and 
the glottis. The result is a rapid deep inspiration followed by closure of the 
glottis. Forced expiration causes the intrathoracic pressure to rise sharply 
to 13kPa (100mm Hg) for 0.2 seconds, which is transmitted to the 
circulatory and cerebrospinal fluids. The glottis then suddenly opens 
allowing expulsion of air, secretions and foreign matter from the airways. 
During this last phase, peak expiratory flow may rise to 6 I/sec and peak 
tracheal flows may approach the speed of sound (Ross et al., 1955). The 
characteristic sound of cough is formed by vibration of the respiratory 
structures, particularly the trachea and larynx. The high flow rates of air 
achieved during this final phase serve to dislodge the sticky secretions 
which are brought to the large airways by mucociliary clearance. 
Stimulation of efferent endings in the larynx provokes coughing and this 
may result in self-potentiation of the response (Widdicombe, 1964). 
1.3 CAUSES AND TREATMENT OF COUGH 
Cough is the commonest symptom of respiratory disease, in 
particular, viral infection which accounts for an estimated 50% of visits to 
General Practitioners during the winter and almost 50% of short-term 
absences from work (Korpas & Tomori, 1979). It has been estimated that 
the prevalence of chronic cough in the population may be as high as 20% 
(Barbee et al., 1991). Based on the last 4 years, approximately 5 million 
prescriptions for antitussives have been dispensed in England each year 
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(personal communication, Department of Health, London, UK) and 10 
million doses of cough remedies are sold over-the-counter. Cough can 
occur as a symptom of over 100 pulmonary and systemic disorders 
reflecting Hippocrates' observation that "cough is the voice of the lung". 
When cough performs its physiological function of clearing secretions and 
foreign matter effectively, it should not be treated. However, when cough 
is unproductive or becomes excessive or persistent, it can become a 
debilitating symptom serving no useful function. Cough is then described 
as pathological and can be associated with adverse events such as cough 
syncope, impaired cardiac activity and circulation, bone fractures and 
sleep disturbance (Banner, 1986). Treatment of pathological cough 
depends on making a diagnosis. Common causes of cough are identified 
in Table 1.1. 
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TABLE 1.1 
Common Causes Of Cough 
1. Infectious disease 
2. Airway disease 
3. Mechanical 
4. Interstitial lung 
disease 
5. Drug Induced 
6. Gastro-intestinal 
7. Psychogenic 
Viral 
Bacterial 
Common cold, influenza 
Pneumonia 
Bordetella pertussis 
Tuberculosis 
Asthma and allergic rhinitis 
Chronic Bronchitis 
Bronchiectasis 
Lung Cancer 
Inhaled foreign bodies 
Auricular hair 
Sarcoidosis 
Diffuse Pulmonary fibrosis 
Connective Tissue Disease 
Angiotensin Converting Enzyme Inhibitors 
Gastro-oesophageal reflux 
'Nervous habit' anxiety states 
The most common cause of cough in all age groups is viral upper 
respiratory tract infection (URTI). The duration of cough however is short, 
generally less than 14 days. Persistent coughing suggests an alternative 
diagnosis and warrants further investigation. Treatment directed at the 
disease (specific therapy) will in most cases alleviate the associated 
cough. For example, cough associated with asthma is effectively treated 
with bronchodilators (Ellul-Micallef, 1983), while treatment of allergic 
rhinitis with either nasal topical steroids or antihistamines will also limit 
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cough. Similarly, cough associated with sarcoidosis will be reduced by 
treatment with oral corticosteroids and cough caused by gastro-
oesophageal reflux can be treated with antacids. Certain therapies are 
known to provoke cough, in particular, the antihypertensive angiotensin 
converting enzyme inhibitors, such as captopril (Sesoko & Kaneko, 1985; 
Semple & Herd, 1986). This phenomenon appears idiosyncratic, 
occurring in 2-10% of patients and usually requires switching to 
alternative therapy. 
Treatment is directed toward the symptom of coughing 
(symptomatic therapy) only when no cause can be identified, no treatment 
is available to reverse the disease process, or when treatment is 
unsuccessful. Examples include lung cancer and self limited disease such 
as upper respiratory tract viral infections. 
The aim of an antitussive would be to decrease the frequency and 
intensity of cough and the sensation of irritation without altering respiratory 
function or inhibiting beneficial coughing. Antitussives can be classified 
according to their site of action; centrally acting which act by increasing 
the threshold of the medullary 'cough centre' neurones, peripherally acting 
which act directly on airway sensory receptors and locally acting which 
alter the characteristics of the airway surface liquid and mucus. 
The opioid narcotics and their derivatives are the principal centrally 
acting antitussives. The most commonly used are codeine and pholcodine 
and products containing these opiates accounted for almost 3 million of a 
total 4.6 million prescriptions for antitussives in 1992 (personal 
communication, Department of Health, London, UK). Whilst generally 
considered to be safe, constipation and more seriously, respiratory 
depression and coma may be induced and they should be avoided in 
patients with respiratory disease (Belville & Seed, 1968). They are 
reserved for the treatment of persistent, troublesome cough while 
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morphine and methadone are only for treatment of cough in the terminally 
ill because of their addictive properties. 
Peripherally acting antitussives include local topical anaesthetics, 
bronchodilators and specific sensory opioid Il-receptor antagonists. Local 
anaesthetics, such as lidocaine, block nervous transmission on all vagal 
afferents within their area of contact and depend upon their ability to 
penetrate the airway wall. They are used successfully during 
investigations including bronchoscopy and are used in some lozenges and 
sprays for oral use. Whilst these may soothe pharyngeal irritation, they do 
not deliver the drug to cough-sensitive airways and therefore have lim ited 
efficacy. Inhaled anaesthetics, delivered by nebulizer, may become an 
alternative treatment for cough, but at present they are associated with 
unacceptable risks and side-effects. 
Bronchodilators are thought to have antitussive activity which may 
be direct or indirect and have been shown to be effective in treating cough 
associated with bronchoconstriction (Ellul-Micallef, 1983). Alpha-
adrenoceptor agonists are reported to be upper respiratory tract 
decongestants due to their vasoconstricting actions. New agents acting on 
specific receptors on vagal afferent nerve endings may also acquire a 
place in the treatment of cough. They are opioid-like but probably act by 
blocking peripheraill-receptors, rather than acting centrally. 
Antihistamines are effective in treating cough associated with 
allergic rhinitis and post nasal drip but have no known direct antitussive 
activity. Their sedative side-effects preclude their use for other forms of 
cough. 
Locally acting antitussives include demulcents, mucolytics and 
expectorants. Over 1.6 million prescriptions for simple linctus were 
dispensed in England in 1992 (personal communication, Department of 
Health, London, UK). This is a demulcent with no pharmacological action 
1 1 
containing mainly syrup and may reflect the importance of the placebo 
effect in treating undiagnosed cough and perhaps also the lack of 
experimentally and Clinically proven antitussives without side-effects. It 
acts by lining the mucous surface so lubricating dry airway walls and is 
purported to soothe a dry irritating cough although, again, treatment will 
not reach the most cough-sensitive airways. Demulcents nevertheless 
offer a safe inexpensive treatment for acute self-lim iting respiratory 
disorders and in particular, paediatric simple linctus offers a safe treatment 
for cough in children. 
Mucolytics and expectorants act similarly by changing the physico-
chemical characteristics of the airway surface liquid. Expectorants, such 
as potassium iodide, are reported to increase mucus secretion, thus 
changing a dry unproductive cough to a productive cough aiding its 
physiological function. However, their actions have not been proven 
experimentally and their efficacy is questionable. Mucolytics which reduce 
sputum viscosity may be beneficial in patients with bronchiectasis and 
chronic bronchitis. 
Many proprietary cough treatments contain mixtures of the above 
antitussives. Often the individual drugs are present in sub-therapeutic 
doses and as yet there is no logical place for them in the treatment of 
cough. 
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1.4 EVALUATION OF ANTITUSSIVES 
The purpose of research into cough has been to develop new 
treatments which do not put the patient at risk but provide an effective 
means of reducing pathological cough. Work has centred upon studies of 
the afferent limb of the cough reflex arc together with the central regulatory 
control. Early studies of cough and antitussives relied on experimental 
studies of animals where cough was evoked using mechanical, electrical 
or chemical stimuli. Mechanical methods are usually performed under 
anaesthesia and irritants such as nylon fibres (Korpas & Tomori, 1979) 
and polyethylene tubing (May & Widdicombe, 1954) are introduced via a 
tracheostomy or pharyngostomy. Electrical methods require surgical 
procedures in anaesthetised animals where stimuli are applied to the 
afferent nerves or central cough centre (Chou & Wang, 1975; Chakravarty 
et al., 1956). Chemical stimuli are applied either into closed cages or 
directly into the airways via masks or tracheal cannulas. Stimulants 
include sulphuric acid (Chen et al., 1960), 802 (May & Widdicombe, 
1954), and citric acid (Forsberg & Karlsson, 1984). 
Centrally acting antitussives such as codeine have been effective in 
treating cough induced by mechanical (May & Widdicombe, 1954) and 
chemical (Jackson, 1988) stimulation. Anaesthetics have been effective in 
treating chemically induced cough in guinea-pigs (Karlsson, 1987) and 
mechanically induced cough in dogs and rabbits (Dain et al., 1975; Cross 
et al., 1976). The anticholinergic bronchodilator, atropine, reduces 
acetylcholine-induced cough (Tiffeneau, 1957) but not 802-induced cough 
(Nadel et al., 1965). 
These early studies provided the basis of efficacy data for the 
opiates, in particular, codeine. Codeine is now generally employed as a 
positive control with which to compare other antitussives. However, there 
are many disadvantages of animal studies. These include marked inter-
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species differences precluding inference to humans, the surgical 
procedures which may injure the airways and the anaesthetics employed 
which may themselves modify the cough response. This may help to 
explain the conflicting evidence of efficacy of antitussives in humans. 
More recently, cough has been studied in humans. However, the 
early clinical studies of pathological cough were often uncontrolled and 
unreliable owing to the subjectiveness of the patient's own assessment of 
cough and the variation arising from the changing status of the patient's 
disease. Effective studies require large numbers of patients, placebo 
controlled, double-blind and random ised design and an elaborate method 
of monitoring cough. For example, continual monitoring of hospitalised 
patients with chronic bronchitis using a tape recorder demonstrated an 
antitussive action of the antihistamine, phenyltoloxamine, but not the 
opiate, pholcodine (Edwards et al., 1977). Another comprehensive study 
demonstrated an antitussive action of the bronchodilator, terbutaline 
sulphate, in chronic allergic cough (Ellul-Micallef, 1983). 
In an attempt to overcome these difficulties, Bickerman and Barach 
in 1954, evoked cough experimentally in normal and asthmatic volunteers 
using nebulized aerosols of various substances including organic acids, 
ethyl alcohol and ether, hydrochloriC and sulphuric acids and ammonium 
hydroxide. All aerosols evoked cough; the organic acids yielding the most 
consistent response and provoking cough in about 80% of subjects. They 
then used aerosols of citric acid to evaluate several centrally acting 
antitussives and found significant activity for codeine, dextromethorphan 
and noscapine (Bickerman et al., 1957). The introduction of this method 
of evoking cough in healthy humans with nebulized stimuli appears to offer 
a means of performing objective placebo controlled studies of antitussives 
which generate reliable data. 
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CHAPTER 2: METHODS 
This chapter presents the methods that are common to most 
studies described in this thesis. Detailed methods relating to individual 
studies are given in their particular sections. 
2.1 AEROSOL GENERATION 
Aerosols offer an easy means of administering stimuli direct to the 
airways of humans and have in recent years been used increasingly in the 
diagnosis and treatment of respiratory disease. An aerosol consists of 
liquid particles in a gas and is usually generated by passing air at high 
velocity with respect to liquid. This is known as 'jet' atomisation and was 
first used in perfume sprayers over 100 years ago. However, to produce 
aerosols with smaller particles, it was found necessary to force liquid 
through a small diameter orifice at high velocity. To achieve this, a high 
velocity air jet is passed over a liquid feed tube creating an area of 
negative pressure. This draws liquid up the tube from where it is 
fragmented into a fine mist. A baffle is placed in front of the jet to remove 
large particles. Such a device is known as a jet nebulizer. 
Another form of nebulizer is the ultrasonic nebulizer which 
generates ultrasonic waves from an oscillating piezoelectric transducer. 
These are transmitted to the liquid to be atomised through water which is 
separated from the liquid by a thin plastic sheet or diaphragm. This 
causes the surface of the liquid to break up to produce large airborne 
droplets which are picked up by the air flow through the chamber. This 
produces a well mixed aerosol of high mass concentration of up to 150 
mg/I air, called a 'fog'. Ultrasonic nebulizers produce a higher output and 
larger particles than jet nebulizers (Sterk et al., 1984); the particle size 
decreasing with increasing frequency of the transducer oscillations. These 
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high frequency conditions heat the liquid by sound absorption in contrast 
to jet nebulizers which lose heat through evaporation. 
The jet and ultrasonic nebulizers are represented schematically in 
Figure 2.1. 
FIGURE 2.1 
Jet and Ultrasonic Nebulizers 
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2.2 ULTRASONIC CHALLENGE 
For the majority of studies a DeVilbiss 65 ultrasonic nebulizer 
(DeVilbiss Healthcare UK Ltd., Feltham, Middlesex, England) operating at 
maximal setting and with the air vent fully open, was used. This produces 
a solution output of approximately 3 ml/minute and particles with a mass 
median aerodynamic diameter (MMAD) of 6-71lm (Sterk et al., 1984). With 
its high output and large particles, deposition when mouth breathing is 
likely to occur mainly in the large central airways where most of the cough 
receptors are thought to be found (Widdicombe, 1954). The aerosol was 
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passed through a 50 cm length of corrugated tubing into a plastic cone-
shaped 1 litre container to ensure a continuous supply of aerosol. Subjects 
then tidally breathed nebulized solutions through a two-way low resistance 
valve and rubber mouthpiece for 1 minute. The valve body was made 
from nickel plated brass and the flaps from flexible soft rubber which 
produced minimal resistance to breathing, did not invert with the high flow 
rates of cough and did not stick when wet with the aerosol. Cough was 
recorded by means of a heated Fleisch pneumotachograph (PK Morgan, 
Chatham, England) calibrated directly with a Godart flow calibration set 
(Gould Electronics Ltd., Hainault, Essex, England) and mounted in the 
expiratory port of the valve. The flow signal obtained was integrated using 
a respiratory integrator mark II (PK Morgan, Chatham, England) and flow 
and volume signals were displayed on a two-channel hot pen chart 
recorder (Brush 220, Gould Electronics Ltd., Hainault, Essex, England). 
The equipment was arranged as shown in Figure 2.2. 
Subjects were instructed prior to all challenges that the aerosol may 
or may not make them cough and to cough only if it was unavoidable. 
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FIGURE 2.2 
Ultrasonic Cough Challenge Eguipment 
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Coughs were identified by their characteristic flow pattern, with a 
very rapid initial rise in expiratory flow rate. A typical trace is shown in 
Figure 2.3. The number of coughs occurring during the one minute 
inhalations were counted for analysis. 
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FIGURE 2.3 
A Typical Cough Challenge Trace 
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2.3 JET CHALLENGE 
2.3.1 Acorn 
Jet nebulizers were used to administer more noxious substances as 
they have a lower output than ultrasonic versions. The jet nebulizer used 
was the Acorn System 22 (Medic Aid Ltd., Pagham, Sussex, England). 
This has a solution output of 0.2-0.3 ml/min. and a MMAD of 2-4 ~m (Sterk 
et al., 1984). The nebulizer was run using air from a pressurised gas 
cylinder at 8 11m in. For the challenge, 5 ml of liquid stimulant was placed in 
the jet nebulizer and the aerosol inhaled using the same equipment as the 
ultrasonic nebulizer for 1 minute periods during which cough frequency 
was counted. 
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2.3.2 Bronchoscreen Dosimeter 
Finally a dosimeter was also used (Bronchoscreen, Erich Jaeger 
UK Ltd., Market Harborough, UK). This is a breath actuated dosimeter 
illustrated in Figure 2.4, which delivers aerosol from 2 jet nebulizers 
(Sandoz 1500), each of which is triggered in a pre-set sequence. One 
nebulizer contains active agent and the other placebo (isotonic saline). In 
this way, the subject is unaware of when the active agent will be delivered. 
During a one minute challenge, the machine was set to deliver 3 doses of 
active agent. Cough frequency was recorded via a tie microphone (RS 
Components, England) which was connected to an audio tape recorder. 
The dosimeter activates the nebulizers for 0.5 seconds, which produces 
an output of approximately 4/11. Data from Sandoz indicates that 52% of 
these particles are between 1.9 and 5.6/1m. 
FIGURE 2.4 
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2.4 PULMONARY FUNCTION 
Basic tests of pulmonary function were performed to assess airway 
calibre. Spirometric assessment of forced vital capacity (FVC) and forced 
expired volume in 1 second (FEV 1) were recorded as the best of 3 
measurements using a dry wedge bellows spirometer (Vitalograph Ltd., 
Maids Moreton House, Buckingham, UK). 
Peak expiratory flow rate (PEFR) was assessed as the best of 3 
measurements using a mini-Wright peak flow meter (Clement Clarke 
International Ltd., London, UK). 
Specific airways conductance (sGaw) was assessed as the average 
of 2 measurements using a whole body plethysmograph (Gould 2800 
Autobox, Coventry, UK). 
Airways resistance (Raw) was assessed using the Bronchoscreen 
dosimeter described in Section 2.3.2 which calculates Raw breath by 
breath by the occlusion method (Mead & Whiteenberger, 1954). Raw was 
measured during both air and aerosol breathing over 1 minute periods and 
the average of the final 5 measurements recorded for analysiS. 
Measurements of Raw during coughing can give artificially high values 
owing to the high expiratory air flow rates. These were rejected 
automatically by the Bronchoscreen. 
2.5 VOLUNTEERS 
Written informed consent was obtained from all volunteers prior to 
their enrolment. Volunteers were healthy male and female members of 
hospital staff. Basic demographic data including age, height and smoking 
history were recorded and the following inclusion and exclusion criteria 
were applied: 
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Inclusion Criteria 
Aged between 18 and 70 years. 
FEV1 greater than 75% of predicted (Cotes, 1979). 
Exclusion Criteria 
Females who were pregnant or lactating. 
Respiratory disease including an upper respiratory tract infection within 6 
weeks of study. 
Cardiovascular disease, hyperthyroidism, hypertension or diabetes. 
2.6 CLINICAL TRIAL DESIGN 
Where appropriate, studies described in this thesis were performed 
using a double-blind, placebo controlled, crossover and randomised 
design. Approval from the hospital Ethical Committee was obtained for all 
studies. 
2. 7 STATISTICAL ANALYSIS 
Analysis of the data was performed in conjunction with the Medical 
Research Council Biostatistics Unit, Institute of Public Health, Cambridge. 
The number of coughs during each 1 minute challenge was 
counted and recorded for analysis. Initial review of the data revealed that 
cough frequency follows a skewed distribution rather than a Normal 
distribution. A square-root transformation (after addition of one), the usual 
transformation for data with a Poisson distribution, was therefore 
performed on the data prior to analysiS. This was found to stabilise the 
within-group variance allowing parametric analysiS of variance (ANOVA) to 
be performed. Factors tested in a two-way analysis of variance were 
subject and treatment/challenge. Pairwise comparisons between means 
were made using the 'least significant difference' (Snedecor & Cochran. 
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1967}. The residual mean square from the ANOVA was used to compute 
95% confidence limits, which together with the resultant means were then 
back-transformed (i.e., squared and 1 subtracted). ANOVA was also 
performed on FEV 1, FVC, PEFR, sGaw and Raw data. 
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CHAPTER 3: CHARACTERISATION OF THE COUGH 
REFLEX 
3.1 INTRODUCTION 
Cough can be induced in animals by chemical stimulation of the 
large central airways (May & Widdicombe, 1954) and peripheral airways 
(Widdicombe, 1954). Administration of chemical stimuli to human airways 
in vivo can be achieved using aerosols and, by using aerosols of different 
particle size, it is possible to deposit solutions in the large central airways 
or in more peripheral regions of the lungs (Lippman ef al., 1980). The 
large particles produced by ultrasonic nebulizers are likely to deposit 
mainly in the larynx and trachea, while the smaller particles produced by 
jet nebulizers will deposit more peripherally. 
An aerosol of ultrasonically nebulized distilled water (UNDW) has 
been introduced as a method of documenting bronchial hyperreactivity 
since it causes a dose-dependent bronchoconstriction in asthmatics but 
not normals (Allegra & Bianco, 1980; Schoeffel ef al., 1981; Anderson & 
Schoeffel, 1984). However, it has also been reported to evoke cough in 
both asthmatics and non-asthmatics (Sheppard ef al., 1983; Anderson & 
Schoeffel, 1984; Chadha ef al., 1984). Water instilled into the larynx of 
animals may also evoke cough but in neonates of many species, the result 
is apnoea (Storey & Johnson, 1975; Harding ef al., 1978; Lucier ef al., 
1979; Boggs & Bartlett, 1982). Since the two responses are mediated by 
the same receptor group within the superior laryngeal nerve, it has been 
postulated that the CNS determines the reflex evoked, i.e. cough in adults 
and apnoea in neonates (Boggs & Bartlett, 1982). The apnoeic reflex has 
also been documented in human infants and may be implicated in sudden 
infant death syndrome (Perkett & Vaughan, 1982). 
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The stimulus for the bronchoconstrictor response to UNDW in 
asthmatics is thought to be the low osmolarity of water (Schoeffel et a/., 
1981), while the lack of a permeant anion is responsible for the apnoeic 
reflex in neonatal puppies (80ggs & Bartlett, 1982). 
Based on these observations, the following studies were designed 
to compare the cough response to inhalation of aerosols of varying ionic 
content, osmolarity, pH and particle size in order to determine the 
chemosensitivity and region of stimulation of aqueous aerosol-induced 
cough in healthy human volunteers. 
3.2 METHODS 
3.2.1 Chemical Sensitivity 
Ten healthy, non-smoking volunteers (5 males and 5 females, age 
range 18 - 42 yrs) were studied. Each subject was challenged with 6 
solutions chosen to provide a range of ionic content. Of these solutions, 5 
were isotonic and 1 was hypotonic (distilled water). The isotonic solutions 
were urea, D-glucose, sodium chloride, sodium acetate and sodium 
bicarbonate. Solutions were administered as aerosols using the method 
described in Section 2.2 for the ultrasonic challenge and given in random 
order, double blind, in duplicate and on separate days at the same time of 
day. Cough frequency, flow rate and volume for each 1 minute challenge 
were recorded for analysis. 
3.2.2 Anion Sensitivity 
To determine whether the lack of a permeant anion is responsible 
for the cough response to aqueous aerosols, 5 healthy, non-smoking 
volunteers (3 males and 2 females; age range 25 - 35 yrs) were studied. 
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Challenges were performed as above with saline solutions containing 
concentrations of chloride of 145 (isotonic), 112, 75, 52, and 31 mmoi/i. 
3.2.3 pH Sensitivity 
The effect of altered pH of inhaled aerosol on cough was studied in 
7 healthy subjects (3 males and 4 females, age range 25 - 57 yrs) using 
isotonic saline. The pH was manipulated by adding small amounts of 
phosphate buffers to achieve solutions with pH values of 4.8 and 8.0. To 
achieve a solution with a pH of 2.6, 2.1 ml of concentrated hydrochloric 
acid and 5.9g of glycerine were made up to 1.5 litres with saline. A pH of 
10.0 was achieved by adding 2.2g of sodium hydroxide and 7.1 g of 
glycerine to 1.5 litres of saline. Aerosols were administered on separate 
days at the same time of day, in random order, single blind and for a 
period of 1 minute during which cough frequency was recorded. 
3.2.4 Osmolarity Sensitivity 
(a) To clarify the effect of changes in osmolarity of inhaled aerosol on 
cough, 7 healthy subjects (1 male and 6 females, age range 23 - 57 yrs, 
mean FEV 1 = 109%, range 97 - 122% of predicted) inhaled 5 aerosols of 
D-glucose in a range from 77 - 1232 mosmolll (calculated values). For 
comparison, saline solutions of matched osmolarities were also inhaled. 
To exclude any effect the low pH of D-glucose may have on cough, small 
amounts of 0.1 molll sodium hydroxide were added to each solution to 
raise the pH to that of saline (pH 5-7). All aerosols were inhaled in 
random order on separate days and as changes in osmolarity of inhaled 
aerosols can cause bronchoconstriction in asthmatics (Schoeffel et al., 
1981), FEV1 was recorded immediately after each challenge. 
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(b) To test further the role of hyperosmolarity in inducing cough, while 
keeping a chloride concentration close to that of isotonic saline, 2 more 
solutions were studied as described above by 7 subjects, three of whom 
had taken part in experiment (a). The solutions were an isotonic and a 
hypertonic mixture of D-glucose and saline created to keep the 
concentration of chloride close to that in isotonic saline and thereby 
excluding an effect of high ionic concentration. The resultant solutions 
were 1.25% D-glucose in 0.68% saline (308 mosmol/l; 112 mmol/I CI-) and 
15% D-glucose in 0.9% saline (1232 mosmolll; 150 mmol/l CI-). 
3.2.5 Citric Acid-Induced Cough 
The mechanism of the irritant property of citric acid, which has been 
introduced as a stimulus for cough (Bickerman & Barach, 1954). was 
examined in 7 healthy subjects (3 males and 4 females, age range 25 - 31 
yrs). To assess the effect of pH and chloride concentration, the cough 
response to isotonic citric acid in saline, isotonic sodium citrate and 
sodium citrate in saline were compared. UNDW and isotonic D-glucose 
were included for comparison. 
3.2.6 Particle Size Dependence 
Aerosols of different particle size were used to determine the 
distribution in humans of receptors causing cough induced by distilled 
water. This was achieved by comparing the cough response to aerosols 
produced by ultrasonic and jet nebulizers. Ultrasonic nebulizers are known 
to produce larger particles than jet nebulizers which will be deposited in 
larger airways. However, as jet nebulizers also have a lower output than 
ultrasonics, it was estimated that 4 jet nebulizers would be needed to 
obtain an equivalent output. The aerosols were matched for output and air 
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flow rate and their particle size distribution measured by Dr Woolman at 
the Department of Nuclear Medicine, Addenbrooke's Hospital, Cambridge. 
The aerosol output was estimated by placing a corrugated filter, 
which collected more than 99.9% of the aerosol particles, on the end of 
the tubing from the nebulizers which were loaded with an aqueous solution 
containing approximately 50MBq of the radioisotope technetium 99m 
(Tc99m) in 0.9% saline. 1 ml of fluid was extracted from the nebulizer 
reservoir and the activity measured. The radioactivity deposited on the 
filter was measured after running the 2 nebulizer systems for 1 minute. 
The ultrasonic nebulizer was run at half power (setting 5) with the air vent 
fully open producing an air flow rate of 27 I/minute as measured with a 
rotating vane mechanical flow meter (Wrights respirometer, Ferraris, 
London, England). Four jet nebulizers (Acorn System 22) were set up in 
parallel with two Y -pieces and short lengths of plastic tubing. The output of 
all 4 nebulizers passed through the same 50 cm tubing and cone used 
with the ultrasonic nebulizer as shown in Figure 3.1. The nebulizers were 
powered from compressed air at a flow rate of 30 I/minute. The output rate 
was calculated in millilitres of fluid produced as aerosol particles per 
minute of operation of the nebulizer systems. This technique excludes the 
output by evaporation as this would have produced an artificially high 
output for the jet nebulizer system. 
Particle sizing of the aerosols was performed using a May cascade 
impacter (Biral, Bristol, England) which involves the separation and 
collection of different size fractions of particles. In each stage, the aerosol 
accelerates through constricting jets and impinges on collecting plates. 
The first stage collects the largest particles and so on until a final filter 
collects all the particles below the size of the last stage. The number of 
particles on each stage are counted to give a cumulative distribution 
frequency. The ultrasonic nebulizer was run at half power for 30 seconds 
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and then a sample of aerosol was taken from the cone for the following 30 
seconds with the nebulizer still running. The nebulizer fluid contained 
approximately 50MBq of Tc99m in 0.9% saline. The radioactivity 
deposited on the plates of the cascade impactor was measured with a 
calibrated scintillation detector. The counts on each plate were used to 
determine the particle size distribution from which the MMAD of the 
aerosol particles was calculated (May, 1975). The particle size distribution 
was also determined for the jet nebulizer system and these, together with 
the output rates, were repeated at the end of the study. 
FIGURE 3.1 
Parallel Arrangement of Jet Nebulizers 
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Twelve healthy volunteers (8 males and 4 females, age range 22 -
49 yrs) inhaled distilled water from each of the nebulizer systems on 
separate days at the same time of day, in random order and for 1 minute 
during which cough frequency was recorded. 
3.2.7 Adaptation of Cough 
Five healthy subjects (1 male and 4 females, age range 19 - 59 yrs, 
mean FEV 1 = 145% of predicted) undertook a 1 minute cough challenge 
to UNDW which was repeated 5 minutes and 3 hours later (This is part of 
a larger study described in detail in Section 6.2.2). In addition to 
comparing the cough frequencies at each of the 3 time points, each 1 
minute challenge was subdivided into the number of coughs over each of 
3 consecutive 20 second periods. This allowed identification of adaptation 
of cough over a continuous challenge and subsequent challenges. All 
subjects performed a cough challenge prior to the study to accustom them 
to the procedure and therefore to exclude any adaptation of cough due to 
a learn ing effect. 
3.3 RESULTS AND STATISTICAL ANALYSIS 
The raw data and ANOVA tables for the following studies are 
presented in Appendix 1 . 
Cough, when provoked, was restricted to the duration of aerosol 
inhalation and no adverse reactions were recorded. 
3.3.1 Chemical Sensitivity 
Distilled water, urea, D-glucose, sodium acetate and sodium 
bicarbonate, but not sodium chloride, evoked cough. One subject did not 
cough in response to any of the aerosols and 1 subject coughed on only 
one occasion during inhalation of D-glucose. For the 5 aerosols resulting 
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in cough, ANOVA revealed no significant difference in cough frequency 
(p>O.05). However, there was a difference between subjects (p<0.001) 
indicating intersubject variation in cough responses. The back-transformed 
mean cough frequencies (MCF) and 95% confidence limits (95% Cl) are 
presented in Table 3. 1 . 
TABLE 3.1 
The Chemical Sensitivity of Induced Cough 
Solution Tonicity pH MCF (95% Cl) 
Urea isotonic 8.2 6.6 (3.7 - 10.2) 
Water hypotonic 8.5 9.4 (6.0 - 13.6) 
Sodium Acetate isotonic 7.5 7.4 (4.3 - 11.2) 
D-Glucose isotonic 3.6 7.3 (4.2 - 11.0) 
Sodium Bicarbonate isotonic 8.9 6.3 (3.5 - 9.8) 
Sodium Chloride isotonic 6.0 0.0 
Peak cough flow rates and volume were measured and the mean 
values and standard deviations (SO) are shown in Table 3.2. The peak 
expiratory flow rate during cough was probably slightly underestimated 
owing to the opening pressure of the expiratory valve and the reaction 
time of the pneumotachograph. Since for practical purposes this was 
constant, comparison between challenges remained valid. No significant 
differences in peak cough flow rates or cough volume were detected on 
occasions where cough occurred (p > 0.05). 
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TABLE 3.2 
Cough Flow Rate and Volume During Aerosol Inhalation 
Cough Flow Rate (SO) Cough Volume (SO) 
(11m in) (I) 
Urea 228 (37) 0.31 (0.10) 
Water 246 (61 ) 0.40 (0.20) 
Sodium Acetate 238 (60) 0.42 (0.19) 
D-Glucose 242 (56) 0.41 (0.15) 
Sodium Bicarbonate 245 (60) 0.43 (0.15) 
Sodium Chloride 0 0 0.00 (0.00) 
3.3.2 Anion Sensitivity 
Cough did not occur with isotonic sodium chloride aerosol 
confirming the previous observation in Section 3.3.1. However, cough 
increased in frequency as the chloride concentration of the inhaled 
aerosol was reduced, signifying a dose response relationship. The 
individual cough frequencies are presented in Figure 3.2 (p<0.001). 
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FIGURE 3.2 
The Effect of Chloride Concentration on Cough 
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3.3.3 pH Sensitivity 
Cough occurred on inhalation of the 2 aerosols of extreme pH, 2.6 
and 10.0 only as shown in Table 3.3. AN OVA revealed no significant 
difference in cough frequency at these 2 levels of pH (p>0.05), but the 
cough response to both aerosols was significantly greater than zero 
(p<0.01 ). 
TABLE 3.3 
The Effect of pH on the Cough Response to Saline 
pH 
MCF (95% CL) 
2.6 4.8 
2.1 (0.6 - 4.2) 0.0 
8.0 
0.0 
10.0 
3.6 (1.7 - 6.0) 
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3.3.4 Osmolarity Sensitivity 
(a) ANOV A revealed no significant difference in the cough response 
between any of the D-glucose aerosols (p>0.05). The dose response 
relationship between decreasing chloride concentration and increasing 
cough frequency was confirmed (p<0.01). At the highest sodium chloride 
concentration occasional coughing was observed. FEV 1 values measured 
after each inhalation did not vary by more than 5% in any subject 
indicating that no significant bronchoconstriction occurred with either 
challenge across the range of osmolarities studied. Back-transformed 
mean cough frequencies and 95% confidence limits are presented in 
Table 3.4 and graphically in Figure 3.3. 
TABLE 3.4 
The Effect of Osmolarity on Cough 
Osmolarity 
(mosmol/l) 
77 
154 
308 
616 
1232 
MCF (95% Cl) 
(coughs/m in ute) 
D-Glucose Saline 
7.6 (4.4 - 11.5) 8.1 (4.8 - 12.1) 
9.5 (6.0 - 13.8) 2.1 (0.4 - 4.6) 
12.0 (8.0 - 16.6) 0.0 
11.5 (7.6 - 16.1) 0.0 
12.1 (8.1 - 16.8) 1.3 (O.O - 3.6) 
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FIGURE 3.3 
The Effect of Osmolarity on Cough 
c (lj 
Q) 
~~ 
15 
-oc-
Q) Q).£ 10 
E :J E L... C"' ___ 
o Q) (/) 
_L....c (/) LL c> 
C .c :J 
(lj c> 0 ~:J~ 
I 0 
~() 
(lj 
en 
5 
77 
D-Glucose 
Saline 
n=7 
154 308 616 1232 
Osmolarity (mosmol/l) 
(b) Cough occurred in response to inhalation of the hypertonic mixture 
of D-glucose and saline as shown in Table 3.5 but not to the isotonic 
mixture suggesting that marked hyperosmolarity of aerosol, rather than 
high ionic concentration, may provoke cough. 
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TABLE 3.5 
The Effect of Hyperosmolarity on Cough 
Cough Frequency (coughs / minute) 
1.25% D-Glucose 
in 0.68% Saline 
15% D-Glucose 
in 0.9% Saline 
Subject 1 
o 
3 
o 
7 
3.3.5 Citric Acid-Induced Cough 
o o o o 
o 4 2 6 
7 
o 
4 
Cough occurred in response to inhalation of citric acid in saline and 
sodium citrate, but not sodium citrate in saline. The cough response to D-
glucose and UNDW was confirmed. ANOVA revealed no difference in 
cough frequency between the aerosols causing cough (p>0.05). Back-
transformed mean cough frequencies and 95% confidence limits are 
presented in Table 3.6. 
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TABLE 3.6 
The Cough Response to Citric Acid 
Aerosol Osmolarity Qtl Chloride MCF(95% CL) 
(mosmol/I) (mmol/I) (coughs/minute) 
0.68% Citric Acid 308 2.0 130 11.4 (7.2 - 16.5) in 0.79% Saline 
Sodium Citrate 308 8.6 0 12.5 (8.1 - 17.7) 
Sodium Citrate in 616 8.2 150 0.0 0.9% Saline 
UNDW 0 8.5 0 15.7 (10.8 - 21.6) 
D-Glucose 308 3.6 0 18.1 (12.8 - 24.3) 
3.3.6 Particle Size Dependence 
The fluid volume output rates for the 2 nebulizer systems were 
matched. That of the ultrasonic system was 0.9 ml/min and that of the jet 
system was 0.85 ml/min. The aerosols, however, differed in their particle 
size distribution. The MMAD of the ultrasonic nebulizer was 6 ~m 
(geometric standard deviation (GSD) = 2.0) whereas the jet system MMAD 
was 3 ~m (GSD = 2.4). Deposition studies demonstrated a peripheral to 
central deposition ratio for the ultrasonic nebulizer to be 0.5 (SD + 0.1) 
whereas that for the jet system was 0.9 (SD + 0.1) suggesting greater 
central deposition for the ultrasonic nebulizer. The total lung deposition 
fraction for the ultrasonic nebulizer was 0.14 (SD + 0.06) compared with 
0.08 (SD + 0.03) for the jet nebulizer system. 
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ANOVA revealed that coughing with distilled water occurred more 
frequently when inhaled from the ultrasonic nebulizer than from the jet 
nebulizer system (p<0.001) as shown in Table 3.7. 
TABLE 3.7 
Ultrasonic versus Jet Nebulized Water-Induced Cough 
Subject CouQh Frequency (couQhs/minute) 
Ultrasonic Jet 
1 14 0 
2 21 5 
3 18 8 
4 3 0 
5 0 0 
6 9 1 
7 22 0 
8 32 0 
9 5 1 
10 10 0 
1 1 21 0 
12 17 0 
12.6 (8.4 - 17.6) 0.85 (0.0 - 2.9) 
3.3.7 Adaptation of Cough 
ANOV A revealed that adaptation of cough frequency occu rred 
when the first UNDW challenge was repeated after 5 minutes (p<0.001). 
but had recovered 3 hours later (p>0.05). (A study, not presented in this 
thesis, suggests that the response recovers after approximately 30 
minutes). When the number of coughs during the first 1 minute challenge 
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were divided into 3 consecutive 20 second periods, adaptation of cough 
again occurred (p<0.001) as shown in Figure 3.4. 
FIGURE 3.4 
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have been broken down into 3 x 20 second periods. 
3.4 DISCUSSION 
In the study investigating the chemical sensitivity of induced cough 
(Section 3.3.1), all aerosols except sodium chloride provoked cough. The 
importance of the chloride ion was further examined (Section 3.3.2) and 
cough was found to increase in frequency as the chloride concentration of 
the inhaled aerosol was decreased below a threshold of approximately 75 
mmoi/i. In this respect it is analogous to the apnoeic reflex in neonatal 
puppies which is provoked by instillation of fluid deficient in chloride (below 
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80 mmol/l) into the larynx (Boggs & Bartlett, 1982). They found that the 
length of apnoea extended as the chloride concentration was further 
reduced, in a dose response relationship. They also found that the 
chloride ion may be replaced by other small permeant anions such as 
iodide or bromide, but not by larger anions such as bicarbonate or 
acetate. Similarly, in the study investigating the chemical sensitivity of 
cough (Section 3.3.1), cough was provoked by aerosols of sodium acetate 
and sodium bicarbonate, but not by sodium chloride. To assess whether 
the dose response relationship between decreasing chloride concentration 
of inhaled aerosol and increasing cough frequency was related to the 
associated decrease in the osmolarity of aerosol, O-glucose was 
compared with saline aerosols (Section 3.3.4 (a)). While Eschenbacher et 
a/. (1984) have subsequently suggested that alterations in osmolarity as 
well as absence of a permeant anion in the inhaled aerosol could provoke 
cough, this study found no change in cough frequency with alterations in 
osmolarity. This is in agreement with the observations of Boggs and 
Bartlett (1982), who found that solutions of sucrose and urea stimulated 
apnoea regardless of their osmolarity. However the 3.6% saline caused 
some coughing. This could have been due to its high ion content or its 
hyperosmolarity. In a further study (Section 3.2.4 (b)), a solution of equal 
osmolarity but only a quarter of the ion content also resulted in occasional 
cough, suggesting that marked hyperosmolarity of the inhaled aerosol is a 
further stimulus for cough. The cough response was not associated with 
bronchoconstriction indicating that the two reflex responses can occur 
independently. 
It is possible that the performance of the nebulizer would be 
affected by hyperosmolar solutions and this was partly assessed by 
measuring the osmolarity of isotonic and hypertonic solutions of saline 
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and D-glucose before and after 1 minute nebulizations. The values did not 
alter by more than 5%. 
Investigating the effect of pH of inhaled aerosol on cough (Section 
3.3.3) demonstrated the ability of extremes of pH, even in the presence of 
chloride, to evoke cough. This pH sensitivity is also similar to that 
observed by Boggs & Bartlett (1982), who found that saline with a pH 
lower than 4.5 or higher than 8.1 induced apnoea when instilled into the 
larynx. 
These results suggest that an additive effect of low pH and lack of 
chloride may be responsible for the tussive properties of citric acid aerosol 
and this was confirmed (Section 3.3.5). Citric acid, even in the presence of 
chloride, and sodium citrate stimulated cough while sodium citrate in 
saline failed to elicit a response. The irritant properties of acetic acid 
(Mitsuhashi et al., 1984) may also be mediated by a similar mechanism. 
Calcium chelation, thought to be responsible for the bronchoconstriction 
observed in Basenji-Greyhound dogs in response to citric acid (Downes & 
Hirshman, 1983), is unlikely to contribute to cough, as sodium citrate in 
saline failed to evoke cough. 
Isolated nerve studies by Boggs & Bartlett (1982), revealed that all 
solutions capable of inducing apnoea in neonatal puppies stimulated 
laryngeal RARs. Other workers have also noted the stimulating effect of 
water on RARs (Boushey et al., 1974; Anderson et al., 1990). Recently, 
laryngeal water-sensitive RARs in dogs have been sub-divided into two 
groups; one responding with a short latency and duration to the low ionic 
content of water, the other responding with a long latency and duration to 
the low osmolarity of water (Sant'Ambrogio et al., 1991) However, those in 
lobar bronchi appear to be only sensitive to low osmolarity (Pisarri et al .. 
1992) These results suggest that RARs that are sensitive to low ion 
concentrations mediate cough and apnoea, while those responsive to 
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changes in osmolarity may mediate the bronchoconstrictor response to 
UNDW. However, both bronchial and pulmonary C-fibres also respond to 
the low osmolarity of water and may also mediate bronchoconstriction 
(Pisarri et al., 1992). 
The mechanism of Ilow chloridel stimulation of RARs is unclear. 
RARs lie within the paracellular spaces of epithelial cells (Jeffery & Reid, 
1973). These paracellular spaces offer a path across the epithelium which 
bypasses the cells. Those in airway epithelium, like the small intestine and 
gall bladder, are classified as Ileakyl (Frizzell et al., 1979) allowing passive 
transport of small molecular weight solutes and ions between the serosal 
and luminal surfaces. The luminal surface is covered by a liquid consisting 
of 2 phases; the inner serous fluid called airway surface liquid (ASL) and 
the outer viscous mucus phase. The ASL covers the cilia providing a 
medium in which they can beat freely, so propelling the mucus upwards 
for expectoration. The interchange between the ASL and paracellular 
spaces suggests that the RARs are able to respond to changes in the 
composition of ASL. The ASL in human trachea and bronchi is believed to 
be 15 to 30 Ilm thick and consists of approximately 90% water with a 
sodium and chloride concentration of approximately 80 mmol/l and a pH of 
6.8 (Mentz et al., 1984; Joris et al., 1993). The ionic concentration of this 
hypotoniC fluid is maintained by active electrolyte transport involving 
sodium absorption. Alterations in the humidity of inspired air can affect the 
composition of ASL; increased humidity increases the volume of ASL and 
decreases the concentration of sodium chloride (Man et al., 1979). The 
ionic composition of ASL appears to be important for a number of 
epithelial cell functions. Ciliary beat frequency is decreased when the 
luminal concentration of sodium chloride is reduced below 80 mmol/l (Luk 
& Dulfano, 1983). Such reduced levels of sodium chloride have been 
observed in severe asthmatics possibly reflecting sodium hyperabsorption 
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while elevated levels are found in cystic fibrosis patients reflecting 
decreased sodium absorption (Joris et al., 1993). Thus, inhalation of a 
large volume of nebulized saline below 80 mmol/l chloride concentration, 
or water, may reduce the chloride concentration of the ASL which could be 
detected by RARs leading to cough. The mechanism of 'low chloride' 
stimulation of RARs could be direct by altering the ion flux across the 
terminals (Shingai, 1979) or indirect by the fluid shifts causing distortion of 
the epithelium (Hogg & Eggleston, 1984). 
The results of the study investigating the effect of particle size on 
cough (Section 3.3.6) suggest regional differences exist in the distribution 
of airway receptors responsible for coughing. In agreement with other 
workers (Sterk et al., 1984), the ultrasonic nebulizer produced larger 
particles than the jet nebulizers. On inhalation these are distributed more 
towards the central airways, including the larynx, than peripherally 
(Emmett et al., 1982). In contrast, the smaller particles from the jet 
nebulizer are distributed more peripherally. The small particle aerosol of 
distilled water induced less coughing than the large particle aerosol 
suggesting that UNDW stimulates receptors that are predominantly 
located in the central airways and larynx. However, a reduction in the 
liquid dose to the airway epithelium caused by an increase in the surface 
area of the peripheral airways and by the reduced total deposition found 
with the jet system, may also contribute to the reduced cough frequency. 
The decreased cough response to UNDW seen in heart-lung transplant 
patients who have an intact larynx, but are permanently denervated below 
the tracheal anastomosis, may be due to a loss of RARs in the lower 
trachea and large bronchi (Higenbottam et al., 1989). 
The cough response to UNDW appears to be subject to rapid 
adaptation (or tachyphylaxis) (Section 3.3.7). The number of coughs 
decreased over a one minute challenge and remained low when re-
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stimulated after five minutes. Cough frequency returned to baseline values 
within three hours although this response again exhibited a rapid 
adaptation during the challenge. 
The studies described in this Chapter also revealed that individuals 
exhibit varied susceptibility to the irritancy of inhaled stimuli ranging from 0 
to 40 coughs / minute in response to UNDW (Appendix 1; 3.3.1). The 
reason for this variation and why some individuals appear to be insensitive 
to UNDW probably arises from differences in the central respiratory control 
mechanisms (Banner, 1988). Central processes may also modify cough at 
different levels of consciousness, for example, during sleep, initiate cough 
voluntarily and suppress cough, which is possible at low levels of irritation. 
In summary, these results suggest that cough can be stimulated in 
approximately 80% of humans by inhalation of aerosols low in chloride 
concentration, extremes of pH and markedly high osmolarity. These 
characteristics are similar to those described for the apnoeic reflex in 
neonatal puppies (Boggs & Bartlett, 1982) and for a group of laryngeal 
RARs in animal studies (Boushey et al., 1974; Boggs & Bartlett, 1982; 
Sant'Ambrogio et al., 1991). In humans, intra-epithelial RARs lie close to 
the airway lumen and are located primarily in the large central airways 
(Laitinen, 1985), the major site for cough provocation (Widdicombe, 1980). 
Similarly, the receptors responsible for UNDW-induced cough appear to 
be situated predominantly in these large airways and larynx and exhibit a 
rapid adaptation of their reflex response. It may be concluded that cough 
induced from inhalation of aqueous aerosols results from stimulation of 
airway RARs which are located in the large conducting airways. Inhalation 
of hypotonic saline and UNDW appears to offer a safe, physiological 
stimulus with which to study cough. 
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CHAPTER 4: THE EFFECT OF ALTERING AIRWAY 
TONE ON COUGH 
4.1 INTRODUCTION 
Cough is often associated with bronchoconstriction and it has been 
suggested that both responses are mediated by RARs since many stimuli 
which discharge RARs also evoke cough and bronchoconstriction 
(Widdicombe, 1954). It has also been suggested that bronchoconstrictor 
agents stimulate RARs indirectly through their action on airway smooth 
muscle (Coleridge et al., 1978) and that a causal relationship, 
bronchoconstriction leading to cough, also exists (Salem & Aviado, 1964; 
Chausow & Banner, 1983). If this is correct, then bronchodilators may be a 
useful strategy for suppressing cough. In support of this hypothesis, cough 
is a common symptom of asthma (Corrao et ai, 1979; Irwin et al., 1981) 
and this 'allergic' cough is inhibited by treatment with bronchodilators 
(Ellul-Micallef, 1983; Corrao et al., 1979). Furthermore non-asthmatic 
volunteers with cough associated with upper respiratory tract infection 
(URTI) have been shown to have hyper-reactive airways and an enhanced 
cough response to citric acid aerosol which is inhibited by bronchodilator 
therapy (Empey et al., 1976). However, in recent years, the relationship 
between these two reflexes has been questioned. The cough response to 
UNDW is not associated with bronchoconstriction in non-asthmatics 
(Schoeffel et al., 1981) and the two responses are mediated by different 
mechanisms of action confirmed by a differential effects of drugs. 
Atropine and sodium cromoglycate inhibit bronchoconstriction but not the 
cough response to UNDW (Sheppard et al., 1983; Fuller & Collier, 1984), 
while lidocaine inhibits cough but not bronchoconstriction (Sheppard et al., 
1983). Furthermore, the cough response to UNDW is immediate and 
adapts over a 1 minute challenge, while the bronchoconstriction follows 
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inhalations of UNDW of over 1 minute duration in a dose-dependent 
manner (Chadha et al., 1984). Cough appears to result from the lack of 
permeant anions in water (Section 3.3.2) while bronchoconstriction results 
from its reduced osmolarity (Eschenbacher et al., 1984). Also, studies 
using citric acid-induced cough have demonstrated conflicting evidence as 
to the efficacy of bronchodilators as antitussives (Karttunen et al., 1987; 
Pounsford et al., 1985). 
In view of these uncertainties, the aims of the following 
experiments were to assess the ability of bronchodilation to inhibit cough 
and bronchoconstriction to promote cough. Bronchodilation can be 
achieved with two classes of drugs; catecholamines cause bronchodilation 
by activating beta2-adrenoceptors, while anticholinergic drugs inhibit 
acetylcholine release from parasympathetic post-ganglionic 
neuromuscular junctions which causes bronchoconstriction. The studies of 
bronchodilation were designed to compare the antitussive properties of 
inhaled and orally administered beta2-adrenergic and anticholinergic 
bronchodilators, administered in therapeutic doses, on cough induced by 
inhalation of aqueous aerosols in normal and asthmatic volunteers. Cough 
challenges were performed at times following treatment to coincide with 
the peak time of action of the drugs. The relationship between 
bronchodilation and inhibition of cough was also determined. 
The ability of bronchoconstriction to promote cough was 
investigated using leukotriene D4 (L TD4), a 5-lipoxygenase metabolite of 
arachidonic acid and an inflammatory mediator. L TD4 is a potent 
constrictor of non-asthmatic as well as asthmatic airways causing a 
prolonged bronchoconstriction which is maximal within 2 to 3 minutes 
(Smith et al., 1985). Coughing has been reported in some (Holroyde et al., 
1981; Kern et al., 1986; Ayala et al., 1988) but not all (Bel et al., 1987; 
Smith et al., 1987) studies and the cough response has not been formally 
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studied. Therefore, the dose response characteristics of both cough and 
bronchoconstriction in response to L TD4 inhalation in healthy subjects 
were determined. In addition, the effect of pre-treatment with a specific 
LTD4 antagonist SK&F 104353, which inhibits L TD4-induced 
bronchoconstriction in asthmatics (Evans et al., 1988) and non-specifically 
with a beta2-adrenergic agonist, salbutamol, was investigated. 
4.2 BRONCHODILATION 
4.2.1 Beta-Adrenergic Bronchodilators 
(a) Inhaled Fenoterol Hydrobromide 
This study aimed to investigate the antitussive property of a 
standard beta2-agonist, fenoterol hydrobromide administered by 
inhalation. Twenty healthy volunteers (7 males and 13 females, age range 
19 to 50 yrs, 10 smokers and 10 non-smokers) completed the study. 
Volunteers received fenoterol hydrobromide by metered dose inhaler (mdi) 
(360 I1g; 2 x 180 I1g / puff) or an identical looking placebo inhaler (2 puffs) 
in random order, double blind and on separate days 30 minutes before a 
cough challenge. Saline solutions containing 150, 112, 75, 31 and 0 
mmol/I chloride were inhaled from the DeVilbiss 65 ultrasonic nebulizer as 
described in Section 2.2 for 1 minute periods and at 10 minute intervals 
during which cough frequency was recorded. 
(b) Oral Salbutamol Sulphate 
The antitussive property of a standard oral presentation of a beta2-
agonist, salbutamol sulphate was investigated using 11 healthy volunteers 
(4 males and 7 females, age range 19 to 50 yrs). Subjects received 
salbutamol sulphate (4 mg: 2 x 2 mg tablets) or matched placebo (2 x 
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tablets) 2 hours before a cough challenge on separate days, in random 
order and double blind. The challenge consisted of inhaling ultrasonically 
nebulized saline solutions containing 150, 75, 31 and 0 mmol/l chloride 
respectively for 1 minute periods and at 10 minute intervals. FEV 1 was 
recorded pre-tablet and pre- and post-challenge. 
(c) Inhaled Salbutamol and Procaterol Hydrochloride 
The antitussive properties of inhaled salbutamol were investigated 
to compare its efficacy with the oral preparation studied above in 
Experiment 4.2.1 (b). Procaterol hydrochloride was also investigated as a 
new highly selective beta2-adrenergic agonist (Siegel et al., 1985) 
comparing 2 doses. Twenty healthy volunteers (5 males and 15 females, 
age range 21 - 60 yrs (mean 40 yrs.), mean FEV 1 = 107%, range 81 -
135% of predicted) completed the study. For this study, it was decided to 
assess the effect of treatment on just 1 challenge to exclude any 
adaptation of cough du ring dose response challenges. Five visits to the 
laboratory were required within a 14 day period. On visit 1, a cough dose 
response challenge was performed using ultrasonically nebulized saline 
containing 150, 75, 31 and 0 mmol/l chloride respectively, which were 
inhaled for 1 minute periods and at 5 minute intervals until more than 10 
coughs occurred during a single inhalation. Subjects who did not cough on 
more than 10 occasions to any aerosol were excluded from the study. The 
concentration causing greater than 10 coughs was then used by the 
volunteer for the remainder of the study. On visits 2 to 5, volunteers 
received salbutamol (200 Jlg: 2 x 100 Jl9/puff), procaterol (10 Jlg: 1 x 10 
Jl9/puff procaterol + 1 puff placebo), procaterol (20 Jlg: 2 x 10 Jlg puffs) or 
placebo (2 puffs) by mdi in random order derived from 5 Latin squares of 
order 4 balanced for 1 st order carryover (residual) effects (Cochran & Cox, 
1966), double blind and on separate days 15 minutes prior to cough 
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challenge. Raw and FEV 1 were recorded pre-treatment and pre- and 
post-cough challenge. 
4.2.2 Anticholinergic Bronchodilators 
(a) Inhaled Ipratropium Bromide 
The antitussive efficacy of a standard inhaled anticholinergic agent, 
ipratropium bromide, was investigated in 14 healthy volunteers (8 males 
and 6 females, age range 19 - 50 yrs). Subjects inhaled ipratropium 
bromide mdi (72 Jlg: 4 x 18 Jlg/puff) or identical placebo (4 puffs) 45 
minutes prior to cough challenge. This consisted of inhaling ultrasonically 
nebulized saline solutions containing 150, 75, 31 and 0 mmolll chloride 
respectively for 1 minute periods and at 10 minute intervals. 
(b) Oral Pirenzepine Hydrochloride 
This study aimed to investigate the antitussive property of an orally 
administered anticholinergic agent. Pirenzepine hydrochloride is 
chemically related to ipratropium bromide and is a selective inhibitor of 
gastric acid secretion (Stockbrugger et a/., 1979). Fourteen healthy 
volunteers (7 males and 7 females, age range 19 - 50 yrs) were given 
pirenzepine (50 mg) or matched placebo tablet 2 hours before cough 
challenge. This consisted of inhaling ultrasonically nebulized saline 
solutions containing 150, 75 31 and 0 m molll ch loride respectively for 1 
minute periods and at 10 minute intervals. 
(c) Inhaled Oxitropium Bromide. Ipratropium Bromide and a 
Combination of Ipratropium and Fenoterol Hydrobromide. 
This study was designed to determine the antitussive efficacy of a 
new anticholinergic, oxitropium bromide (Peel et al., 1984) compared with 
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placebo. A compound preparation of a beta-agonist with an anticholinergic 
was also investigated to determine whether this produced a greater 
antitussive effect than the anticholinergic component alone. Sixteen 
healthy non-smOking volunteers (8 males and 8 females, age range 21 -
39 yrs) who coughed in response to UNDW completed this study. FEV1 
was measured in 12 of the volunteers (mean FEV1 = 119% of predicted, 
range 103 to 153%). After studying 6 subjects, a learning effect on cough 
frequency was thought to occur and the data were analysed (author 
remaining blind). This confirmed a learning effect which was most 
apparent between days 1 and 2 of the study. Although this was statistically 
insignificant and was less than the overall treatment effect, an extra open 
placebo control day on day 1 was incorporated for each subject and the 
study restarted. Data from this open placebo day were not included in the 
analysis. Subjects attended the laboratory on 5 consecutive days. On day 
1 placebo (2 puffs) was administered. On days 2 - 5, treatment with 
oxitropium bromide mdi (200J.1g: 2 x 100 J.1g/puff), ipratropium bromide 
(80J.1g: 2 x 40 J.1g/puff), ipratropium bromide (80J.1g) + fenoterol 
hydrobromide (200J.1g) (2 x puffs ipratropium bromide 40 J.1g/puff + 
fenoterol hydrobromide 100 J.1g/puff) or placebo (2 puffs) were 
administered in random order and double-blind 60 minutes before a cough 
challenge consisting of inhaling ultrasonically nebulized saline solutions 
containing 53, 31, and 0 mmol/l chloride respectively for 1 minute periods 
and at 5 minute intervals. 
4.2.3 The Association Between Alterations in Airway Tone and the 
Inhibition of Cough 
The aims of this study were to investigate the relationship between 
the bronchodilation produced by inhaled and orally administered beta-
agonists and anticholinergics and the inhibition of cough. Six healthy 
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volunteers (1 male and 5 females, age range 21 - 39 yrs, mean FEV1 = 
122% of predicted, range 110 - 142%), completed this study. Each 
underwent whole body plethysmographic measurement of sGaw followed 
by flow/volume curves from which FEV1 was derived. These 
measurements were performed in duplicate before and immediately after a 
cough challenge and this procedure was repeated after each treatment. 
Challenge for cough consisted of UNDW delivered for 1 minute duration 
during which cough frequency was recorded. Treatments were fenoterol 
hydrobromide mdi (360 ~g) 30 minutes prior to challenge; salbutamol 
sulphate tablets (4 mg) 2 hours prior to challenge, ipratropium bromide 
mdi (72 ~g) 45 minutes prior to challenge, pirenzepine tablets (50 mg) 2 
hours prior to challenge, placebo mdi (2 puffs) 30 minutes prior to 
challenge and placebo tablets 2 hours prior to challenge. Treatments were 
administered on separate days with the order randomised for each subject 
using a Latin square design. 
4.2.4 The Antitussive Effect of Bronchodilators in Asthmatics 
(a) Inhaled Salbutamol and Procaterol Hydrochloride 
This study of asthmatics was performed in conjunction with 
experiment 4.2.1 (c) in healthy subjects to determine whether they 
responded to a greater extent to the antitussive properties of inhaled beta-
agonists. 
Twenty volunteers with stable bronchial asthma (9 males and 11 
females, age range 18 - 61 yrs (mean 33 yrs), mean FEV 1 = 103% of 
predicted, range 74 - 129%) completed this study. Asthma was confirmed 
by a 15% or more increase in FEV 1 following salbutamol (200 ~g) 
inhalation. None were taking oral steroids and the previous 3 months had 
been free of acute exacerbations of their asthma requiring hospital 
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admission. Inhaled steroids continued unchanged during the study period 
but all bronchodilators were withheld for 8 hours prior to each visit. 
The experimental procedure followed that described in 4.2.1 (c). 
(b) Inhaled Oxitropium Bromide, Ipratropium Bromide and a 
Combination of Ipratropium and Fenoterol Hydrobromide. 
This study of asthmatics was performed in conjunction with 
experiment 4.2.2.(c) which was performed in healthy subjects to determine 
whether they responded to a greater extent to the antitussive properties of 
inhaled anticholinergic bronchodilators. 
Ten non-smoking subjects with stable bronchial asthma (3 males 
and 7 females, age range 20 - 32 yrs) who coughed in response to UNDW 
completed this study. None were taking oral steroids and the previous 3 
months had been free of acute exacerbations. Beta agonists were 
withheld for 8 hours and all other medication for 12 hours prior to each 
visit. FEV 1 was recorded in 9 of the subjects prior to the study (mean 
FEV1 = 107% of predicted, range 95 to 124%). 
The experimental procedure followed that described in 4.2.2 (c). 
4.3 STATISTICAL ANALYSIS 
4.2.1 (a),(b) 4.2.2 (a),(b): (Fenoterol. Salbutamol. Ipratropium, Pirenzepine) 
Each active drug was compared with placebo for its effect on 
cough frequency at each concentration of chloride. As the cough 
response to solutions with chloride concentrations greater than 75 mmol/l 
was low, these results were not included in the analysis. The justification 
for this was that to include them would have artificially reduced the 
residual variance. 
The cough frequency values were first transformed as described in 
Section 2.7. Three factor ANOVA was then performed where the factors 
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were subjects, drugs (active/placebo) and concentration of chloride. The 
interaction term was used to compute the 95% confidence limits for the 
drug means at each chloride concentration. A probability level of p=0.05 
was set to test the main factors of the analysis and the interactions. 
Comparisons between means were however made using a least 
significant difference with a p value of 0.01 to reduce the risk of a Type 1 
statistical error. 
4.2.3: (The Association Between Alterations In Airway Tone and the 
Inhibition of Cough) 
Cough frequencies were again transformed prior to analysis. A 
logarithmic transformation was performed on values of FEV 1 and sGawas 
the data was not Normally distributed. Three way ANOVA was used to test 
whether these values changed with the cough challenge or with 
treatment. The least significant difference was calculated to enable 
comparisons to be made between oral and inhaled preparations for each 
type of drug. Finally the 2 placebo preparations were combined and 
compared with the oral and inhaled beta agonists using William's test for 
ordered means (Shirley, 1979) (one tailed) with respect to the mean 
values of FEV1, sGaw and cough frequency. This was repeated for the 
anticholinergics. 
The association between the changes in FEV 1 and cough 
frequency and sGaw and cough frequency were assessed with correlation 
analysis. 
4.2.2 (c), 4.2.4 (b): (Oxitropium Bromide) 
After transformation, ANOV A was performed on cough frequency 
data combining the 2 experiments in healthy and asthmatic subjects in a 
balanced repeated measures design. Differences between the means 
were assessed by the method of least significant difference. 
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4.2.1 (C), 4.2.4 (a): (Salbutamol and Procaterol) 
Analysis was performed on the combined data from the 2 
experiments in healthy and asthmatic subjects. Cough frequency, FEV 1 
and Raw values from the 4 treatment days were recorded for analysis. 
Initial review of the data confirmed a skewed distribution for cough 
frequency and also for Ra w. A square-root and a logarithmic 
transformation, respectively, was therefore performed on the data prior to 
ANOVA to normalise their distributions. Comparisons between means 
were made using the least significant difference. Correlation analysis was 
performed on the % change in cough frequencies between active 
treatments and placebo, and the % change in FEV1 measured 15 minutes 
post treatment between active treatments and placebo. 
4.4 RESULTS 
The raw data and ANOVA tables for the following studies are 
presented in Appendix 2. 
4.4.1 Beta-Adrenergic Bronchodilators 
(a) Inhaled Fenoterol Hydrobromide 
No cough occurred on any occasion to saline aerosols containing 
150 and 112 mmol/I chloride but increased as the chloride concentration 
was reduced below 75 mmol/I (p<0.01) confirming the dose/response 
relationship described in Section 3.3.2. No difference in cough responses 
could be detected between smokers and non-smokers (mean UNDW-
induced cough frequency = 13.7 coughs / minute for smokers and 13.6 for 
non-smokers on placebo), but there was a difference in cough responses 
between subjects in general, with 3 subjects failing to cough on any 
occasion (p<0.01). A statistically significant reduction in cough frequency 
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occurred with fenoterol hydrobromide compared with placebo for distilled 
water (p<0.001) and 31 mmol/I chloride (p<0.02). The back-transformed 
mean cough frequencies are presented in Table 4.1 and graphically in 
Figure 4.1. 
TABLE 4.1 
The Effect of Bronchodilators on Cough Freguency 
Placebo 
Fenoterol mdi 
Placebo 
Oral Salbutamol 
Placebo 
Ipratropium mdi 
Placebo 
Oral Pirenzepine 
MCF (95% Cl) (coughs/minute) 
Chloride Concentration (mmolll) 
o 
11.6 (9.3-14.2) 5.6 
5.1 (3.5-6.9) 2.9 
11.5 (7.4-16.3) 6.7 
9.7 (6.0-14.2) 3.8 
13.3 (10.5-16.3) 3.4 
3.4 (1.9-5.1) 1.3 
12.8 (9.5-16.5) 4.8 
7.3 (4.8-10.3) 4.1 
(4.0-7.5) 1.2 
(1.7-4.4) 0.1 
(3.6-10.6) 0.4 
(1.4-7.0) 0.3 
(1.9-5.1 ) 0.4 
(0.3-2.6) 0.0 
(2.8-7.3) 0.2 
(2.2-6.5) 0.1 
(0.3-2.4) 
(0.0-0.9) 
(0.0-2.3) 
(0.0-2.2) 
(0.0-1.5) 
(0.0-0.9) 
(0.0-1.4) 
(0.0-1.3) 
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FIGURE 4.1 
The Antitussive Effect of Inhaled Fenoterol 
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.... 
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o 31 75 112 150 
Chloride Concentration (mmol/l) 
(b) Oral Salbutamol Sulphate 
The reduction in cough frequency with oral salbutamol compared 
with placebo did not reach statistical significance (p>0.05). However, the 
dose I response relationship between decreasing chloride concentration 
and increasing cough frequency was again confirmed (p<0.01). The mean 
cough frequencies are presented in Table 4.1 and graphically in Figure 
4.2. Placebo did not affect FEV 1 but salbutamol increased FEV 1 slightly 
by an average of 3%. 
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FIGURE 4.2 
The Antitussive Effect of Oral Salbutamol 
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D Placebo 
Iiill Salbutamol 
n = 11 
75 150 
Chloride Concentration (mmolll) 
(c) Inhaled Salbutamol and Procaterol Hydrochloride 
Thirty-two healthy volunteers were screened to achieve the target 
of 20 completing the trial. Of the 12 volunteers who failed to meet the 
entry criteria, 10 failed to produce more than 10 coughs to UNDW 
confirming the intersubject variation in cough response, 1 had a recent 
respiratory tract infection and 1 was on active medication. 17 of the 
volunteers required UNDW to elicit 10 or more coughs during a 1 minute 
inhalation, the other 3 required saline containing 31 mmolll chloride. 
ANOVA performed on square-root transformed cough frequency 
data revealed a highly significant difference between treatments 
(p<0.001). Cough was inhibited by procaterol hydrochloride (10 and 20 
~g) and salbutamol (200 ~g) compared with placebo (p<0.001) with no 
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statistically significant difference detected between the 3 treatments 
(p>0.05). The back-transformed mean cough frequencies and 95% 
confidence limits are presented in Figure 4.3. 
ANOV A of the FEV 1 data revealed significant differences between 
treatments (p<0.001) and time of measurement (baseline, 15 min post 
treatment and post challenge) (p<0.001). However, interactions between 
these 2 factors indicated that these effects were not consistent. Further 
analysis revealed that all 3 active treatments, but not placebo, induced a 
clinically small but statistically significant increase in FEV 1 above baseline 
values (mean = 3%) (p<0.01). Cough challenge did not alter FEV1 
(p>0.05) verifying that this type of challenge is not associated with 
bronchoconstriction in healthy individuals. The mean FEV1 data are 
presented in Table 4.2 and Figure 4.4. 
ANOV A was performed on log transformed Raw data and revealed 
significant differences between treatments (p<0.001) and time of 
measurement (p<0.001). Again, interactions between the 2 factors 
indicated that the responses were not consistent. Only procaterol (20 I1g) 
and salbutamol resulted in a clinically small but statistically significant fall 
in Raw compared with baseline (p<0.05 and p<0.001 respectively). Cough 
challenge produced no change in Raw (p>0.05). The mean Raw values are 
presented in Table 4.2 and Figure 4.5. 
The degree of bronchodilation as measured by the % increase in 
FEV 1 post treatment compared with placebo did not correlate with the % 
reduction in cough with treatment compared with placebo (r = -0.19, -0.05 
and 0.29 for procaterol 10 and 20 Ilg and salbutamol respectively) (p > 
0.05) as shown in Figure 4.6. 
1 volunteer reported mild, transient hand tremor after the 3 active 
treatments. which is a known and common side-effect of beta-adrenergic 
therapy. 
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FIGURE 4.3 
The Antitussive Effect of Inhaled Procaterol and Salbutamol 
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TABLE 4.2 
The Effect of Treatment and Challenge on FEV 1 and Raw 
MEAN FEV1 BACK-TRANSFORMED MEAN 
(I) flaw (kPaJl/s) 
Base Post Post Base Post Post 
Treat Chall Treat Chall 
Placebo 3.26 3.26 3.26 0.32 0.30 0.31 
Procaterol 1 0 ~g 3.24 3.33 3.34 0.29 0.27 0.26 
Procaterol 20 ~g 3.24 3.33 3.34 0.29 0.26 0.26 
Salbutamol 3.21 3.31 3.35 0.30 0.26 0.26 
FEV1 SE = 0.021 
Raw SE (transformed data) = 0.012 
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FIGURE 4.4 
The Effect of Treatment and Challenge on FEV1 
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The Effect of Treatment and Challenge on Raw 
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FIGURE 4.6 
The Association Between Bronchodilation and Inhibition 
of Cough 
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4.4.2 Anticholinergic Bronchodilators 
(a) Inhaled Ipratropium Bromide 
No cough occurred with saline containing 150 mmol/l chloride but 
cough increased with decreasing chloride concentration (p<0.01). A 
statistically significant reduction in cough frequency occurred with 
ipratropium bromide compared with placebo when UNDW was inhaled 
(p<0.001). The mean cough frequencies are presented in Table 4.1 and 
graphically in Figure 4.7. 
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FIGURE 4.7 
The Antitussive Effect of Inhaled Ipratropium 
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(b) Oral Pirenzepine Hydrochloride 
Pirenzepine did not produce a statistically significant reduction in 
cough frequency compared with placebo (p>0.05) . However, cough 
frequency increased with decreasing chloride concentration with both 
treatments (p<0.01) . The mean cough frequencies are presented in Table 
4.1 and graphically in Figure 4.8. 
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FIGURE 4.8 
The Antitussive Effect of Oral Pirenzepine 
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(c) Inhaled Oxitropium Bromide, Ipratropium Bromide and a 
Combination of Ipratropium and Fenoterol Hydrobromide. 
Oxitropium bromide, ipratropium bromide and the combination 
preparation a" resulted in fewer coughs than placebo in response to 
UNDW (p<0.01). Cough frequencies in response to the saline solutions 
were too low to show a statistically significant difference with the active 
treatments. No important residual effects of treatment between laboratory 
visits were found. The inhibitory effect of ipratropium bromide on UNDW-
induced cough confirms the previous findings in Section 4.4.2.(a) . The 
mean cough frequencies are presented in Table 4.3 and graphically in 
Figure 4.9 
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TABLE 4.3 
The Antitussive Effects of Inhaled Anticholinergics 
MCF (95% CL) (coughs/m in) 
Chloride Concentration (mmol/l) 
0 ~ 53 
Placebo 12.8 (10.1-15.7) 3.3 (1.9-5.0) 3.7 (2.2-5.5) 
Oxitropium 6.5 (4.6-8.7) 1.9 (0.8-3.3) 1.2 (0.3-2.5) 
Ipratropium 6.2 (4.3-8.3) 1.8 (0.7-3.2) 1.6 (0.5-3.0) 
Ipratropiuml 4.7 (3.0-6.6) 1.6 (0.5-3.0) 0.8 (0.0-2.0) 
Fenoterol 
FIGURE 4.9 
The Antitussive Effects of Inhaled Anticholinergics 
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4.4.3 The Association Between Alterations in Airway Tone and the 
Inhibition of Cough 
In this study, oral salbutamol but not oral pirenzepine diminished 
cough frequency, again with lesser effect than the inhaled drugs fenoterol 
or ipratropium (p<0.05). 
For FEV1, sGaw and cough frequency, the differences between 
treatments were significant (p<0.01). Investigations of the sub components 
of the treatment effect revealed significant differences between 
presentation (oral vs. inhaled) and between drugs (placebo vs. beta 
agonist and anticholinergic) for all three variables. 
The means for FEV 1 and sGaw are plotted in Figures 4.10 and 4.11 
respectively. UNDW challenge did not affect either FEV 1 or sGaw (p>0.05) 
confirming the fact that UNDW-induced cough is not associated with 
bronchoconstriction. Both inhaled treatments increased these 
measurements and decreased cough frequency. These physiologically 
small but statistically significant increases in FEV1 and sGaw correlated 
with the reduction in cough frequency as plotted in Figures 4.12 and 4.13 
respectively. The correlation coefficients were r = 0.67 (p<0.001) and r = 
0.68 (p<0.001) respectively. 
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FIGURE 4.10 
The Effect of Treatment and Cough Challenge on FEV1 
--...-
T"'"" 
> W 
LL 
c 
cu Q) 
~ 
4.2 
4.1 
4.0 
3.9 
o Fenoterol mdi 
o Ipratropium mdi 
• Oral Salbutamol 
Il. Placebo mdi 
• Oral Placebo 
• Oral Pirenzepine 
n=6 
3.8..L--_--__r_------.L..-----
Baseline Post Post Post 
Challenge Treatment Challenge 
FIGURE 4.11 
The Effect of Treatment and Cough Challenge on sGaw 
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FIGURE 4.12 
The Relationship Between Inhibition of Cough and 
the Increase in FEV1 in Response to Treatment 
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FIGURE 4.13 
The Relationship Between Inhibition of Cough and 
the Increase in sGaw in Response to Treatment 
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the pre and post treatment values of transformed cough 
frequencies and the log (sGaw (2) I sGaw (1)) is the 
transformed ratio of pre to post treatment sGaw. 
4.4.4 The Effect of Bronchodilators in Asthmatics 
(a) Inhaled Salbutamol and Procaterol Hydrochloride 
Twenty-seven asthmatic volunteers were screened for the study; 5 
subjects failed to cough sufficiently to UNDW and 2 withdrew their consent 
prior to entry. Ten volunteers required UNDW to elicit more than 10 
coughs during a 1 minute inhalation, 9 required saline containing 31 
mmol/l chloride and 1 required 75 mmolll chloride indicating a lower 
threshold for cough than the healthy volunteers. 
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The AN OVA was performed in conjunction with experiment 4.2.1 (c) 
which was performed in healthy subjects. This revealed a highly significant 
difference between treatments (p<0.001). Cough was inhibited by 
procaterol (10 and 20 I1g) and salbutamol compared with placebo 
(p<0.001) with no statistically significant difference detected between the 3 
treatments (p>0.05). The back-transformed mean cough frequencies and 
95% confidence limits are presented in Figure 4.14. ANOVA of FEV1 data 
revealed significant differences between treatments (p<0.001) and time of 
measurement (baseline, 15 min post treatment and post challenge) 
(p<0.001). However, interactions between the 2 factors indicated that 
these effects were not consistent. Further analysis revealed that all 3 
active treatments, but not placebo, induced a clinically small but 
statistically Significant increase in FEV 1 above baseline by an average of 
6% (p<0.001). Cough challenge induced a fall in FEV1 on the placebo day 
of 5% (p<0.001) reflecting the initial stages of the dose-dependent 
bronchoconstrictor response to UNDW which occurs in asthmatics after 
exposures greater than 1 minute (Chadha et al., 1984). Treatment with the 
3 active drugs prevented the fall in FEV1 with cough challenge (p<0.05). 
The mean FEV 1 values are presented in Table 4.4 and Figure 4.15. 
ANOVA performed on log-transformed Ra w data revealed 
significant differences between treatments (p<0.001) and time of 
measurement (p<0.001). Again, interactions between the 2 factors 
indicated that the responses were not consistent. All 3 active treatments 
resulted in a clinically small but statistically significant reduction in Raw 
compared with baseline values (p<0.001). Cough challenge increased Raw 
on the placebo day (p<0.001). The mean Raw values are presented in 
Table 4.4 and Figure 4.16. 
The degree of bronchodilation as measured by the % increase in 
FEV1 post- treatment compared with placebo did not correlate with the % 
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reduction in cough with treatment compared with placebo (r = -0.04, -0.05 
and 0.23 for procaterol 10 and 20 ~g and salbutamol respectively) 
(p>0.05) as shown in Figure 4.17. 
Four asthmatics reported mild transient hand tremor after procaterol 
20 ~g, 2 of whom also reported tremor after procaterol 1 0 ~g. Two 
asthmatics reported mild wheezing on the placebo day after cough 
challenge reflecting the known bronchoconstrictor response to UNDW in 
asthmatics (Schoeffel et al., 1981), 1 of whom also felt wheezy on the day 
procaterol 20 ~g was given. 
FIGURE 4.14 
The Antitussive Effect of Procaterol and Salbutamol in Asthmatics 
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TABLE 4.4 
The Effect of Treatment and Challenge on FEV 1 and Raw 
MEAN FEV1iD. BACK-TRANSFORMED MEAN 
BawjkPall/s) 
Base Post Post Base Post Post 
Treat Chall Treat Chall 
Placebo 3.42 3.40 3.22 0.34 0.31 0.37 
Procaterol 1 0 ~g 3.45 3.63 3.67 0.33 0.27 0.27 
Procaterol 20 ~g 3.45 3.67 3.70 0.30 0.25 0.26 
Salbutamol 3.45 3.70 3.69 0.32 0.25 0.27 
FEV1 SE = 0.021 
Raw SE (transformed data) = 0.012 
FIGURE 4.15 
The Effect of Treatment and Challenge on FEV1 
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The Effect of Treatment and Challenge on Raw 
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The Association Between Bronchodilation and Inhibition 
of Cough in Asthmatics 
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(b) Inhaled Oxitropium Bromide, Ipratropium Bromide and a 
Combination of Ipratropium and Fenoterol Hydrobromide. 
ANOVA was performed in conjunction with experiment 4.2.2 (c) 
which studied healthy subjects. This showed a difference between the 2 
groups of subjects with healthy subjects coughing more than asthmatics 
in response to placebo (p<0.05) in contrast to the previous experiment 
(Section 4.4.4 (a)) where the asthmatics exhibited a lower threshold for 
cough. However. there was no significant statistical interaction between 
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the groups of subjects (healthy and asthmatic) and treatment. This 
suggests that both groups of subjects responded similarly to treatment, 
although with the lower cough frequencies encountered with the asthmatic 
subjects, the effect is less evident and did not reach statistical significance 
(p>O.05). 
Analysis of the combined data revealed that cough frequency in 
response to UNDW was significantly higher than to either 31 or 53 mmol/l 
chloride (p<O.005) for all treatments. There was no significant difference 
between the cough response to 31 and 53 mmol/l chloride (p>O.05). 
Oxitropium bromide, ipratropium bromide and the combination 
preparation all resulted in fewer coughs than placebo in response to 
UNDW (p<O.001). There was no difference between oxitropium bromide 
or ipratropium bromide (p>O.05) but the combination preparation reduced 
cough more than either oxitropium (p<O.05) or ipratropium (p<O.025). No 
important residual effects of treatment between visits were found. 
Back-transformed mean cough frequencies and 95% confidence 
limits for the asthmatics and the combined data with the healthy subjects 
are shown in Table 4.5 and presented graphically in Figure 4.18. 
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TABLE 4.5 
The Antitussive Effects of Inhaled Anticholinergics in Asthmatics 
and Healthy Subjects 
MCF (95% Cl) (coughs/m in) 
Chloride Concentration (mmol/l) 
0 ~ 53 
Asthmatics n = 10 
Placebo 6.1 (3.8-8.9) 0.5 (0.0-1.9) 1.0 (0.0-2.6) 
Oxitropium 3.1 (1.5-5.3) 0.5 (0.0-1.8) 0.9 (0.0-2.4) 
Ipratropium 3.6 (1.8-5.9) 0.9 (0.0-2.4) 1.2 (0.0-2.8) 
Ipratropiuml 1.3 (0.1-2.9) 0.4 (0.0-1.7) 0.7 (0.0-2.2) 
Fenoterol 
Combined Data of Asthmatics and Healthy Subjects n = 26 
Placebo 10.0 (8.1-11.9) 2.1 (1.1-3.2) 2.6 (1.5-3.7) 
Oxitropium 5.1 (3.7-6.6) 1.3 (0.5-2.3) 1.1 (0.3-2.0) 
Ipratropium 5.2 (3.8-6.7) 1.4 (0.6-2.5) 1.5 (0.6-2.5) 
Ipratropiuml 3.2 (2.1-4.5) 1.1 (0.3-2.0) 0.8 (0.0-1.7) 
Fenoterol 
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FIGURE 4.18 
The Antitussive Effect of Anticholinergics in Asthmatics 
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A summary of the antitussive efficacy of all the inhaled 
bronchodilators studied in this Chapter in healthy and asthmatic volunteers 
is presented in Figure 4.19. 
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FIGURE 4.19 
The Antitussive Effects of Inhaled Bronchodilators 
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4.5 BRONCHOCONSTRICTION 
4.5.1 Cough and Bronchoconstrictor Responses to Leukotriene D4 
This study aimed to determine the cough and bronchoconstrictor 
responses to L TD4 inhalation. A preliminary study to evaluate the 
production of cough using increasing concentrations of L TD4 found that, 
unlike other challenges, coughing started after inhalation had ceased and 
occurred most frequently during the 5 minutes following challenge. 
Five healthy subjects (1 male and 4 females, age range 27 - 60, 
mean FEV 1 = 116%, range 108 - 127% of predicted), performed dose 
response studies to inhaled L TD4. L TD4 (Cascade Biochem Ltd., 
Berkshire, UK) was diluted in phosphate buffered saline to minimise 
deterioration of L TD4 during nebulization (Bisgaard et al., 1987) and 
inhaled from the Bronchoscreen dosimeter as described in Section 2.3.2 
at increasing concentrations of 1, 5, 10, 50 and 100 119/ml, each for 15 
doses and at approximately 10m inute intervals. FEV 1 and sGa w were 
measured before, 5 and 10 minutes after each inhalation. The number of 
coughs was recorded for 5 minutes following each inhalation. The study 
continued until greater than 10 coughs occurred after a challenge or a fall 
in FEV 1 of 20% or more occurred. FEV 1 and sGaw were monitored for 15 
minutes after the final inhalation and then salbutamol (200 I1g) 
administered if bronchoconstriction was evident. FEV1 was then recorded 
at intervals until values returned to within 5% of baseline. 
4.5.2 Inhibition Studies 
(a) Specific L TD4 Antagonist. SK&F 104353 
This study aimed to determine whether a specific LTD4 antagonist 
inhibited both the cough and bronchoconstrictor responses to L TD4 
inhalation. Six healthy volunteers (1 male and 5 females, age range 18 -
25. mean FEV 1 = 113%, range 100 - 122% of predicted) completed this 
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study. Each subject was studied on 4 occasions 1 week apart. On visit 1, 
a baseline dose response study was performed to determine a dose for 
each subject causing greater than 10 coughs during the 5 minutes post 
challenge. L TD4 (Miles Laboratories, Slough, UK) (3 x 1 00 ~g ampoules) 
was delivered on dry ice on the morning of the challenge, diluted in 3 ml 
phosphate buffered saline and used immediately. All 6 subjects were 
completed within 3 hours and were tested in the same order each week to 
minimise the effect of any deterioration of LTD4 with nebulization. A 2 x 
10-4 molll (1 00 ~g/m I) solution of L TD4 was inhaled from the 
Bronchoscreen with increasing numbers of active breaths over the minute 
challenge. The challenge was stopped when greater than 10 coughs 
occurred during the 5 minutes post challenge. Coughs were recorded 
using a tie microphone connected to a tape recorder. FEV 1 was recorded 
pre challenge and 0, 5 and 10 minutes post challenge. Raw was recorded 
using the Bronchoscreen as the average of the final 5 measurements of 1 
minute air breathing pre-, during and 5 minutes post- challenge. 
On visits 2 to 4, SK&F 104343 50 ~g, 400 ~g or matched placebo 
(diluent alone) was inhaled from the Bronchoscreen in random order 
determined by two Latin squares of order 3, balanced for 1 st order 
residual effects, 20 minutes prior to L TD4 cough challenge. FEV 1 was 
recorded in duplicate pre, immediately and 5 minutes post treatment and 5 
min post L TD4 challenge. Raw was measured pre-, during and 5 min post-
treatment and during and 5 min post L TD4 challenge. 
(b) Non-Specific Inhibition with Salbutamol 
This study aimed to determine whether a non-specific 
bronchodilator prevented both the cough and bronchoconstrictor response 
to L TD4 inhalation. Five healthy subjects (1 male and 4 females, age 
range 18 - 30 yrs, mean FEV1 = 108%, range 95 - 120% of predicted), 
who had previously performed a dose response study to inhaled L TD4 
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completed this two day study. After baseline measurements of FEV 1 and 
sGaw, treatment with salbutamol mdi 200 ~g (2 x 1 00 ~g/puff) or matched 
placebo (2 puffs) was administered in random order and double-blind. 15 
minutes later, FEV1 and sGaw were repeated followed by a 1 minute 
challenge with L TD4 delivered from the Bronchoscreen at a dose causing 
greater than 10 coughs in the 5 minutes following challenge. Cough 
frequency was recorded for the following 5 minutes. FEV1 and sGaw were 
recorded 5 and 15 minutes post L TD4 challenge. Salbutamol (200 ~g) was 
then administered if bronchoconstriction was evident and FEV1 monitored 
until baseline values had returned. 
4.6 RESULTS AND STATISTICAL ANALYSIS 
The raw data and ANOVA tables for the following studies are 
presented in Appendix 2. 
4.6.1 Cough and Bronchoconstrictor Responses to Leukotriene D4 
L TD4 did not cause cough during the minute inhalations. Cough 
occurred only at doses of L TD4 that caused marked bronchoconstriction 
and occurred with most frequency during the 5 minutes following 
inhalation in line with the time course of bronchoconstriction. Cough and 
bronchoconstriction followed a dose-dependent manner. The association 
between cough and bronchoconstriction as measured by a fall in FEV 1 is 
presented in Figure 4.20. 
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FIGURE 4.20 
The Cough and Bronchoconstrictor Responses to L TD4 
4.6.2 Inhibition Studies 
(8) Specific LTD4 Antagonist. SK&F 104353 
ANOVA was performed on square-root transformed cough 
frequencies and log transformed values of FEV 1 and Raw. SK&F 104353 
50 and 400 ~g did not alter FEV1 or cause cough but inhibited L TD4-
induced cough (p<0.05) and bronchoconstriction (p<0.05) in a dose 
dependent manner The mean % fall in FEV 1 after L TD4 was 20%, 16% 
and 6% for placebo, 50 and 400 ~g SK&F 104353 respectively. The 
inhibition of cough correlated with the inhibition of bronchoconstriction (r = 
0.65; p<O.02). The back-transformed mean cough frequencies, FEV 1 and 
Raw values are presented in Table 4.6 and Figures 4.21, 4.22 and 4.23 
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respectively. The association between inhibition of cough and inhibition of 
bronchoconstriction is presented in Figure 4.24. 
FIGURE 4.21 
The Effect of SK&F 104353 on L TD4-lnduced Cough 
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TABLE 4.6 
The Effect of SK&F 104353 on FEV 1 and Raw 
Baseline 
Treatment 
5 min Post-
Treatment 
PLACEBO 
FEV1-.Baw 
3.67 0.27 
3.58 0.18 
3.64 0.20 
L TD4 Challenge 0.25 
5 min Post L TD4 2.90 0.54 
FIGURE 4.22 
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FIGURE 4.23 
The Effect of SK&F 104353 on Raw 
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FIGURE 4.24 
The Inhibition of Cough Associated with the 
Inhibition of Bronchoconstriction 
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(b) Non-Specific Inhibition with Salbutamol 
ANOV A was performed on transformed data for cough frequency, 
FEV1 and Raw. This revealed that pre-treatment with salbutamol inhibited 
both the cough (p<0.05) and bronchoconstriction (p<0.02) induced by 
inhalation of L TD4 (mean % fall in FEV 1 after L TD4 = 15% and 2% for 
placebo and salbutamol respectively). Salbutamol caused a mean 2% 
increase in FEV 1 and 66% increase in sGaw which was reversed by L TD4 
inhalation. The back-transformed mean cough frequencies and 95% 
confidence lim its are presented in Figure 4.25 and the back-transformed 
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means for FEV1 and sGaw In Table 4.7 and Figures 4.26 and 4.27 
respectively. 
FIGURE 4.25 
The Effect of Salbutamol on L TD4-lnduced Cough 
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TABLE 4.7 
Effect of Salbutamol on L TD4-lnduced Changes in FEV 1 and sGaw 
PLACEBO SALBUTAMOL 
FEV1 sGaw FEV1 sGaw 
Baseline 3.36 2.24 3.38 2.14 
15 min Post- 3.37 2.24 3.45 3.55 
Treatment 
5 min Post- 2.85 0.66 3.37 2.29 
LTD4 
15 min Post- 3.02 1.00 3.33 2.88 
LTD4 
(Values are the mean) 
FIGURE 4.26 
The Effect of Salbutamol on L TD4-lnduced Fall in FEV1 
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FIGURE 4.27 
The Effect of Salbutamol on L TD4-lnduced Fall in sGaw 
---I:x- Placebo 
3: 4 --0- Salbutamol 
ctS n=5 (!) 
en 
c 3 ctS Q) 
~ 
"0 Q) 2 E 
L... 
0 
-en c 1 ctS L... 
l-
I 
.::,t:. 
U 
ctS 0 CD 
Baseline Pre 5 min 15 min 
Challenge Post Challenge 
4.7 DISCUSSION 
UNDW induces cough but not bronchoconstriction in healthy 
subjects. However, the studies described in this chapter show convincingly 
that inhaled bronchodilators inhibit this UNDW-induced cough. Coughing 
was reduced by both beta-adrenergic agonists and anticholinergics in 
healthy and asthmatic subjects by between 41 - 87% compared with 
placebo. Investigation of the association between alteration in airway tone 
and inhibition of cough (Section 4.3.3) found that a very small 
bronchodilation occurred in conjunction with the inhibition of cough 
suggesting an association between the two variables. However, the later 
studies of procaterol and salbutamol which employed large numbers of 
subjects failed to detect a correlation between this bronchodilation, as 
measured by an increase in FEV 1, and the inhibition of cough. In addition, 
although oral salbutamol induced a similar increase in FEV 1 as the inhaled 
preparation (both mean of 3%), their effects on UNDW-induced cough 
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were very different. Oral salbutamol resulted in a mean 16% reduction in 
cough compared to placebo while inhaled salbutamol resulted in an 83% 
reduction. Furthermore, the asthmatic subjects studied (Section 4.4.4), 
despite having a greater bronchodilator response than the healthy 
subjects to the drugs tested, did not exhibit a greater antitussive response. 
The observation that non-asthmatics develop bronchial 
hyperresponsiveness and an increased cough response to citric acid 
during URTI (Empey ef al., 1976) suggests that asthmatics may be more 
sensitive to tussive stimuli. However, the asthmatics studied in this 
Chapter, although they were mild asthmatics without significant airways 
obstruction, did not generally appear to exhibit a lower threshold for cough 
in response to 'low chloride' aerosols than the healthy subjects. This is in 
agreement with other workers who found that citric acid (Pounsford ef al., 
1985), tartaric acid (Fujimura ef al., 1992 a) and capsaicin (Collier & Fuller, 
1984) cough thresholds were similar in asthmatic and non-asthmatic 
subjects. Furthermore, no correlation could be found between tartaric acid 
cough threshold and the concentration of methacholine causing a 20% fall 
in FEV1 (PC20) (Fujimura ef al., 1992 a). Therefore cough can be induced 
independently of bronchoconstriction and is not affected by bronchial 
hyperreactivity. 
These results suggest that small changes in airway tone are not 
associated with the inhibition of cough. Therefore, the antitussive action of 
bronchodilators on UNDW-induced cough appears to result from a topical 
effect on airway epithelium, separate from their action on airway smooth 
muscle. This is supported by the greater efficacy of bronchodilators given 
by inhalation rather than orally. 
UNDW-induced cough appears to be mediated by stimulation of 
RARs located within the paracellular spaces of the laryngeal and 
tracheobronchial epithelium by the reduced concentration of chloride in 
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ASL. One mechanism of inhibiting cough would be to reduce the access of 
ASL to the RARs. Cyclic AMP appears to control the paracellular spaces 
of 'Ieaky' epithelium (Moreno et al., 1986). Beta-adrenergic agonists 
increase intraepithelial levels of cyclic AMP (AI-Bazzaz, 1981) and may 
reduce the volume of the paracellular spaces (Rose & Loewenstein, 1975) 
by an action on epithelial beta-adrenoceptors (Morrison et al., 1993). 
Similarly, cholinergic drugs increase permeability of the gastric mucosa 
(Shoemaker et al., 1970) suggesting that anticholinergics may decrease 
permeability. Therefore, topical bronchodilators may inhibit UNDW-
induced cough by decreasing the permeability of the paracellular spaces 
and thereby reducing access of the 'Iow chloride' ASL to the RARs. 
Another mechanism of action of bronchodilators is their effect on 
epithelial ion transport. However, whilst beta-adrenergic agonists are 
thought to increase passive transepithelial chloride secretion towards the 
lumen by increasing intracellular cAMP in both animal and human airways 
(AI-Bazzaz & Cheng, 1979; Davis et al., 1979; Knowles et al., 1982) which 
could dilute the effect of 'Iow chloride ' aerosols on the ASL, 
anticholinergics appear to have no effect on basal secretory rates (Joris et 
al., 1993), but rather prevent increases that occur during vagal reflex 
stimulation (Marin et al., 1976; German et al., 1980). Beta-adrenergic 
agonists also increase mucus secretion from epithelial glands and 
increase mucociliary clearance (Foster et al., 1976; Phipps et al., 1982) 
but anticholinergics are thought to have little effect (Foster et al., 1976). 
Another mechanism of inhibition of UNDW-induced cough would be 
a direct action on RARs but so far, only the existence of beta2 
-adrenoceptors on vagal efferent terminals in humans has been postulated 
(Aizawa et al., 1991). 
In contrast to the inhibition of UNDW-induced cough by 
bronchodilators described in this Chapter, other investigators have found 
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no effect using a sim ilar anticholinergic to ipratropium, atropine (Sheppard 
et al., 1983; Fuller & Collier, 1984). Other studies of the antitussive effects 
of bronchodilators on cough induced by other stimuli have produced 
variable results. Nebulized bronchodilators (salbutamol and ipratropium) 
decreased citric acid-induced cough in asthmatics but not healthy subjects 
(Pounsford et al., 1985) although others have found that inhaled 
(Karttunen et al., 1987) but not oral (Belcher & Rees, 1986) salbutamol is 
effective in healthy subjects. Bronchodilators also appear to be ineffective 
against capsaicin-induced cough (Nichol et al., 1990 a; Smith et al., 1991; 
Fujimura et al., 1992 b). This suggests that coughing in response to these 
stimuli are mediated by different mechanisms than UNOW-induced cough. 
The ability of bronchoconstriction to promote cough was studied 
using inhaled L T04 (See Section 4.6.1). L T04 is not irritant during 
inhalation, unlike UNOW which causes cough immediately on inhalation 
and ceases on removing the stimulus. However, coughing occurred most 
frequently during the 5 minutes following inhalation coinciding with the 
onset of bronchoconstriction which was also most pronounced within 5 
minutes of inhalation. However, cough only occurred with L T04 at high 
doses which caused marked bronchoconstriction associated with a 20% or 
more fall in FEV1. Inhibition of bronchoconstriction either by the specific 
L T04 antagonist, SK&F 104353, or with salbutamol, which inhibits 
bronchoconstriction regardless of the stimulus, also inhibited cough. The 
degree of inhibition of cough correlated with the degree of inhibition of 
bronchoconstriction. These results suggest that L T04 does not cause 
cough directly but rather, indirectly through marked bronchoconstriction. 
L T04-induced bronchoconstriction is thought to result from direct 
stimulation of airway smooth muscle rather than via a vagal reflex or from 
release of other inflammatory mediators (Smith et al., 1987; Ayala et al., 
1988) The anaesthetic, lidocaine does not inhibit the bronchoconstrictor 
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response to L T04 suggesting that RARs do not mediate the response 
(Smith et al., 1987) and L T04 does not directly stimulate RARs in cats and 
dogs (Holroyde & Jackson, 1983). This suggests that RAR stimulation by 
L T04 leading to cough, is indirect and a result of bronchoconstriction. 
Similarly, standard bronchial challenge testing in asthmatics with 
histamine is only associated with coughing at concentrations causing a 
similar degree of bronchoconstriction (Chausow & Banner, 1983). 
Bronchoconstriction may stimulate RARs (Widdicombe & Sterling, 1970) 
and sensitise SARs (Widdicombe, 1961) which could lead to cough by 
altering the threshold of the medullary Icoughl neurones (Hanacek et al., 
1984; SanfAmbrogio et al., 1984). However, participation of C-fibres in 
these responses cannot be excluded. 
In summary, coughing may be induced either by direct stimulation 
of RARs or indirectly through marked bronchoconstriction which could 
stimulate RARs as a result of the physical changes in airway tone. Cough 
associated with bronchoconstriction may explain the apparent efficacy of 
bronchodilators in treating chronic cough in asthmatics (Ellul-Micallef, 
1983). Small changes in airway tone are not responsible for cough 
production or inhibition. Rather, the inhibitory action of bronchodilators on 
UNDW-induced cough appears to result from a mechanism separate from 
their action on airway smooth muscle. The role of bronchodilators in 
treating pathological cough in the absence of marked bronchoconstriction 
is unclear. 
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CHAPTER 5: ANTITUSSIVE STUDIES 
5.1 INTRODUCTION 
This chapter describes studies of UNDW-induced cough with a 
variety of centrally and peripherally acting drugs with possible antitussive 
properties. Opiates are the most commonly prescribed group of 
antitussives in the UK and in particular, codeine has been used for many 
years as a positive control with which to test other antitussives. This was 
based on an extensive review by Eddy ef al. (1969), and early studies of 
cough, many of which were performed on animal models. With the advent 
of experimentally induced cough with citric acid aerosols in humans, the 
effectiveness of many opiates, including codeine, noscapine and 
dextromethorphan was confirmed (Bickerman ef al., 1957). Opiates are 
thought to inhibit the central integration of the cough reflex (Eddy ef al., 
1969) and would therefore be expected to inhibit cough regardless of the 
stimulus or afferent pathway. However, the clinical efficacy of opiates as 
antitussives has been questioned by their lack of effect on cough 
associated with chronic obstructive airways disease (Edwards ef al., 1977) 
and upper respiratory tract infection (Eccles ef al., 1992) and their potency 
is questioned in the British National Formulary (1992). 
Nedocromil sodium, however, has been reported to inhibit citric 
acid-induced cough in dogs (Jackson, 1988) possibly by a peripheral 
action on airway sensory nerves (Barnes, 1986) and may reduce cough 
severity in asthmatics (Grief ef al., 1989; Cherniack ef al., 1990). 
Nedocromil sodium is a non-steroidal prophylactic treatment for asthma 
having no bronchodilator action. It is an anti-inflammatory agent with 
actions in humans similar to sodium cromoglycate including stabilisation of 
mast cells (Leung ef al., 1988) and inhibition of reflex bronchoconstriction 
(Shaw & Kay, 1985). 
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Diuretics alter the ion transport mechanisms of epithelial cells which 
may be important in 'low chloride' stimulation of cough. Amiloride 
hydrochloride is a potassium sparing diuretic which acts on the apical 
surface of cells blocking sodium absorption (Benos, 1982) which 
stimulates chloride secretion (Knowles et al., 1984). The loop diuretic 
frusemide acts on the basolateral surface (Knowles et al., 1984) inhibiting 
sodium, potassium and chloride co-transport and inhibits chloride 
secretion in dog tracheal epithelium (Widdicombe et al., 1983). Amiloride 
and frusemide inhibit the fall in nasal potential difference (a measure of 
epithelial resistance) induced by UNDW inhaled intranasally (Wood et al., 
1989) and frusemide is reported to inhibit exercise and UNDW-induced 
bronchoconstriction (Robuschi et al., 1989; Bianco et aI, 1988). 
5.2 METHODS 
5.2.1 Opiates 
This study examined the antitussive efficacy of the commonly 
prescribed opiate, codeine phosphate, with another opiate, noscapine 
hydrochloride (Loder, 1969), administered in therapeutic doses, compared 
with placebo on cough induced by UNDW and ultrasonically nebulized 
citric acid (UNCA). Citric acid challenge was included to allow comparison 
with previous published reports. 
Twenty-four healthy volunteers completed the study (8 males and 
16 females, age range 20-40 yrs, of whom 5 were smokers). All coughed 
in response to UNDW and an isotonic mixture of 0.68% citric acid in saline 
and all had normal spirometric values (mean FEV1 = 112% of predicted) 
prior to study. 
Subjects attended the laboratory on 12 occasions; 3 consecutive 
days per week for 4 weeks. Treatments were administered on separate 
weeks, the order of administration randomised using 6 Latin squares of 
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order 4 balanced for residual (carryover) effects. Placebo was given on 
day 1 of each week to minimise learning effects on cough frequency. Data 
from this open placebo day were not included in the analysis. On days 2 
and 3 of each week, subjects were given either noscapine hydrochloride 
50 mg (1 x 50 mg noscapine + 2 placebo tablets), noscapine 150 mg (3 x 
50 mg noscapine tablets), codeine phosphate 60mg (1 x 60mg codeine + 
2 placebo tablets) or placebo (3 x placebo tablets). 
Ninety minutes after treatment, a cough challenge was performed 
to either UNDW or UNCA. These were inhaled for 1 minute periods during 
which cough frequency was recorded. Distilled water was always given on 
the placebo control day of each week. Twelve subjects were challenged 
with UNDW on days 2 and UNCA on days 3 while the remaining 12 
subjects were challenged in the reverse order. 
5.2.2 Nedocromil Sodium 
The aims of this study were to compare the antitussive properties of 
inhaled nedocromil sodium with the beta-adrenergic agonist, fenoterol 
hydrobromide, and placebo on cough induced by UNDW, UNCA and 
capsaicin, the hot extract of red pepper, which may induce cough by 
stimulation of C-fibres (Collier & Fuller, 1984). The purpose of using the 3 
challenges was to determine whether antitussive efficacy was stimulus-
dependent and therefore to elucidate the afferent pathways involved and 
the mechanisms of drug action. 
Eighteen healthy volunteers (7 males and 11 females, age range 19 
- 31 yrs, mean FEV 1 = 113% of predicted, range 88 - 145%) completed 
this 4 day study. On visit 1, baseline cough challenges were performed to 
familiarise subjects with the procedure and to determine a dose of 
capsaicin causing greater than 10 coughs during a 1 minute inhalation. 
Capsaicin (Sigma Chemicals Ltd., Poole, Dorset, UK) was dissolved in 
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ethanol before dilution in isotonic saline and delivered by jet nebulizer 
(Section 2.3.1) in increasing concentrations from 1 to 5 ~mol/1. On visits 2 
to 4, treatment by mdi with nedocromil sodium 4 mg (2 x 2 mg/puff), 
fenoterol hydrobromide 0.36 mg (2 x 0.18 mg/puff) or placebo (2 puffs) 
was administered in random order determined by 6 Latin squares of order 
3, 30 minutes before cough challenges. UNDW, UNCA (0.68% citric acid 
in 0.79% saline) and capsaicin were delivered for 1 minute periods and at 
5 minute intervals respectively. Adaptation of cough during challenges was 
also assessed by recording the number of coughs over the 3 consecutive 
20 second periods of each challenge. FEV 1 was recorded post-treatment. 
5.2.3 Diuretics 
Inhalation of UNDW results in both cough and a dose-dependent 
bronchoconstriction in asthmatics (Chadha et al., 1984). Similar to other 
standard bronchial reactivity tests, for example, using histamine or 
methacholine, the severity of asthma is related to the duration of exposure 
to UNDW inhalation; the more severe the asthma, the lower the exposure 
to UNDW required to produce a 20% fall in FEV 1. The aims of this study 
were to determine whether amiloride and frusemide, administered at 
doses which inhibit the UNDW-induced fall in nasal potential difference, 
inhibit both the cough and bronchoconstrictor responses to inhaled UNDW 
in asthmatics. 
Eight volunteers from hospital staff with stable bronchial asthma 
requiring daily bronchodilator therapy (2 males and 6 females, age range 
18 -34 yrs, mean FEV 1 = 98%, range 77 - 118% of predicted) completed 
this 4 day study. None were taking oral steroids and the previous 3 
months had been free of acute exacerbations of their asthma. All 
bronchodilators and inhaled corticosteroids were withheld for 12 hours 
prior to each study day. On visit 1, a baseline UNDW challenge was 
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performed. This consisted of inhaling increasing amounts of UNDW for 30, 
60, 90 and thereafter 120 seconds until a 20% or more fall in FEV 1 was 
recorded (Chadha et al., 1984). FEV 1 was recorded prior to challenge and 
then 30 and 90 seconds after each inhalation. The total duration of 
exposure to inhalation required to cause a 20% fall in FEV 1 was recorded 
as the PD20. Cough frequency during the first 30 second inhalation was 
recorded for analysis as adaptation occurred to subsequent inhalations. 
On visits 2 to 4, at the same time of day, treatment with amiloride 
hydrochloride 16 ml (2 x 10-4 molll diluted in isotonic saline), frusemide 16 
ml (9 x 10-3 molll diluted in isotonic saline) or placebo 16 ml (isotonic 
saline) was inhaled from the ultrasonic nebulizer in random order, 5 
minutes prior to PD20 UNDW challenge. FEV1 was recorded pre- and 
post- treatment and post UNDW as described above. Again, cough 
frequency was recorded during the first 30 second UNDW inhalation. 
5.3 RESULTS AND STATISTICAL ANALYSIS 
The raw data and ANOVA tables relating to these experiments are 
presented in Appendix 3. 
5.3.1 Opiates 
After transformation, three-way analysis of variance was performed 
on all data, the factors being subjects, treatments and challenge. The 
resultant means and 95% confidence limits were then back-transformed. 
ANOVA revealed no significant reduction in cough frequency in response 
to either UNDW or UNCA with either doses of noscapine or codeine when 
compared with placebo (p>0.05). Back-transformed mean cough 
frequencies and 95% confidence limits are shown in Table 5.1 and 
presented graphically in Figure 5.1. 
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TABLE 5.1 
The Effect of Opiates on UNDW- and UNCA-Induced Cough 
Back-transformed mean couQh frequency (couQhs/min) 
(95% confidence limits) 
UNDW UNCA 
Placebo 15.0 (12.7-17.3) 10.9 (9.0-13.0) 
Codeine 15.3 (13.0-17.7) 10.2 (8.3-12.2) 
Noscapine (50mg) 13.5 (11 .4-15.8) 11.1 (9.1-13.1) 
Noscapine (150mg) 13.1 (11.1-15.4) 13.5 (11.4-15.8) 
FIGURE 5.1 
The Effect of Opiates on UNDW and UNCA-Induced Cough 
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5.3.2 Nedocromil Sodium 
ANOVA was performed on transformed cough frequencies allowing 
analysis of the effects of subjects, visit, treatment, challenge and period of 
challenge. 
Fenoterol hydrobromide inhibited UNDW-induced cough (p<O.001) 
confirming the previous observation (Section 4.4.1 (a)), but had no effect 
on capsaicin-induced cough (p>0.05). A small reduction in cough induced 
by UNCA occurred but this did not reach statistical significance. However. 
it is possible that the prior administration of UNDW may have reduced the 
response to UNCA. Nedocromil sodium inhibited cough induced by UNDW 
(p<0.001) and capsaicin (p<0.05) but had no effect on UNCA-induced 
cough (p>0.05). Adaptation of cough occurred during all challenges 
irrespective of treatment (p<0.001). FEV1 did not alter with any of the 
treatments (mean FEV 1 = 3.80, 3.84 and 3.74 after placebo, fenoterol and 
nedocromil respectively). The back-transformed mean cough frequencies 
and 95% confidence limits are presented in Table 5.2 and Figure 5.2. The 
adaptation of cough during challenges after placebo is presented in Figure 
5.3. 
TABLE 5.2 
The Antitussive Effects of Inhaled Nedocromil and Fenoterol 
MCF (95% Cl) (coughs/minute) 
PLACEBO NEDOCROMIL FENOTEROL 
UNDW 17.2 (14.0-20.8) 8.2 (6.0-10.8) 4.3 (2.6 - 6.3) 
UNCA 9.0 (6.6-11.7) 9.0 (6.7-11.7) 5.8 (3.9 - 8.1) 
CAPSAICIN 16.1 ( 12.9-19.5) 9.4 (7.0-12.1) 15.0 (12.0-18.4) 
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FIGURE 5.2 
The Antitussive Effects of Nedocromil and Fenoterol 
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5.3.3 Diuretics 
ANOVA was performed on transformed cough frequency data. Two 
asthmatics failed to cough during the first 30 second exposure to UNDW. 
Frusemide inhibited cough compared with placebo (p<0.05). Amiloride had 
a smaller effect which did not reach statistical significance. The back-
transformed mean cough frequencies and 95% confidence limits are 
presented in Figure 5.4. 
Baseline values of FEV1 did not alter over the 3 study days 
indicating that no significant changes had occurred in their asthmatic 
status (p>0.05). No treatment altered FEV 1 compared with baseline values 
(p>0.05). The dose of UNDW causing a 20% fall in FEV1 (PD20) for each 
subject ranged from 30 to 300 seconds indicating a variation in the 
severity of asthma in the subjects studied. This was unrelated to cough 
frequency. The percent fall in FEV 1 at this dose was compared between 
the 3 treatments. Both amiloride (p<0.01) and frusemide (p<0.001) 
inhibited UNDW-induced bronchoconstriction compared with placebo 
(mean % fall in FEV1 (SE) = 24.0 (1.8),14.6 (1.7) and 5.9 (1.8) % for 
placebo, amiloride and frusemide respectively). The mean values for FEV 1 
are presented in Figure 5.5. 
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FIGURE 5.4 
The Antitussive Effect of Amiloride and Frusemide on 
UNDW-Induced Cough in Asthmatics 
£ ~ 
o>(J) 
:::J"O 
o C 08 
C 0) 
Ct3 (J) 
0)0 ~~ 
"0£ 
0)0> 
E :::J ~ 0 
o () _ .......... 
(J)>. 
C () ~ C r- 0) 
I :::J 
.:£0-() 0) 
Ct3 ~ 
COLL 
10-
5-
(5.1-12.1) 
,/ 
:: ~ : ~: ~ : ~ : ~: ~ : ~ : ~: ~ : ~: ~ : ~ : ~ ~ ~: : 
.. . . ... . .. . .... .. 
. .. . ..... ...... . 
... . ... . ... ... .. . 
....... .. .... .. . 
.... ..... . .... .. . 
.. .. .. . ........ . 
... ... . . . . . .. ... . 
. .. . .. ........... 
....... .... .. ... . 
.... . ... ....... . 
.. .. . .. .... .... . . 
... .. .. . ....... . 
.. ... . ......... .. 
... .... .. .. . ... . 
... . .. . . ..... . . . . 
......... . . . . . . . 
. . . . .... . . . . . . . . . 
... .. ...... .. .. . 
..... ........... . 
... . ........ .. . . 
......... . . . . . . . . 
. . . . . . .. ... . .. . . 
.. .... . . . . ... . .. . 
.. ... . . .. ...... . 
.. ... ...... . ... . . 
.. ... .... .. . . . . . 
.. . . ... .... ... . . . 
.. . ...... . . . ... . 
... . .. ..... . ... . . 
..... . .... .. ... . 
.. . .. .. ...... .. .. .. .. .. .. .. .. 
.. .. .. .... .. .. ...... .. .. .. .. .. .. 
.... .. .. .... ...... .. .. ...... .. .. .. 
.............................. .. 
-- : :::::: :::::::: :::::::::::::::::: o .... ... ... ..... . 
I 
PLACEBO 
n=8 
(95 % Confidence Lim its) 
(2.3-7.9) 
' :·:,:,:::·::··::::,::·:.::·::t 
.. ...... .... .... .. .... .. ...... .. 
.. .. .. .. ...... .... .. .. ........ .. 
.. .... .... .... .. .. ........ .. .. .. 
.. .................. .. .. .. .... .. 
.. .. .... ........ .............. .. 
.. .. .......................... .. 
.. ...... .. ................ .... .. 
.. .. ............ .. .. .. .. .. .... .. 
.. ............................ .. 
.. .... .. ........ .. ............ .. 
.. .............. .. ............ .. 
.. .. ........ .. ...... .. .. .... .. .. 
.. ...... .. .... .. .......... .. .. .. 
.. .............. .. ............ .. 
.. ...... ...... .... .. ...... .. .. .. 
.. ............................ .. 
.. ............................ .. 
................ .. ........ .. .. .. 
.. .. ........ .. ............ .... .. 
.. .... .. ...... .. .. .. ........ .. .. 
.. ...... .... .......... .. ...... .. 
.... .............. .. .......... .. 
................ .. .... .. ...... .. 
.... ........ .. .. .. .. .. ...... .. .. 
.. .......................... .. .. 
.... .......................... .. 
........ .. .................... .. 
........................ .. .... .. 
.. .. .... .. .. .. .. .... .. .. .. .... .. 
.. .. .......................... .. 
.. .. .... .... .. .. .......... .... .. 
........ .. .. .. ........ .. ...... .. 
.. .. .... ...... .... .. ...... .. .. .. 
(1.2-6.0) 
/ 
. ...... -:< .................. . . 
.. .... .. ........ .. ........ .. .. .. 
.. ...... .... ....... .. .. .. .. .. .. 
.. .......... .. ................ .. 
.. ...... .... ................ .. .. 
.. ......... .. ........ .... .... .. 
.. .......... .. .... .... ...... .. .. 
.. ............................ .. 
.. ........ .. ...... .. .......... .. 
.. ............................ .. 
.. ............................ .. 
.. ............ .. .............. .. 
.. ........................ .. .. .. 
.. .... .. .... .. ........ .... .... .. 
.. ............ .. ............ .. .. 
.. ............................ .. 
.. .......................... .. .. 
.. ........................... . 
.. ............. .. .. .. ........ .. 
.. ....................... .. 
.. ......................... .. .. 
.. ............................. .. 
.. ......................... .. 
.. .... .. .................. .. .. .. .. 
.. ........................... .. 
.. .. .. ........................ .. 
.. ...................... .... .. .. 
.. .... ...... .. ... .. .......... . 
.. ...... .. ........ .. ....... .. 
... .. ............ .... . .. ..... 
...... .. .... ........ .. ........ .. 
.. .. .... ...... .. .. .... .. .. .. .. .. 
.. .. .. .. ............ .. ........ .. 
---f:.:.:-:.:-:.:-:.:.:.:-:.:-:-:.:. 
.. .. .... .. .. .. .. ...... .... .. .. .. 
-----4:::}:::::::-:-:-:::::::::::::: 7 
I I 
AMILORIDE FRUSEMIDE 
102 
FIGURE 5.5 
The Effect of Amiloride and Frusemide on UNDW-Induced 
Bronchoconstriction in Asthmatics 
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5.4 DISCUSSION 
Using UNDW and UNCA aerosols to stimulate RARs, no apparent 
antitussive activity of the opiates, codeine and noscapine was found. 
Similar studies have found codeine (Rees & Clark, 1983; Cox et al., 1984), 
noscapine (Bickerman et al., 1957), pholcodine (Belcher & Rees, 1986) 
and dextromethorphan (Karttunen et al., 1987) to be effective in reducing 
citric acid-induced cough in normal subjects, although others have failed to 
obtain significant results (Empey et al., 1979). This discrepancy may lie in 
the specificity of the challenge. Citric acid used in previous studies has 
been hypertonic and lacking in chloride. This combination of hypertonicity, 
low pH and lack of chloride may have a disruptive effect upon the integrity 
of the epithelial lining (Erlij & Martinez-Palomo, 1972; Wade et al., 1973; 
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Ferreira & Hill, 1982), and such an intense stimulus may affect C-fibre 
nociceptors. Although the antitussive activity of opiates is thought to result 
from depression of the medullary cough centre, recent evidence suggests 
a possible site of action at peripheral opioid receptors on vagal sensory 
nerves where they may inhibit substance P release from C-fibres 
(Lembeck & Donnerer, 1985). This inhibitory effect of opiates on the 
release of sensory neuropeptides from airway C-fibres has also been 
observed by other workers (Frossard & Barnes, 1987; Belvisi et al., 1988; 
Belvisi et al., 1989; Rogers & Barnes, 1989). The lack of effect of codeine 
and noscapine on UNDW- and UNCA-induced cough supports a 
mechanism of action for opiates other than central inhibition as this would 
be expected to inhibit cough regardless of the afferent pathway. The 
observation that codeine inhibits capsaicin-induced cough (Fuller et al., 
1988) which may be mediated by C-fibres also supports a peripheral site 
of action. 
Capsaicin-induced cough was therefore included in the studies of 
nedocromil sodium, which together with UNDW and UNCA provided a 
comprehensive range of cough challenges. This study confirmed that 
differences in antitussive efficacy could be detected by using these various 
challenges. Whilst fenoterol only inhibited UNDW-induced cough, 
nedocromil inhibited both UNDW- and capsaicin-induced cough with 
neither drug significantly affecting UNCA-induced cough. The lack of effect 
of bronchodilators on capsaicin-induced cough has also been observed by 
other investigators (Smith et al., 1991). Thus all 3 challenges appear to be 
mediated by different mechanisms. As discussed above, the low pH of 
UNCA may be injurious to epithelium which could block the mechanism of 
antitussive action. The antitussive efficacy of nedocromil on both UNDW 
and capsaicin-induced cough suggests that it may have a direct inhibitory 
action on vagal sensory nerves including both C-fibres and RARs. Recent 
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reports suggest that nedocromil may inhibit C-fibres in guinea-pigs 
(Verleden et al., 1991) and in human subjects, S02-induced broncho-
constriction which may be mediated by C-fibres, is inhibited by nedocromil 
(Altounyan et al., 1986; Dixon et al., 1987). 
Despite the previous observations that marked bronchoconstriction 
can be associated with coughing (Section 4.6.1), UNDW-induced cough 
and bronchoconstriction in asthmatics are not related. UNDW induces a 
rapidly adapting cough response immediately on inhalation which is 
thought to be mediated by RARs. The bronchoconstrictor response follows 
inhalations of over 1 minute duration and increases with increasing doses 
of UNDW. This effect is thought to be mediated by the low osmolarity of 
water which may stimulate a sub-group of RARs and SARs 
(Sant'Ambrogio et a/., 1993). The antitussive action of frusemide (Section 
5.3.3) was not due to inhibition of bronchoconstriction since coughing was 
assessed during the first 30 second exposure prior to the 
bronchoconstrictor response. However, the relative potencies of am iloride 
and frusemide in inhibiting cough and bronchoconstriction were similar. 
The mechanism of the antitussive action of frusemide is unclear. 
Frusemide does not inhibit capsaicin-induced cough (Ventresca et a/., 
1990; Karlsson et al., 1992) suggesting that frusemide may have a direct 
inhibitory action on RARs. In support of this, Sant'Ambrogio et a/. (1993) 
found that frusemide inhibited the response of laryngeal RARs to low 
chloride solutions. If the low concentration of chloride in ASL results in loss 
of chloride from the nervous endings leading to depolarisation, then 
inhibition of chloride transport by frusemide could reduce this effect. 
Frusemide does not affect baseline activity of RARs (Sant'Ambrogio et aI., 
1993; Mohammed et al., 1992) but appears to only inhibit activity when the 
receptors are stimulated. The reason for the reduced efficacy of amiloride 
is unclear. Both amiloride and frusemide inhibited UNDW-induced 
105 
bronchoconstriction confirm ing previous reports (Robuschi et al., 1989). 
The mechanism for this inhibition of bronchoconstriction is unlikely to be a 
direct effect on airway smooth muscle since frusemide does not inhibit 
methacholine-induced bronchoconstriction (Nichol et al., 1990 b; Vaghi et 
al., 1988). Frusemide also has no effect on the stimulation of laryngeal 
SARs by water (Sant'Ambrogio et al., 1993) which is mediated by the low 
osmolarity. This could have been due to reduced access of frusemide to 
the SARs which are located deep in the airway wall. Alternatively, RARs in 
the intrapulmonary bronchi of dogs are responsive to alterations in 
osmolarity rather than low chloride concentrations (Pisarri et al., 1992). 
The inhibitory action of frusemide on these endings is not known. It is 
possible that these mediate UNDW-induced bronchoconstriction and that 
frusemide may inhibit these RAR endings. 
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CHAPTER 6: AFFERENT LUNG C-FIBRE STIMULANTS 
AND COUGH 
6.1 INTRODUCTION 
The afferent vagal innervation of the lungs involves three distinct 
groups of nerve fibres; RARs, SARs and C-fibres. Whilst these are 
morphologically distinct, the functional difference in terms of the relative 
sensitivity of their receptors to humoral and pharmacological stimuli is 
unclear. All types of vagal afferent nerves appear to be involved in the 
cough reflex. The RARs are, as previously discussed, an integral part of 
the cough reflex while SARs may facilitate cough since inhibition of SARs 
results in inhibition of RAR-mediated cough (SanfAmbrogio et al., 1984; 
Hanacek et al., 1984). Pulmonary and bronchial C-fibres may also cause 
coughing (Collier & Fuller, 1984). They are the most numerous of the 
afferent vagal nerves accounting for up to 80% of vagal afferent fibres in 
the cat (Jammes et aI, 1982). C-fibres contain a variety of sensory 
peptides including substance P which are released from afferent terminals 
by local axon reflexes (Barnes, 1986). 
The product of arachidonic acid metabolism, prostaglandin E2 
(PGE2) is also thought to stimulate C-fibre receptors (Coleridge et al., 
1976). In the skin (Ferreira, 1981), it can cause a long lasting 
hyperalgesia, i.e. a persistent lowering of polymodal nociceptor threshold 
to both mechanical and chemical stimulation which lasts several hours. 
This hyperalgesia of the skin also potentiates the response to capsaicin 
(Otsuka & Yanagisawa, 1987). By contrast, repeated application of 
capsaicin to the skin causes hypoalgesia or anaesthesia (Hayes et al., 
1984). It can also inhibit the production of PGE2 in the epithelium (Flynn et 
at., 1986). Both aerosols of capsaicin and PGE2 when inhaled by humans 
cause coughing (Collier & Fuller, 1984; Costello et al., 1985), but the 
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afferent nerves involved remain unconfirmed. Indeed, it has also been 
argued that stimulation of C-fibres can inhibit cough (Tatar et al., 1988). 
Part of the difficulty in interpreting experimental data is the knowledge that 
whilst C-fibres appear particularly sensitive to substances such as 
capsaicin, RARs may also be stimulated by these agents (Tatar et al., 
1988; Karlsson et al., 1988). 
The aims of the following studies were to characterise the cough 
responses to the two putative C-fibre stimulants, capsaicin and PGE2. 
6.2 METHODS 
6.2.1 Cough Responses To Inhaled Capsaicin And Prostaglandin E2 
Twelve healthy volunteers (3 males and 9 females, age range 19 -
59 yrs) performed dose response studies to inhaled PGE2. Initial studies 
revealed that the cough response was subject to marked and prolonged 
tachyphylaxis and therefore challenges were performed on separate days. 
PGE2 (Prostin E2, Upjohn Ltd., Crawley, West Sussex, UK) was diluted in 
isotonic saline and administered in random order from the Bronchoscreen 
in a ratio of 1:5 with placebo (isotonic saline) for 18 breaths i.e. a total of 3 
doses of active stimulant being inhaled, in concentrations ranging from 
0.028 to 28 Ilmoi/i. Cough frequency was recorded over each 18 breath 
challenge. 
Dose response studies for capsaicin were performed as above by 
10 of the subjects. Capsaicin was dissolved in ethanol and diluted in 
isotonic saline and then inhaled in increasing concentrations of 1, 2 and 5 
Ilmol/l at 5 minute intervals until greater than 10 coughs occurred during a 
single challenge. 
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6.2.2 Adaptation And Cross-Adaptation Of Cough 
The aims of this study were to determine whether the stimulants 
UNDW, capsaicin and PGE2 act on the same afferent pathways by 
determining the adaptation and cross-adaptation of cough in response to 
these agents. Adaptation of reflex activity occurs when repetition of 
sensory stimuli induces a lowering of the frequency of impulses and this 
response is also known as tachyphylaxis. By contrast, cross-adaptation 
occurs between 2 or more stimuli when a common afferent pathway is 
involved. 
Five healthy volunteers (1 male and 4 females, age range 19 -59 
yrs, mean FEV1 = 145% of predicted) were studied. All subjects had 
previously performed baseline dose response curves in Experiment 6.2.1 
for PGE2 and capsaicin to determine a dose causing greater than 10 
coughs. A baseline challenge to UNDW was also performed. An 
ultrasonic nebulizer had to be used for this challenge as coughing does 
not occur when water is inhaled from a jet nebulizer (See Section 3.3.6). 
Subjects then attended the laboratory on 9 separate days at the 
same time of day. On each visit, subjects received 3 challenges; the first 
was followed 5 minutes later by a second challenge which was then 
repeated 3 hours after the first challenge. Challenge 1 consisted of 
inhalation of one of the 3 stimulants UNDW, capsaicin or PGE2 
administered in random order and on 3 occasions. Challenges 2 and 3 
consisted again of one of the 3 stimulants, thus each stimulant was 
followed by itself and the other 2 stimulants so giving the 9 possible 
combinations. 
Cough frequency was recorded as the total number of coughs 
during a challenge. This total was also divided into the number of coughs 
occurring during 3 equal and consecutive periods of the challenge, i.e. for 
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capsaicin and PGE2, the number of coughs following each of the 3 active 
breaths and for UNDW, the number of coughs during each 20 second 
period of challenge. This allowed assessment of any adaptation of cough 
occurring immediately during the challenge. 
Raw, which was measured breath by breath during both air and 
challenge breathing from the Bronchoscreen was recorded as the average 
of the final 5 measurements from 1 minute air breathing pre- and post-
challenge and during challenge with capsaicin and PGE2. 
6.2.3 The Antitussive Efficacy Of Nedocromil Sodium 
To determine whether the choice of stimulus as well as the method 
of aerosol delivery are important variants when testing antitussives, the 
efficacy of nedocromil sodium, which inhibited UNDW-induced cough and 
jet nebulized capsaicin-induced cough, has been studied on cough 
induced by capsaicin and PGE2 delivered by ultrasonic and jet nebulizers. 
Sixteen healthy volunteers (6 males and 10 females, age range 19-
59, mean FEV 1 = 113%, range 85-133%) were recruited, 8 to each trial. 
Trial 1 used ultrasonically nebulized stimuli, while trial 2 used the 
Bronchoscreen. For trial 1, 0.4 JlmolJI capsaicin and 1.4 JlmolJI PGE2 were 
used which elicited greater than 10 coughs for all subjects. For trial 2, 
subjects had previously performed dose response curves for capsaicin 
and PGE2 and concentrations causing greater than 10 coughs were used. 
On each of 4 visits, nedocromil sodium 4 mg (2 x 2 mgJpuff) or 
placebo (2 puffs) were administered 30 minutes prior to challenge with 
either capsaicin or PGE2. Treatment and challenge were randomised by 2 
Latin squares of order 4. Cough frequency during each challenge and 
during the 5 minutes following ultrasonic challenge was recorded. FEV1 
was recorded pre- and post-treatment and post-ultrasonic challenge. Raw 
was recorded pre- and post- treatment and during jet challenge. 
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6.3 RESULTS AND STATISTICAL ANALYSIS 
6.3.1 Cough Responses to Capsaicin and Prostaglandin E2 
The cough response to PGE2 was found to exhibit marked 
adaptation (tachyphylaxis) requiring the different concentrations to be 
inhaled on separate days. Some coughing following challenge was also 
noted confirming the observations of Costello et al. (1985). Capsaicin 
produced a steeper gradient of dose response curve and did not produce 
cough following inhalation. Both challenges were however associated with 
transient retrosternal soreness. The dose response curves are presented 
in Figure 6.1. 
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6.3.2 Adaptation and Cross-Adaptation of Cough 
ANOVA was first performed on the transformed baseline 
(Challenge 1) cough frequencies to assess repeatability of the 
measurements and comparability of the 3 challenges. This found no 
differences between stimulants (p>O.05) or days of challenge (p>O.05) as 
presented in Figure 6.2. 
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Subsequent analyses examined carryover effects from one 
challenge to the next and within challenges and revealed significant 
carryover effects from one challenge to the next (p<0.01). Examining this 
further found no difference in the cough response from Challenge 1 
(baseline) and Challenge 3 (3 hours) (p>0.05) but significant carryover 
effects were found from Challenge 1 to Challenge 2 (5 minutes) (p<O.01). 
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Adaptation of cough from Challenge 1 to Challenge 2 occurred with 
both UNDW (p<0.001) and PGE2 (p<0.001) but not with capsaicin 
(p>0.05) as presented in Figure 6.3. Cross-adaptation of cough occurred 
after PGE2 which inhibited subsequent cough at 5 minutes to UNDW 
(p<0.001) as presented in Figure 6.4. Back-transformed mean cough 
frequencies and 95% confidence limits are shown in Table 6.1. 
TABLE 6.1 
Adaptation and Cross-Adaptation of Cough 
MCF (95% Cl) (coughs/m inute) 
Challenge 
1 ~ BASELINE 5 MIN 3 HRS 
UNDW UNDW 27.0 (19.6-35.5) 8.3 (1.3-13.5) 25.5 (18.3-33.8) 
PGE2 PGE2 16.7 (10.9-23.6) 3.1 (0.6-6.7) 10.6 (6.1-16.3) 
CAPS CAPS 16.2 (10.5-23.1) 16.3 (10.6-23.2) 18.0 (12.0-25.1) 
UNDW PGE2 24.6 (17.5-32.8) 21.2 (14.6-28.8) 17.7 (11.7-24.7) 
UNDW CAPS 21.2 (14.7-28.9) 9.9 (5.5-15.5) 18.6 (12.5-25.9) 
PGE2 UNDW 19.9 (13.6-27.3) 6.3 (2.8-10.9) 23.1 (16.2-31.0) 
PGE2 CAPS 16.6 (10.8-23.5) 11.7 (6.9-17.7) 18.5 (12.4-25.7) 
CAPS UNDW 17.1 (11.2-24.0) 20.5 (14.0-28.0) 23.3 (16.4-31.3) 
CAPS PGE2 14.1 (8.8-20.6) 20.7 (14.3-28.3) 19.7 (13.4-27.1) 
To assess any immediate adaptation of coughing during a 
challenge, ANOVA was performed on the data obtained by dividing the 
cough frequencies to Challenge 1 into 3 equal and successive time 
periods. This showed a significant difference between periods (p<0.05) 
and an interaction between challenge and periods (p<0.01) which 
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suggests that not all challenges adapted in the same way. Further analysis 
revealed that adaptation of cough during baseline challenges occurred 
with UNDW (p<O.001) and with PGE2 (p<O.OS), but the cough response to 
capsaicin increased from period 1 to 2 (p<O.001) as presented in Figure 
6.S. 
Values of Raw were log transformed prior to ANOVA which 
compared values pre- and post-challenges and pre- and during challenge 
(excluding UNDW). ANOVA revealed no difference between pre- and 
post- challenge measurements (p>O.OS). However, Raw, increased slightly 
during the first challenge with both PGE2 and capsaicin compared with 
pre-challenge values (p<O.OS). This airway constriction was reduced when 
the stimuli were given at Challenges 2 and 3 (p>O.OS) as presented in 
Figure 6.6. 
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FIGURE 6.3 
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FIGURE 6.4 
Cross-Adaptation of Cough 
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FIGURE 6.5 
Adaptation of Cough During Baseline Challenge 
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6.3.3 The Antitussive Efficacy of Nedocromil Sodium 
ANOV A of transformed cough frequencies revealed no effect of 
nedocromil sodium on PGE2-induced cough delivered by ultrasonic or jet 
nebulizer (p>0.05). However, nedocromil sodium inhibited capsaicin-
induced cough delivered by the jet nebulizer Bronchoscreen (p<0.02) but 
not by ultrasonic nebulizer (p>0.05). Adaptation of cough was assessed by 
breaking down cough frequencies into 3 equal and successive periods of 
challenge. This revealed adaptation of cough with PGE2 regardless of the 
delivery system (p<0.01), but adaptation of capsaicin-induced cough only 
occurred when delivered from the ultrasonic nebulizer (p<0.01). Cough 
recorded over the 5 minutes following ultrasonic challenge was higher 
after PGE2 than capsaicin (p<0.01). FEV1 did not alter with treatment or 
ultrasonic challenge (p>0.05). However, analysis of log transformed Raw 
data revealed an increase during challenge (p<0.01) which was 
independent of treatment or challenge stimulus. 
TABLE 6.2 
The Antitussive Effect of Nedocromil Sodium 
MCF (95% Cl) (coughs/minute) 
Ultrasonic Nebulizer 
PGE2 Placebo 12.6 (6.5-20.4) 
Nedocrom il 12.1 (6.2-19.9) 
CAPSAICI N Placebo 15.9 (9.1-24.6) 
Nedocromil 19.6 (11.9-29.0) 
Jet Nebulizer 
11 .7 (9.3-1 4.4 ) 
10.3 (8.0-12.9) 
15.0 (12.2-18.0) 
10.2 (7.9 -12.8) 
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FIGURE 6.7 
The Effect of Nedocromil on Ultrasonic Challenge 
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FIGURE 6.8 
The Effect of Nedocromil on Jet Challenge 
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FIGURE 6.9 
Adaptation of Cough During Ultrasonic Challenge 
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FIGURE 6.10 
Adaptation of Cough During Jet Challenge 
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FIGURE 6.11 
Change in Raw During Jet Challenge 
1.6 ~ PGE2 SE = 0.022 
0 Capsaicin ,q n=8 
Placebo \ 1.55 
---. 
- - Nedocromil \ en 
.......... 
co 
a.. 
.:::t:. 
.......... 1.5 ~ 
ell 
a: 
0> 
0 
....J 1.45 
1.4~----~------~----~----------~ 
Baseline Post Challenge Post 
Treatment Challenge 
6.4 DISCUSSION 
Inhalation of UNDW, PGE2 and capsaicin appear to evoke cough 
by different mechanisms. UNDW-induced cough exhibited a rapid 
adaptation which recovered within 3 hours, consistent with an effect on 
RARs. No effect on the cough response to capsaicin or PGE2 following 
UNDW was observed. 
Capsaicin-induced cough, however, did not exhibit adaptation of 
response when delivered by the Bronchoscreen or cross-adaptation with 
either of the other 2 challenges suggesting mediation by a different 
receptor. It has been suggested that capsaicin has dual actions depending 
on the dose administered. Low doses of capsaicin stimulate C-fibre 
receptors while high doses may stimulate RARs (Karlsson et al., 1988; 
Tatar et aI, 1988). This dual action of capsaicin has been observed by 
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other workers. Hua & Lundberg, (1986), found that low doses inhibited 
guinea-pig ureter motility which was mediated by calcitonin gene related 
peptide while high doses stimulated motility and this was effected by 
tachykinins. Inhalation of capsaicin in humans produces a small transient 
bronchoconstriction (Collier & Fuller, 1984) which could reflect a laryngeal 
response rather than airway smooth muscle bronchoconstriction, but in 
certain circumstances, for example, in heart-lung transplant patients, 
capsaicin can initiate a bronchodilator reflex (Lammers et aI, 1989; 
Hathaway et aI, 1993). Capsaicin-induced cough may be related to the 
tachykinin release at sensory C-fibre endings as cough is augmented by 
the angiotensin converting enzyme inhibitor, captopril (Morice et aI, 1987) 
and by neutral endopeptidase inhibitors (Kohrogi et aI, 1988) which delay 
the breakdown of tachykinins released into the airways by C-fibre 
stimulation. The nature of tachykinins released appears to depend on the 
dose of capsaicin administered and these in turn determine the effect on 
target cells (Lundberg et aI, 1985). 
PGE2-induced cough, unlike capsaicin, exhibited rapid adaptation, 
similar to UNDW-induced cough, but which had not fully recovered after 3 
hours. PGE2 inhibited subsequent UNDW-induced cough, but not vice 
versa, disproving a common receptor. However, UNDW was administered 
from a different nebulizer than PGE2 and capsaicin, and despite evoking 
comparable cough frequencies during baseline challenges, may have 
resulted in a different pattern of aerosol deposition. 
The different characteristics of cough induced by capsaicin and 
PGE2 oppose the view that both stimulate the same C-fibres. It is possible 
that PGE2 and capsaicin stimulate functionally distinct sub-groups of C-
fibres. The afferent innervation of the lower respiratory tract appears to 
resemble that of the skin (Coleridge & Coleridge, 1985). Cutaneous C-
fibres can be classified into four major groups according to their response 
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profiles; warm and cold thermoreceptors, mechanoreceptors and 
polymodal nociceptors. Polymodal nociceptors account for 80% of afferent 
nerve fibres from rat skin (Lynn & Hunt, 1984). Nociceptors can be further 
sub-divided. One sub-group, for example, responds to itching powder 
(cowhage) (Tuckett, 1980). In addition, 15-30% of cutaneous C-fibres 
contain neuropeptide tachykinins such as substance P (Hokfelt et aI, 
1976) which is released at sensory nerve endings, experimentally, by 
capsaicin. A similar functional heterogeneity of pulmonary C-fibres may 
exist. Indeed, phenyldiguanide, another C-fibre stimulant appears to act on 
a different population of airway C-fibres than capsaicin (Skofitsch et aI, 
1983). 
No potentiation of cough, suggesting a hyperalgesic effect, was 
found with any of the cough stimuli used in contrast to other studies which 
have found a small potentiation of capsaicin-induced cough after PGF2a 
(Nichol et aI, 1990 a) and PGE2 (Choudry et aI, 1989). Indeed, PGE2 
inhibited water-induced cough suggesting an inhibitory effect on RARs. 
Thus all three stimuli evoke cough by different mechanisms. 
Capsaicin and PGE2, once thought of as specific C-fibre stimulants, may 
selectively stimulate sub-populations of vagal airway C-fibre receptors. 
The differential effects of nedocromil sodium on capsaicin and 
PGE2-induced cough also supports different mediation of cough. 
Nedocromil inhibited capsaicin- but not PGE2-induced cough. However, 
this effect was only apparent when the stimulus was delivered by jet 
nebulizer and not by ultrasonic nebulizer. Also, adaptation of capsaicin-
induced cough only occurred during continuous challenge with the 
ultrasonic nebulizer but not with the dosimeter. PGE2, however, exhibited 
adaptation during challenge from both nebulizers. The inhibitory effect of 
nedocrom il on UNDW- and jet-nebulized capsaicin suggests that 
123 
nedocromil may inhibit RARs and a sub-population of capsaicin-sensitive 
C-fibres located in the intrapulmonary airways. 
In conclusion, capsaicin and PGE2 evoke cough by different 
mechanisms which are distinct from UNDW-induced cough. Differences 
between stimuli can be detected by studying their differential responses to 
adaptation and antitussives and this may also be influenced by the mode 
of aerosol delivery which can affect deposition. This variability may need 
to be taken into account when assessing the clinical application of 
antitussives based on efficacy studies using induced cough. 
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CHAPTER 7: THE EFFECT OF BRONCHODILATOR 
THERAPY ON COUGH ASSOCIATED WITH VIRAL 
INFECTION 
7.1 INTRODUCTION 
Cough is a common symptom of upper respiratory tract infection 
(URTI), often developing within a few days of the initial symptoms and 
sometimes lasting for several weeks or even months after infection. When 
cough is troublesome, serving no useful function and when no effective 
treatment for the underlying disease exists, symptomatic treatment is 
indicated. The need for such treatment of URTI-associated cough is 
apparent from the wide range of medications available over-the-counter 
and by prescription and from the fact that cough may be responsible for up 
to 50% of visits by patients to their General Practitioner during the winter 
months (Korpas & Tomori, 1979). However, an effective symptomatic 
treatment for cough associated with URTI has yet to be identified. Many 
therapies contain no known antitussives and act simply as demulcents; 
others contain doses of antitussives too low to be effective. However, 
objective studies in volunteers with URTI have demonstrated antitussive 
activity of an antihistamine-decongestant therapy (Curley et al., 1988) and 
a dextromethorphan-beta2-agonist combination (Tukiainen et a/., 1986), 
but not of the expectorant guaifenesin (Kuhn et al., 1982) or of the 
commonly prescribed opiate, codeine (Eccles et al., 1992). 
As URTI is associated with a transient bronchial hyper-
responsiveness In non-asthmatics (Empey et al., 1976) and as 
bronchodilators inhibit cough in asthma (Ellul-Micallef, 1983), a possible 
role of bronchodilators in treating cough during URTI is implied. 
The aim of the following study was to evaluate the role of 
oxitropium bromide, an anticholinergic bronchodilator, in the management 
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of those who acquired a community based URTI including cough during 
the winter season. Oxitropium bromide inhibits UNDW-induced cough 
(See Section 4.4.2(c)) and therefore this study was also designed to 
ascertain the relationship between induced cough and naturally occurring 
cough. 
7.2 METHODS 
Fifty-six non-asthmatic volunteers (age range 18 - 60 years) from 
hospital staff entered the study, 2 of whom withdrew before completion of 
the study. The study design was randomised, double-blind, parallel group 
and placebo-controlled. 
Volunteers were asked to attend the laboratory as soon as possible 
after onset of the symptom of cough and not later than 72 hours. 
Volunteers who had a cough and at least 2 other symptoms of URTI 
undertook a cough challenge consisting of a one minute inhalation of 
UNDW during which cough frequency was recorded. Nine volunteers were 
unable to complete the challenge because of the severity of their cough, 
and in these cases, the duration of UNDW inhalation was recorded for use 
during the second visit. FEV1, FVC and PEFR were recorded. Subjects 
were then randomly assigned to treatment with either oxitropium bromide 
(200 fl9) or identical placebo aerosols delivered by metered dose inhalers. 
They were also provided with a mini-Wright peak flow meter to record 
PEFR at home and a diary card. All volunteers were trained in the use of 
the inhaler and peak flow meter. The trial treatment was taken 8-hourly 
after recording PEFR (best of 3 attempts) at approximately 7am, 3pm and 
11 pm for 10 days. Frequency of cough, severity of cough, nocturnal 
symptoms and general malaise were assessed using 5cm Visual 
Analogue Scales (VAS) in the diary card at the end of each day. After the 
10 day period, subjects returned to the laboratory for repeat tests. No 
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treatment was taken on the day of this 2nd visit to allow comparison of 
measurements with those from Visit 1. 
7.3 STATISTICAL ANALYSIS 
ANOV A was performed to assess the changes in FEV 1, FVC and 
PEFR data collected during Visits 1 and 2. 
The diary PEFR data were analysed by fitting 3 regression lines (for 
7am, 3pm and 11 pm) for each subject and the mean slopes and intercepts 
analysed using ANOV A. The slope represented the change over the 10 
day period and the intercept (fitted across the middle of the treatment 
period) the average over the 10 day period. The factors fitted were drug, 
subject, time of day and the interaction between time of day and drug. 
Cough frequencies, in response to UNDW, obtained during Visits 1 
and 2, were transformed as previously described to the square-root prior 
to ANOVA. Where a full minute challenge was not completed, the number 
of seconds of challenge was recorded and used for the 2nd challenge. 
Non-parametric summary statistics of median and 25th and 75th 
percentiles were produced for the VAS scores. 
7.4 RESULTS 
The principal raw data and ANOVA tables for this study are 
presented in Appendix 5. 
Fifty-four completed records were collected for analysis. The 
subjects within each of the two groups, placebo (28 subjects) and 
oxitropium (26 subjects), were comparable for age (mean placebo = 31 yrs; 
oxitropium = 30yrs) and sex (8 of 15 males and 18 of 39 females were 
assigned oxitropium). Seven of 12 smokers and 4 of 9 ex-smokers were 
assigned oxitropium. Baseline measurements of lung function (Table 7.1), 
VAS scores (Table 7.2) and UNDW-induced cough frequency (Table 7.3) 
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taken at Visit 1 were also comparable. Mean predicted PEFR was 480 
11m in for both groups. 
TABLE 7.1 
The Change In Lung Function During URTI And The Effect Of 
Treatment 
FEV1 (I) 
FVC (I) 
PEFR 
(I/min) 
PLACEBO (n = 28) OXITROPIUM (n = 26) 
Visit 1 Visit 2 Visit 1 Visit 2 
3.8 (0.13) 3.8 (0.14) 3.7 (0.18) 3.7 (0.18) 
4.5 (0.16) 4.5 (0.17) 4.3 (0.22) 4.3 (0.22) 
480 (16) 500 (14) 460 (17) 490 (16) 
Values are the mean (with standard error) 
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TABLE 7.2 
The Change In VAS Scores From Baseline To Recovery Visit 
PLACEBO (n = 28) OXITROPIUM (n = 26) 
Visit 1 Visit 2 Visit 1 Visit 2 
Cough frequency 24 1 24 4 
Cough severity 24 1 26 1 
Nocturnal symptoms 5 o 9 o 
General malaise 25 3 24 2 
Values are median scores based on a scale of 0 to 50. 
TABLE 7.3 
The Change In Cough Response To UNDW Inhalation 
MCF (95% Cl) 
PLACEBO (n = 28) OXITROPIUM (n = 26) 
VISIT 1 20.4 (17.1 - 24.1) 22.0 (18.0 - 26.4) 
VISIT 2 12.3 ( 9.7 - 15.2) 12.4 ( 9.4 - 15.8) 
FEV1 and FVC did not alter during the trial from Visits 1 to 2 and 
there was no statistically significant difference between placebo and 
oxitropium groups (p>0.05) but PEFR improved by an overall mean of 23 
I/min, (SE 5.5 I/min) from Visit 1 to 2 (p<0.05). This increase occurred 
regardless of treatment. 
PEFR data from the subject diaries revealed an overall 
improvement over the 10 days of study. In addition, ANOVA revealed that 
values were on average, highest in the afternoon and lowest on waking 
(p<0.001) similar to a 'morning dip' usually found in asthma. The average 
variation between morning and afternoon recordings with 95% confidence 
limits was 15.0 I/min (7.9, 22.0). There was no treatment with time 
interaction in the ANOVA suggesting that treatment with oxitropium did not 
differ from placebo in respect of this circadian rhythm (p>0.05). The PEFR 
data is represented graphically in Figure 7.1. 
VAS scores of frequency of cough, severity of cough, nocturnal 
symptoms and general malaise became less severe over the 10 day 
treatment period as shown in Figure 7.2 but again, oxitropium fared no 
better than placebo. 
The cough response to UNDW was similar for both the placebo and 
oxitropium groups. A similar reduction in cough frequency occurred in both 
groups from Visit 1 to 2 (p<0.001) as shown in Table 7.2 which probably 
reflects the combination of a learning effect on cough which occurs after 
the first challenge (See Section 4.2.2 (c)) and amelioration of symptoms. 
The 1 0 day treatment regime with oxitropium did not alter the sensitivity of 
the cough reflex to a greater extent than placebo. Treatment was not given 
on the day of the challenge so no comparison can be made with our 
previous study (See Section 4.4.2 (c)) where a single dose of oxitropium 
administered 1 hour before challenge inhibited water-induced coughing. 
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FIGURE 7.1 The Diary Recordings of PEFR 
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The median VAS score recorded daily on a scale from 0 to 50. The 
higher the score, the more severe the symptom was. Although the scores 
decrease over the study, oxitropium failed to enhance the improvement. 
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7.5 DISCUSSION 
This study describes the daily time-course of cough and pulmonary 
function (as measured by PEFR) associated with an upper respiratory 
tract infection in a large sample of otherwise healthy volunteers. Although 
cough improved steadily over the 10 days of study as expected, treatment 
with oxitropium bromide failed to enhance the reduction in either the 
frequency or severity of cough. A similar study also found no effect on 
cough during URTI with another anticholinergic therapy, ipratropium 
bromide (Salzman et al., 1990). This lack of effect of oxitropium on 
naturally occurring cough differs from the study of UNDW-induced cough, 
where oxitropium was highly effective in inhibiting cough in healthy and 
asthmatic volunteers (Section 4.4.2 (c) & 4.4.4 (b)). The reason for this 
may be that different afferent pathways are involved in cough induced by 
UNDW and URTI or that the mechanism of bronchodilator inhibition of 
UNDW-induced cough in ineffective against URTI-associated cough. 
Whilst UNDW-induced cough is thought to be mediated by 'low 
chloride' stimulation of RARs, the stimulus for URTI-induced cough may 
be mechanical deformation of the airway epithelium by mucus or 
postnasal drip (Curley et al., 1988) and/or exposure and sensitisation of 
RARs as a result of epithelial damage (Empey et al., 1976). This could 
lead to a transient mild airway hyperreactivity (Empey et al., 1976; Hall & 
Hall, 1979). This study found that PEFR appeared to be reduced during 
infection, with a clinically small but statistically significant diurnal variation. 
This could reflect hyperresponsiveness, although the overall increase in 
PEFR over the treatment period may be due to a learning effect on the 
measurement. The fact that oxitropium, a long-acting bronchodilator, failed 
to affect PEFR, supports this view. An alternative explanation, is that a 
reduction in PEFR without a corresponding decrease in FEV1 may 
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suggest an extra-thoracic airway obstruction, which has been previously 
observed during URTI (Curley et al., 1988), and this would not be 
expected to respond to bronchodilator therapy. 
However, recent theories of cough and hyperresponsiveness during 
URTI have focused on the possible decreased degradation of sensory 
neuropeptides during URTI (Borson et al., 1989; Jacoby et al., 1988). 
Levels of neutral endopeptidase (NEP), which degrades neuropeptides 
can be reduced by 40% in the airway mucosa during experimental viral 
infections (Dusser et al., 1989) and inhibitors of endopeptidase potentiate 
coughing in response to capsaicin (Kohrogi et al., 1988). Similarly, viral 
infection appears to enhance airway responses to substance P and 
capsaicin (Dusser et al., 1989). These results suggest that cough 
associated with URTI may be due to stimulation of unmyelinated C-fibre 
afferents, rather than RARs by increasing the levels of sensory 
neuropeptides in the airways. This would explain the lack of effect of 
oxitropium on cough associated with URTI since bronchodilators appear to 
inhibit cough mediated by RARs but not by C-fibres (Section 5.3.2). 
An alternative explanation for the difference in UNDW- and URTI-
induced cough is that exposure and sensitisation of RARs during URTI 
may mask an inhibitory action of bronchodilators. A topical effect of 
bronchodilators on airway epithelium inhibiting access to paracellular 
RARs through the 'tight' junctions would be ineffective in the presence of 
epithelial damage. 
This study demonstrates that antitussive efficacy demonstrated 
using induced cough studies may not be indicative of efficacy against 
naturally occurring cough. 
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CHAPTER 8: DISCUSSION 
The use of 'low chloride' aerosols such as UNDW to evoke cough 
represents a novel method of studying the human cough reflex in vivo. 
The cough response is prone, however, to intersubject variation, with 
cough being evoked in approximately 80% of subjects. The reason for this 
variation may lie within the central control mechanisms which may modify 
cough (Banner, 1988). A small learning effect on cough frequency after 
subjects are first exposed to the stimulus may also occur but thereafter 
cough appears to be reproducible within subjects between challenges 
performed on separate days. Adaptation of cough occurs during a one 
minute challenge which can reduce the response to successive 
challenges. These findings have implications for the design of studies 
investigating alterations in cough response. The intersubject variation 
suggests the use of crossover rather than parallel group trials to identify 
differences within subjects, while the possibility of a learning effect 
warrants the use of 'trained' subjects. The adaptation of cough that occurs 
suggests the use of a single challenge to evoke cough rather than 
performing dose response challenges and that the treatments be 
administered on separate days. The use of similarly designed protocols in 
this thesis has demonstrated that the model is capable of identifying 
antitussive activity of drugs compared with placebo. 
The model has also been used successfully to investigate the 
afferent pathway of cough and has found that UNDW-induced cough 
results from the lack of chloride rather than the low osmolarity of water. 
Extremes of pH and marked hyperosmolarity of inhaled aerosols were 
further stimuli for cough provocation. The rapid adaptation of UNDW-
induced cough implies an involvement of RARs. while the preferential 
induction of cough with large particle aerosols suggests that these RARs 
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are located primarily within the central airways. A comparison of these 
results with animal studies (described in detail in Section 3.4), in particular, 
the apnoeic reflex in neonatal puppies (Boggs & Bartlett, 1982), suggests 
that a group of RARs responsive primarily to a low chloride concentration 
of the ASL may exist within human large airway epithelium which mediate 
cough. 
On the other hand, the bronchoconstrictor response to UNDW in 
asthmatics is thought to result from the low osmolarity (Schoeffel et al., 
1981; Eschenbacher et al., 1984) and may be mediated by another sub-
group of RARs or C-fibres that are sensitive to changes in osmolarity of 
the ASL (Sant'Ambrogio et al., 1991; Pisarri et al., 1992). Marked 
bronchoconstriction induced by L TD4 (Section 4.6) appears to be 
associated with coughing possibly by mechanical distortion of the airway 
epithelium. Histamine is reported to stimulate RARs in this way (Mills et 
al., 1969) but may also have an additional direct effect on RARs (Vidruk et 
al., 1977). Thus RAR-mediated cough appears to be induced by two 
mechanisms, direct stimulation of RARs and indirectly through marked 
bronchoconstriction. 
Despite the fact that UNDW is not associated with 
bronchoconstriction in normal subjects, inhaled bronchodilators were 
remarkably effective at inhibiting UNDW-induced cough. That their effect 
was independent of the small degree of bronchodilation achieved in both 
healthy and asthmatic volunteers, suggests that their antitussive efficacy is 
independent of their action on airway smooth muscle. A comparison of 
bronchodilators on cough induced by other stimuli (citriC acid, capsaicin 
and URTI), however, failed to corroborate their antitussive efficacy. This 
suggests that antitussive activity may be stimulus dependent and may 
explain the variable efficacy of antitussives on induced cough observed by 
other investigators described previously. The specificity of bronchodilators 
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for UNDW-induced cough implies that their mechanism of action is 
dependent on the mechanism of cough induction with UNDW, i.e. the low 
concentration of chloride in the ASL. The protective effect of 
bronchodilators on 'low chloride' sensitive RARs could result from a 
reduced permeability of the paracellular spaces where the RARs are 
located or from a direct inhibitory action on RARs. Although there is little 
evidence to support a direct inhibition of RARs, inhibition of ion co-
transport in afferent nerves has been suggested as a possible mechanism 
of action for frusemide (SanfAmbrogio et al., 1993), which also inhibits 
UNDW-induced cough. A reduction in the permeability of the paracellular 
spaces could be ineffective against citric acid and URTI associated cough 
where disruption of the epithelium may occur. However, against this 
hypothesis is the observation that the inhibition of UNDW-induced cough 
by bronchodilators was still apparent in mild asthmatics, where the 
epithelium may be damaged (Laitinen, 1985). Thus, it is possible that 
these stimuli may induce cough by mechanisms other than this group of 
RARs. Capsaicin and PGE2-induced cough certainly differs from that 
induced by UNDW, being independent of the chloride concentration and 
may be mediated by C-fibres. Although the precise location of C-fibres is 
not known, they may also lie within the paracellular spaces and would also 
be expected to be inhibited by a reduced paracellular pathway. 
Differential antitussive activity was also observed with nedocromil 
sodium which inhibited cough induced by UNDW and capsaicin but not by 
citric acid or PGE2. This suggests that in addition to the proposed 
inhibition of capsaicin-sensitive C-fibres (Barnes, 1993), nedocromil may 
also inhibit 'low chloride' RARs. Further differences between the cough 
responses induced by these various stimuli were identified by studying 
their properties of adaptation and cross-adaptation. UNDW and PGE2 but 
not capsaicin, exhibited a rapid adaptation of cough and PGE2 inhibited 
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the subsequent cough response to UNDW. The lack of cross-adaptation 
suggests that all 3 stimuli evoke cough via distinct afferent pathways. The 
differential responses of capsaicin and PGE2 to adaptation and 
antitussives may reflect selectivity to sub-groups of C-fibres. 
A surprising finding in this thesis was the lack of effect of codeine 
on induced cough. This suggests that the mechanism of antitussive action 
of opiates is not central, but rather peripheral, perhaps inhibiting C-fibres 
which would explain their inhibition of capsaicin-induced cough (Fuller et 
al., 1988). This aspect requires further investigation. 
The use of induced cough provides an important tool with which to 
study the mechanisms of cough induction and suppression. A wide range 
of stimuli are now being used by several investigators to induce cough 
including citric, acetic and tartaric acids, capsaicin and prostaglandins 
(Fujimura et al., 1992 a & b; Hansson et al., 1988; Choudry et al., 1989). 
However, the lack of correlation of the antitussive efficacy of 
bronchodilators between UNDW-induced cough and cough associated 
with URTI (Section 7.4) suggests that the clinical relevance of antitussive 
studies using induced cough may not be applicable in all cases. The 
significance of this is illustrated by the fact that the Food and Drug 
Adm inistration in the USA accept data from such studies of induced 
cough, in addition to clinical trials, as supportive evidence for antitussive 
registration (Food & Drug Administration, 1976). Capsaicin-induced cough, 
which is resistant to many agents that are also clinically ineffective as 
antitussives (Fuller, 1991) may be more representative of pathological 
cough than UNDW. Although the stimuli for pathological cough are not 
known, release of neuropeptides which mediate neurogenic inflammation 
by antidromic stimulation of nonadrenergic, noncholinergic nerves, may be 
involved. These neuropeptides include substance P and are degraded by 
an enzyme, neutral endopeptidase (enkephalinase) (NEP) which is 
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present within airway epithelium where it may correspond to the putative 
'epithelium relaxant factor' and may also be present within vagal afferent 
nerves (Nadel, 1991). URTI exaggerates neurogenic inflammation and is 
associated with reduced levels of NEP (Jacoby et al., 1988; Dusser et al., 
1989). Furthermore, NEP inhibitors have been found to potentiate 
capsaicin-induced cough in guinea-pigs (Kohrogi et aI., 1988). This 
suggests that the cough associated with inflammatory processes may be 
mediated by neuropeptides and requires further investigation. 
Since the optimum site of action for antitussives probably lies within 
the afferent limb of the cough reflex, the possibility of delivering 
peripherally acting antitussives direct to the cough sensitive airways 
should also be considered. Treatments for asthma have for many years 
been administered by inhalation to maximise their effectiveness and 
minimise systemic effects. Such principles can also be applied to the 
treatment of cough. 
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APPENDIX 1 - Characterisation Of The Cough Reflex 
Raw Data And Anova Tables 
3.3.1 Chemical Sensitivity: 
Raw Data Table 
Cough Frequencies (coughs/min) 
Urea UNDW Sodium D-Glucose Sodium Sodium 
Acetate Bicarbonate Chloride 
1 10 6 7 7 0 0 
7 14 1 1 6 6 0 
2 1 1 12 22 18 17 0 
16 15 20 16 17 0 
3 5 14 17 1 1 2 0 
3 5 7 6 3 0 
4 21 16 7 18 8 0 
10 16 1 1 12 1 1 0 
5 8 12 8 2 16 0 
14 9 6 6 6 0 
6 0 0 0 0 0 0 
0 0 0 0 0 0 
7 14 18 0 7 5 0 
7 40 22 13 4 0 
8 5 20 1 18 21 0 
14 7 14 5 8 0 
9 16 1 1 24 16 1 1 0 
0 1 1 9 6 24 0 
10 0 0 0 0 0 0 
0 0 0 3 0 0 
ANOVA Table 
Transformed Cough Frequencies (excluding sodium chloride) 
SQurQe Qf VariatiQn df SSg MSg F 
Between Subjects 9 79.21 8.80 10.17 p<0.001 
Between Challenges 4 3.36 0.84 0.97 P >0.05 
Interaction 36 39.72 1.10 1.27 p>0.05 
Within 50 43.27 0.87 
TOTAL 99 165.56 
SE = 0.29 
95% CL = 0.59 
3.3.2 Anion Sensitivity: 
Raw Data Table 
Cough Frequencies (coughs/min) 
Chloride Concentration (mmol/I) 
147 112 75 53 
1 0 6 17 18 
0 0 1 1 15 
2 0 0 10 12 
0 0 0 10 
3 0 0 0 6 
0 0 4 6 
4 0 0 0 6 
0 0 9 7 
5 0 0 0 0 
0 0 0 12 
AN OVA Table 
Transformed Cough Frequencies 
Source of Variation df SSg MSg 
Between Subjects 
Between Challenges 
Interaction 
Within 
TOTAL 
4 
4 
16 
25 
49 
10.85 2.71 
88.25 22.06 
7.48 0.47 
13.94 0.56 
120.53 
~ 
30 
26 
33 
17 
14 
14 
22 
8 
21 
23 
F 
4.87 p<0.01 
39.57 p <0.001 
0.84 p>0.05 
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3.3.3 pH Sensitivity: 
Raw Data Table 
Cough Freguencies (coughs/m in) 
Qti 
SYQieQt 2.6 4.8 8.0 10.0 
1 2 0 0 5 
2 5 0 0 10 
3 0 0 0 2 
4 4 0 0 7 
5 4 0 0 0 
6 2 0 0 6 
7 0 0 0 0 
ANOVA Table 
pH 2.6 & 10.0 only 
Source of Variation df SSg MSg F 
Between Subjects 
Between pH 
Residual 
TOTAL 
SE = 0.206 
95% CL = 0.504 
6 
1 
6 
13 
5.29 0.88 2.96 NS 
0.48 0.48 1.60 NS 
1.79 0.30 
7.55 
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3.3.4 Osmolarity Sensitivity: 
Raw Data Table 
Cough Frequencies (coughs/min) 
Sodium Chloride D-Glucose 
Osmolarity (mosmol/I) 
77 154 308 616 1232 77 154 308 616 1232 
7 0 0 0 1 7 25 28 15 20 
22 4 0 0 0 27 21 26 22 31 
8 2 0 0 3 14 14 16 19 26 
1 1 0 0 0 0 6 2 0 2 6 
13 15 0 0 10 3 12 10 18 1 1 
4 1 0 0 0 5 3 19 5 7 
0 0 0 0 0 1 2 2 8 0 
AN OVA Table 
Transformed Cough Frequency 
Source of Variation df SSq MSq F 
D-Glucose 
Between Subjects 6 49.16 8.19 13.83 
Between Challenges 4 2.51 0.63 1.06 p>0.05 
Residual 24 14.22 0.59 
TOTAL 34 65.90 
SE = 0.29 
95% CL = 0.60 
Sodium Chloride (excluding 308 & 616 data which did not cause cough) 
Between Subjects 6 13.77 2.3 4.2 p<0.02 
Between Challenges 2 8.81 4.40 8.1 p<0.01 
Residual 
TOTAL 
SE = 0.28 
95% CL = 0.61 
12 6.51 0.54 
20 29.08 
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3.3.5 Citric Acid-Induced Cough: 
Raw Data Table 
Cough Freguencies (coughs/min) 
0.68% Citric Acid D-Glucose Water Sodium Sodium 
in Q. 7~0/0 NaCI Citrate Citrate in NaCI 
6 30 26 22 0 
8 10 10 6 0 
1 1 26 27 28 0 
12 6 6 6 0 
23 18 23 17 0 
18 23 6 9 0 
6 20 20 7 0 
AN OVA Table 
Transformed Cough Freguencies (excluding sodium chloride) 
Source of Variation df SSg MSg F 
Between Subjects 6 14.29 2.38 3.42 p<0.05 
Between Challenges 3 3.15 1.05 1.51 p>0.05 
Residual 18 12.55 
TOTAL 27 29.98 
SE = 0.32 
95% CL = 0.66 
3.3.6 Particle Size Dependence: 
AN OVA Table 
Transformed CouQh Freguencies (couQhs/min) 
Source of Variation 
Between Subjects 
Between U/S vs Jet 
Residual 
TOTAL 
SE = 0.28 
95% CL = 0.62 
df 
1 1 
1 
SSg 
14.64 
32.78 
11 10.54 
23 57.96 
MSg 
1.33 
32.78 
0.96 
F 
1.39 p>O.05 
34.2 p<O.001 
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APPENDIX 2 - The Effect Of Altering Airway Tone On Cough 
Raw Data And Anova Tables 
4.4.1 (a) Inhaled Fenoterol Hydrobromide: 
Raw Data Tables 
CouQh Frequencies (couQhs/min) 
Chloride Concentration (mmol/l) 
0 ~ 75 112 
P A P A P A P A 
1 9 0 0 0 0 0 0 0 
2 14 12 10 12 2 0 0 0 
3 0 0 0 0 0 0 0 0 
4 14 4 11 4 6 2 0 0 
5 17 10 11 0 0 0 0 0 
6 13 0 0 0 0 0 0 0 
7 15 10 8 0 0 0 0 0 
8 1 0 2 0 0 0 0 0 
9 15 0 13 0 1 0 0 0 
10 9 5 6 1 0 0 0 0 
1 1 42 12 23 10 3 0 0 0 
12 0 0 0 0 0 0 0 0 
13 28 24 18 9 0 0 0 0 
14 0 0 0 0 0 0 0 0 
15 2 0 1 0 0 0 0 0 
16 27 13 4 24 15 0 0 0 
17 25 17 7 18 0 0 0 0 
18 12 8 11 5 0 0 0 0 
19 12 6 1 5 3 0 0 0 
20 27 17 19 2 8 0 2 0 
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P A 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
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4.4.1 (8) Inhaled Fenoterol Hydrobromide: 
ANOVA Table 
Transformed Cough Frequencies (excluding 112 & 150 data) 
Source of Variation df SSq MSq F 
Between Subjects 19 92.1 4.85 8.49 p<0.01 
Between Challenges 2 61.6 30.82 31.2 p<0.01 
Between Treatments 1 15.0 15.00 23.2 p<0.01 
Subjects x Challenges 38 37.5 0.99 1.73 NS 
Subjects x Treatment 19 12.3 0.65 1.13 NS 
Challenge x Treatments 2 2.19 1.10 1.92 NS 
Residual 38 21.7 0.57 
TOTAL 119 242.4 
SE = 0.17 
95% CL = 0.34 
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4.4.1 (b) Oral Salbutamol Sulphate: 
Cough Frequencies (coughs/min) 
Chloride Concentration (mmol/I) 
0 a1 75 150 
P A P A P A P A 
1 13 35 32 0 0 1 0 0 
2 2 18 2 3 0 0 0 0 
3 16 13 9 9 0 0 0 0 
4 18 19 14 8 9 4 0 0 
5 12 9 0 0 0 0 0 0 
6 42 37 24 25 0 0 0 0 
7 3 1 0 0 0 0 0 0 
8 6 0 0 0 0 0 0 0 
9 12 5 7 14 0 0 0 0 
10 29 4 16 3 0 0 0 0 
1 1 0 0 0 0 0 0 0 0 
ANOVA Table 
Transformed Cough Freguencies (excluding 150 mmol/I data) 
Source of Variation df SSg MSg F 
Between Subjects 10 60.51 6.05 6.07 p<0.01 
Between Challenges 2 55.20 27.60 18.16 p<0.01 
Between Treatments 1 1.42 1.42 2.18 NS 
Subjects x Challenges 20 30.38 1.52 1.52 NS 
Subjects x Treatment 10 6.54 0.65 <1 NS 
Challenges x Treatments 2 0.78 0.39 <1 NS 
Residual 20 19.95 1.00 
TOTAL 65 174.76 
SE = 0.30 
95% CL = 0.63 
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4.4.2 (a) Inhaled Ipratropium Bromide: 
Raw Data Table 
Cough Frequencies (coughs/min) 
ChlQride ConcentratiQn (mmol/I) 
0 
.3.1 75 150 
P A P A P A P A 
1 26 6 8 0 4 0 0 0 
2 32 0 6 0 0 0 0 0 
3 15 4 4 2 0 0 0 0 
4 17 8 15 8 0 0 0 0 
5 29 7 16 9 0 0 0 0 
6 0 0 0 0 0 0 0 0 
7 26 7 20 0 5 0 0 0 
8 22 4 0 3 0 0 0 0 
9 0 0 0 0 0 0 0 0 
10 21 0 0 0 0 0 0 0 
1 1 5 8 2 0 0 0 0 0 
12 0 0 0 0 0 0 0 0 
13 8 1 0 0 0 0 0 0 
14 1 1 15 0 5 0 0 0 0 
AN OVA Table 
TransfQrmed Cough Frequencies (excluding 150 mmol/I data) 
Source Qf Variation df SSq MSq F 
Between Subjects 13 32.72 25.20 5.23 p<0.01 
Between Challenges 2 47.97 23.99 31.7 p<0.01 
Between Treatments 1 14.07 14.07 11.78 p<0.01 
Subjects x Challenges 26 19.67 0.76 1.57 NS 
Subjects x Treatment 13 15.52 1.19 2.48 p<0.05 
Challenges x Treatments 2 8.55 4.27 8.89 p<0.01 
Residual 26 12.50 0.48 
TOTAL 83 15Q.99 
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4.4.2(b) Oral Pirenzepine Hydrochloride: 
Raw Data Table 
Cough Frequencies (coughs/min) 
Chloride Concentration (mmol/I) 
0 3.1 75 150 
P A P A P A P A 
1 0 3 0 8 0 0 0 0 
2 26 26 1 1 8 0 0 0 0 
3 8 6 0 3 0 0 0 0 
4 9 3 15 4 0 0 0 0 
5 22 14 0 22 0 0 0 0 
6 22 15 10 6 0 0 0 0 
7 14 4 10 0 4 0 0 0 
8 15 13 2 9 0 0 0 0 
9 1 1 0 9 0 0 1 0 0 
10 33 13 28 5 0 0 0 0 
1 1 10 16 2 1 1 0 0 0 0 
12 32 0 6 0 0 0 0 0 
13 0 0 0 0 0 0 0 0 
14 7 14 0 0 0 0 0 0 
ANOVA Table 
Transformed Cough Frequencies (excluding 150 mmol/I data) 
Source of Variation df SSg MSg F 
Between Subjects 13 30.87 2.37 3.22 p<0.01 
Between Challenges 2 70.88 35.44 34.20 p<0.01 
Between Treatments 1 2.47 2.47 1.44 NS 
Subjects x Challenges 26 26.95 1.04 1.41 NS 
Subjects x Treatment 13 22.24 1.71 2.32 p<0.05 
Challenges x Treatments 2 2.49 1.24 1.69 NS 
Residual 26 19.10 0.74 
TOTAL 83 175.05 
4.4.2 (c) & 4.4.4 (b) Inhaled Oxitropium Bromide. Ipratropium Bromide and a 
Combination of Ipratropium and Fenoterol Hydrobrom ide in Healthy and 
Asthmatic Subjects: 
Raw Data Tables 
Healthy Subjects 
CouQh Frequencies (coughs/min) 
Placebo Oxitropium Ipratropium Ip/Fen 
Chloride Concentration (mmol/l) 
Q 
1 11 8 15 1 2 7 2 1 5 0 2 5 
2 6 0 14 2 3 10 2 3 8 0 0 4 
3 3 5 9 3 0 6 2 3 4 0 3 3 
4 3 0 6 0 2 2 3 0 0 0 0 0 
5 3 2 30 5 3 7 12 5 36 3 16 35 
6 6 0 12 0 0 2 0 0 0 0 0 0 
7 0 7 13 0 4 12 15 0 16 2 0 9 
8 6 6 21 0 7 13 0 16 15 0 0 2 
9 10 4 9 2 0 0 2 2 6 0 2 0 
10 2 8 23 0 0 5 0 0 1 1 2 6 
11 2 5 14 0 0 0 0 0 0 0 0 4 
12 6 4 14 10 0 8 0 0 10 4 6 12 
13 0 2 5 0 4 7 0 0 4 0 2 2 
14 2 1 8 0 3 10 0 3 8 0 0 8 
15 4 7 14 4 12 24 1 8 19 5 4 10 
16 3 2 8 0 0 7 0 0 0 2 0 0 
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4.4.2 (c) & 4.4.4 (b) Raw Data Tables continued 
Asthmatic Subjects 
Cough Frequencies (coughs/min) 
Placebo Oxitropium Ipratropium Ip/Fen 
Chloride Concentration (mmolll) 
Q 
1 0 0 12 0 0 0 0 5 8 0 0 0 
2 0 0 0 1 1 0 2 0 0 2 0 2 
3 0 0 16 0 1 15 0 0 17 0 0 1 
4 0 0 1 0 0 0 0 0 0 0 0 1 
5 9 8 7 0 0 10 0 3 9 1 0 2 
6 0 1 8 3 0 0 3 0 0 1 0 0 
7 0 0 7 0 0 4 3 0 3 0 0 0 
8 1 0 5 1 0 6 3 0 5 1 0 0 
9 6 0 8 7 4 9 1 4 6 4 6 14 
10 0 0 5 0 0 0 2 0 0 0 0 0 
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4.4.2 (c) & 4.4.4 (b) continued 
ANOVA Tables 
Healthy Subjects Only (transformed cough frequencies) 
Source of Variation df SSg MSg F 
Between Subjects 15 59.93 4.00 
Between Periods 3 1.03 0.34 <1 
Between Treatments 3 20.88 6.96 8.52 p<0.01 
Residual 42 34.31 0.82 
Between Challenges 2 58.39 29.19 57.92 p<0.01 
Linear 1 47.74 47.74 94.71 p<0.01 
Quadratic 1 10.65 10.65 21.12 p<0.01 
Challenges x Treatments 6 4.50 0.58 1.16 
Residual 120 60.48 0.50 
TOTAL 191 238.52 
4.4.2 (C) & 4.4.4 (b) ANOVA Tables continued 
Heallthy and Asthmatic Groups (transformed data) 
Source of Variation df SSq 
Between Groups (G) 1 20.29 
Residual 24 80.56 
Between Treatments (T) 3 20.89 
G x T 3 3.26 
Residual 72 46.18 
Between Challenges (C) 2 71.29 
Linear 1 53.95 
Quadratic 1 17.34 
GxC 2 3.43 
Residual 48 37.44 
TxC Q 6.74 
T x C linear 3 3.55 
T x C quadratic 3 3.19 
GxTxC 6 0.58 
Residual 144 53.88 
Total 311 344.55 
MSq 
20.29 
3.36 
6.96 
1.09 
0.64 
35.64 
53.95 
17.34 
1.71 
0.78 
1.12 
1.18 
1.Q7 
0.10 
0.37 
F 
6.05 p<0.05 
10.86 p<0.01 
1.70 
45.69 p<Q.Q1 
69.16 p<0.01 
22.22 p<Q.Q1 
2.20 
3.QO p<0.01 
3.16 p<0.05 
2.85 p<Q.05 
<1 
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4.4.1 (C) & 4.4.4 (a) Inhaled Salbutamol and Procaterol Hydrochloride in 
Healthy and Asthmatic Subjects: 
Raw Data Tables 
Healthy Subjects 
Cough Frequencies (coughs/min) 
Subject Placebo Procaterol 
(1 O~g) (20~g) 
1 6 1 0 
2 26 2 2 
3 7 4 1 
4 16 2 0 
5 9 2 1 
6 13 0 0 
7 12 1 0 
8 14 0 3 
9 10 1 0 
10 8 6 7 
1 1 27 3 1 
12 6 0 2 
13 10 4 3 
14 14 4 1 
15 5 0 3 
16 26 12 0 
17 8 6 0 
18 9 10 9 
19 1 1 10 3 
20 0 0 0 
Salbutamol 
(200~g) 
0 
6 
4 
0 
3 
0 
4 
0 
0 
4 
1 
0 
3 
3 
2 
9 
0 
1 
0 
5 
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4.4.1 (C) & 4.4.4 (a) Raw Data Tables continued 
Healthy Subjects 
PLACEBO 
FEV1 (I) 
PROCATEROL 
20mcg 
PROCATEROL 
10mcg 
SALBUTAMOL 
BASE POST POST BASE POST POST BASE POST POST BASE POST POST 
LINE TREAT CHAL LINE TREA CHALL LINE TREAT CHAL LINE TREAT CHAL 
1 2.25 2.25 2.20 2.20 2.30 2.25 2.30 2.35 2.30 2.15 2.35 2.35 
2 2.60 2.60 2.60 2.50 2.60 2.60 2.55 2.60 2.55 2.60 2.60 2.60 
3 2.95 2.90 2.80 2.95 2.90 2.90 2.90 2.90 2.80 3.00 2.90 2.90 
4 2.80 2.80 2.80 2.80 2.85 2.85 2.85 2.80 2.80 2.75 2.80 2.85 
5 2.35 2.40 2.40 2.30 2.45 2.45 2.35 2.45 2.45 2.40 2.50 2.50 
6 3.10 3.00 3.15 3.05 3.20 3.20 3.00 3.15 3.20 3.10 3.05 3.15 
7 2.55 2.70 2.60 2.50 2.60 2.50 2.70 2.50 2.50 2.55 2.50 2.60 
8 3.45 3.40 3.20 3.40 3.50 3.50 3.35 3.50 3.55 3.35 3.55 3.65 
9 4.85 4.75 4.65 5.00 5.10 5.20 4.80 4.95 5.00 5.00 5.15 5.30 
10 2.75 2.85 2.70 2.85 2.95 2.95 2.80 2.95 2.85 2.65 2.85 2.85 
11 3.80 3.75 3.80 3.80 3.70 3.90 3.80 3.90 3.95 3.80 3.95 3.90 
12 3.55 3.65 3.75 3.50 3.65 3.75 3.60 3.80 3.90 3.55 3.65 3.70 
13 4.35 4.60 4.50 4.35 4.60 4.60 4.60 4.75 4.75 4.40 4.55 4.70 
14 3.65 3.60 3.70 3.65 3.65 3.75 3.60 3.70 3.75 3.45 3.50 3.55 
15 4.35 4.30 4.45 4.25 4.30 4.40 4.35 4.30 4.30 4.05 4.40 4.30 
16 3.80 3.75 3.80 3.75 3.70 3.75 3.70 3.75 3.75 3.75 3.90 3.80 
17 1.50 1.30 1.40 1.55 1.55 1.45 1.50 1.50 1.55 1.45 1.40 1 .50 
18 4.10 4.10 4.10 4.20 4.45 4.45 4.00 4.35 4.40 4.20 4.40 4.45 
19 2.85 2.95 2.95 2.75 2.95 2.85 2.65 2.95 2.95 2.80 2.80 2.85 
20 3.50 3.45 3.45 3.40 3.50 3.50 3.35 3.40 3.50 3.25 3.40 3.45 
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4.4.1 (C) & 4.4.4 (a) Raw Data Tables continued 
Healthy Subjects 
PLACEBO 
Raw (kPail/s) 
PROCATEROL 
10 Jl9 
PROCATEROL 
20 Jl9 
SALBUTAMOL 
BASE POST POST BASE POST POST BASE POST POST BASE POST POST 
LINE TREA CHAL LINE TREA CHAL LINE TREA CHAL LINE TREA CHAL 
1 0.43 0.38 0.40 0.38 0.37 0.28 0.51 0.42 0.38 0.46 0.42 0.33 
2 0.29 0.39 0.35 0.29 0.26 0.29 0.31 0.28 0.25 0.26 0.22 0.24 
3 0.42 0.30 0.31 0.26 0.32 0.34 0.31 0.28 0.30 0.52 0.33 0.35 
4 0.30 0.25 0.23 0.25 0.25 0.26 0.31 0.29 0.29 0.24 0.26 0.25 
5 0.55 0.56 0.63 0.44 0.51 0.39 0.45 0.52 0.45 0.36 0.33 0.39 
6 0.34 0.24 0.29 0.25 0.24 0.25 0.26 0.27 0.26 0.34 0.23 0.23 
7 0.49 0.43 0.39 0.48 0.42 0.40 0.40 0.32 0.31 0.41 0.32 0.34 
8 0.43 0.41 0.44 0.45 0.39 0.35 0.33 0.26 0.36 0.51 0.42 0.31 
9 0.33 0.27 0.31 0.28 0.20 0.22 0.20 0.20 0.20 0.31 0.22 0.21 
10 0.34 0.40 0.39 0.35 0.38 0.35 0.37 0.35 0.33 0.35 0.34 0.37 
11 0.25 0.24 0.26 0.26 0.22 0.19 0.22 0.19 0.21 0.25 0.21 0.20 
12 0.32 0.39 0.32 0.34 0.32 0.26 0.29 0.25 0.28 0.34 0.31 0.32 
13 0.16 0.17 0.17 0.16 0.14 0.14 0.16 0.14 0.14 0.14 0.11 0.11 
14 0.20 0.19 0.23 0.18 0.19 0.19 0.20 0.16 0.18 0.21 0.18 0.16 
15 0.30 0.24 0.29 0.23 0.25 0.25 0.28 0.30 0.24 0.28 0.28 0.24 
16 0.26 0.22 0.25 0.26 0.21 0.26 0.33 0.31 0.22 0.27 0.25 0.25 
17 0.63 0.66 0.48 0.40 0.38 0.39 0.49 0.46 0.37 0.38 0.37 0.37 
18 0.15 0.20 0.22 0.15 0.13 0.11 0.14 0.14 0.14 0.17 0.13 0.14 
19 0.33 0.24 0.31 0.32 0.29 0.26 0.25 0.25 0.26 0.31 0.25 0.30 
20 0.22 0.24 0.26 0.25 0.22 0.25 0.26 0.21 0.25 0.22 0.21 0.25 
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4.4.1 (c) & 4.4.4 (a) Raw Data Tables continued 
Asthmatic Subjects 
CouQh Frequencies (coughs/min) 
SUBJ PLACEBO PROCATEROL SALBUTAMOL 
(10 I1g ) (20I1g) (2OO l1g) 
1 1 1 4 5 3 
2 1 1 0 4 12 
3 8 0 2 0 
4 13 5 6 7 
5 32 14 4 2 
6 19 2 0 5 
7 6 0 0 0 
8 9 0 0 0 
9 22 8 0 0 
10 7 3 2 2 
1 1 16 2 0 0 
12 15 7 5 5 
13 15 8 9 1 1 
14 24 1 1 1 1 12 
15 16 9 8 0 
16 24 16 17 16 
17 0 0 0 0 
18 1 1 7 0 7 
19 17 9 15 10 
20 5 0 2 4 
4.4.1 (C) & 4.4.4 (8) Raw Data Tables continued 
Asthmatic Subjects 
PLACEBO 
FEV1 (I) 
PROCATEROL 
20J,.l9 
PROCATEROL 
10 J,.l9 
SALBUTAMOL 
BASE POST POST BASE POST POST BASE POST POST BASE POST POST 
LINE TREA CHAL LINE TREA CHAL LINE TREA CHAL LINE TREA CHAL 
1 4.05 3.90 3.70 4.00 4.05 4.00 4.00 4.00 4.00 4.10 4.00 4.00 
2 2.75 2.70 2.40 2.40 3.00 3.00 2.40 2.95 2.75 2.75 3.10 3.05 
3 3.00 2.80 2.85 2.95 3.15 3.25 2.90 3.15 3.30 2.95 3.25 3.30 
4 1.70 1.95 1.80 2.10 2.15 2.35 2.20 2.10 2.15 2.00 2.30 2.30 
5 3.25 3.40 3.20 3.40 3.50 3.60 3.45 3.45 3.40 3.35 3.50 3.40 
6 3.50 3.40 3.50 3.40 3.50 3.45 3.45 3.50 3.60 3.70 3.90 3.80 
7 2.45 2.55 2.15 2.70 3.15 3.15 2.65 3.00 2.90 2.50 2.95 2.95 
8 3.35 3.25 3.05 3.30 3.50 3.70 3.50 3.55 3.60 3.50 3.65 3.60 
9 3.25 3.05 2.55 3.20 3.05 3.10 3.30 3.05 3.15 3.10 3.15 3.15 
10 3.40 3.30 3.50 3.40 3.50 3.50 3.30 3.45 3.65 3.50 3.55 3.55 
11 4.80 4.70 4.40 4.90 4.95 4.95 4.60 4.80 4.90 4.70 4.85 5.00 
12 4.10 4.10 3.80 4.25 4.25 4.25 4.00 4.15 4.10 3.80 4.10 4.10 
13 4.75 4.80 4.55 4.65 5.30 5.30 4.90 5.00 5.00 4.80 5.15 5.00 
14 3.85 3.90 4.00 4.00 4.00 4.00 4.10 3.95 4.10 4.00 4.15 4.10 
15 1.80 1.55 0.75 1.80 2.70 2.65 1.65 2.40 2.50 1.90 2.40 2.55 
16 2.95 2.95 2.90 3.10 3.10 3.10 2.95 3.10 3.05 3.05 3.20 3.20 
17 2.50 2.55 2.30 2.25 2.55 2.75 2.30 2.70 2.80 2.15 2.50 2.60 
18 3.20 3.20 3.00 3.25 3.35 3.35 3.50 3.80 3.70 3.25 3.75 3.60 
19 5.45 5.40 5.45 5.50 5.65 5.60 5.45 5.60 5.65 5.50 5.60 5.55 
20 4.30 4.50 4.50 4.50 5.00 5.00 4.30 4.95 5.00 4.40 4.90 5.05 
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4.4.1 (C) & 4.4.4 (8) Raw Data Tables continued 
Asthmatic Subjects 
PLACEBO 
Raw (kPa/l/s) 
PROCATEROL 
10 )l9 
PROCATEROL 
20 )l9 
SALBUTAMOL 
BASE POST POST BASE POST POST BASE POST POST BASE POST POST 
LINE TREA CHAL LINE TREA CHAL LINE TREA CHAL LINE TREA CHAL 
1 0.33 0.30 0.32 0.25 0.18 0.20 0.31 0.23 0.25 0.28 0.28 0.25 
2 0.36 0.39 0.44 0.44 0.33 0.31 0.33 0.34 0.30 0.36 0.30 0.28 
3 0.33 0.38 0.46 0.33 0.23 0.24 0.39 0.25 0.29 0.32 0.21 0.22 
4 0.39 0.35 0.46 0.42 0.32 0.34 0.31 0.37 0.35 0.35 0.27 0.34 
5 0.32 0.34 0.30 0.36 0.38 0.28 0.24 0.23 0.24 0.31 0.28 0.25 
6 0.26 0.23 0.24 0.24 0.16 0.19 0.21 0.16 0.15 0.21 0.16 0.16 
7 0.48 0.33 0.50 0.33 0.29 0.26 0.28 0.26 0.24 0.31 0.24 0.27 
8 0.39 0.41 0.48 0.52 0.30 0.34 0.39 0.30 0.35 0.39 0.34 0.43 
9 0.33 0.32 0.39 0.20 0.40 0.35 0.20 0.24 0.33 0.21 0.20 0.35 
10 0.36 0.33 0.33 0.40 0.31 0.38 0.33 0.34 0.29 0.32 0.38 0.32 
11 0.24 0.28 0.28 0.33 0.24 0.25 0.27 0.26 0.24 0.31 0.24 0.25 
12 0.29 0.28 0.33 0.37 0.36 0.36 0.23 0.23 0.30 0.39 0.31 0.26 
13 0.21 0.17 0.22 0.18 0.14 0.17 0.33 0.15 0.15 0.18 0.15 0.15 
14 0.32 0.26 0.29 0.32 0.25 0.25 0.29 0.21 0.34 0.28 0.23 0.27 
15 0.98 0.66 1.13 0.89 0.66 0.73 0.66 0.68 0.89 0.77 0.67 0.89 
16 0.40 0.39 0.38 0.33 0.35 0.36 0.32 0.33 0.29 0.36 0.33 0.32 
17 0.56 0.48 0.70 0.83 0.40 0.32 0.61 0.29 0.27 0.83 0.33 0.44 
18 0.34 0.35 0.46 0.34 0.22 0.22 0.39 0.25 0.25 0.46 0.19 0.26 
19 0.15 0.12 0.16 0.12 0.14 0.11 0.12 0.12 0.11 0.17 0.13 0.12 
20 0.22 0.19 0.20 0.21 0.14 0.13 0.25 0.14 0.14 0.17 0.14 0.12 
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4.4.1 (c) & 4.4.4 (a) Inhaled Salbutamol and Procaterol Hydrochloride in 
Healthy and Asthmatic Subjects: 
ANOVA Tables 
All Subjects (Including 13 Bronchitic Subjects: not included in this thesis) 
Transformed Cough Frequencies 
(Square-root (cough + 1)) 
Source of Variation 
group ptno stratum 
Between Groups (G) 
Residual 
grp ptno trt stratum 
Between Treatments 
GxT 
Residual 
Total 
(T) 
df SSg 
2 8.00 
50 125.78 
3 71.68 
6 12.49 
150 93.18 
211 311.13 
MSg F 
4.00 1.59 p=0.214 
2.52 
23.89 38.46 p<0.001 
2.08 3.35 p=0.004 
0.62 
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4.4.1 (C) & 4.4.4 (8) ANOVA Tables continued 
All Subjects (Including 13 Bronchitic Subjects) 
FEV1 
Source of Variation 
grp.ptno.stratum 
Between Groups (G) 
Residual 
grp.ptno.trt stratum 
Between Treatments (T) 
GxT 
Residual 
grp.ptno.occas stratum 
Occasion (0) 
GxO 
Residual 
grp.ptno.trt.occas stratum 
df SSg 
2 544.7 
50 438.8 
3 2.256 
6 1.113 
150 3.944 
2 1.329 
4 0.4365 
100 2.221 
TxO 6 1.431 
0.4381 
2.662 
GxTxO 12 
Residual 300 
Total 635 999.3 
MSg 
272.4 
8.776 
0.7521 
0.1855 
0.02629 
0.6647 
0.1091 
0.02221 
0.2386 
0.03651 
0.008873 
F 
31.03 p<0.001 
28.60 p<0.001 
7.06 p<0.001 
29.93 p<0.001 
4.91 p<0.001 
26.89 p<0.001 
4.11 p<0.001 
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4.4.1 (C) & 4.4.4 (a) ANOVA Tables continued 
All Subjects (Including 13 Bronchitic Subjects) 
Source of Variation 
grp.ptno.stratum 
Between Groups (G) 
Residual 
grp.ptno. trt stratum 
Between Treatments (T) 
GxT 
Residual 
grp.ptno.occas stratum 
Between Occasion (0) 
GxO 
Residual 
grp.ptno.trt.occas stratum 
TxO 
GxTxO 
Residual 
Total 
Transformed Raw 
(Log (Raw X 100)) 
df SSg 
2 7.53 
50 15.91 
3 0.66 
6 0.03 
150 1.18 
2 0.39 
4 0.09 
100 0.72 
6 0.16 
12 0.06 
300 0.92 
635 27.63 
MSg 
3.76 
0.32 
0.22 
0.00 
0.01 
0.20 
0.02 
0.01 
0.03 
0.00 
0.00 
F 
11.83 p<0.001 
28.13 p<0.001 
0.62 p=0.712 
27.31 p<0.001 
3.28 p=0.014 
8.67 p<0.001 
1.51 p=0.121 
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4.4.3 Alteration in Airway Tone Associated with Inhibition of Cough 
Raw Data Tables 
Cough Frequency Pre- and Post -Treatments (n = 6) 
PI In Fen Pir Sal ill PIT 
Pre Pos Pre Pos Pre Pos Pre Pos Pre Pos Pre Pos 
1 7 19 15 5 9 10 10 4 9 5 6 5 
2 54 48 30 0 28 26 48 31 31 7 31 28 
3 18 6 26 9 6 6 16 9 7 5 12 13 
4 25 28 33 2 33 31 37 20 28 6 33 30 
5 18 18 19 13 25 16 31 23 21 22 23 18 
6 21 12 18 3 18 20 19 1 1 13 9 23 17 
4.4.3 Raw Data Tables continued 
FEV1 (n=6) 
Time 1 =baseline 
Subj 
1 
2 
3 
4 
5 
6 
2=post 1 st challenge 
3=post treatment 
4=post 2nd challenge 
Time PI In 
1 4.57 
2 4.63 
3 4.59 
4 4.59 
1 5.05 
2 5.16 
3 5.01 
4 5.23 
1 3.32 
2 3.35 
3 3.34 
4 3.30 
1 3.32 
2 3.27 
3 3.34 
4 3.31 
1 4.10 
2 4.10 
3 4.10 
4 4.22 
1 3.33 
2 3.33 
3 3.38 
4 3.39 
Fen 
4.62 
4.64 
4.70 
4.80 
5.07 
4.98 
5.63 
5.52 
3.52 
3.46 
3.57 
3.72 
3.20 
3.17 
3.42 
3.42 
3.75 
3.77 
3.81 
3.91 
3.46 
3.48 
3.70 
3.71 
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Pir Sal 1Q PIT 
4.48 4.37 4.58 4.85 
4.53 4.28 4.63 4.82 
4.54 4.62 4.65 4.65 
4.44 4.45 4.84 4.60 
5.11 5.91 4.98 4.96 
4.90 5.21 4.87 4.84 
5.04 5.27 5.70 4.59 
4.80 5.68 5.81 4.81 
3.26 3.38 3.26 3.30 
3.28 3.41 3.25 3.25 
3.15 3.49 3.42 3.26 
3.24 3.60 3.50 3.23 
3.28 2.89 3.05 3.17 
3.15 3.02 3.00 3.24 
3.07 3.19 3.30 3.16 
3.13 3.11 3.33 3.25 
3.96 4.33 3.71 3.94 
3.96 4.19 3.75 3.91 
4.11 4.07 3.95 3.85 
4.06 4.08 3.85 3.85 
3.19 3.33 3.44 3.48 
3.16 3.46 3.42 3.26 
3.33 3.62 3.56 3.35 
3.23 3.57 3.61 3.28 
4.4.3 Raw Data Tables continued 
sGaw (n=6) 
Time 1 =basel ine 
Subj 
1 
2 
3 
4 
5 
6 
2=post 1 st challenge 
3=post treatment 
4=post 2nd challenge 
Time PI In 
1 0.222 
2 0.216 
3 0.191 
4 0.200 
1 0.217 
2 0.194 
3 0.216 
4 0.202 
1 0.165 
2 0.181 
3 0.180 
4 0.169 
1 0.225 
2 0.234 
3 0.207 
4 0.203 
1 0.210 
2 0.254 
3 0.228 
4 0.241 
1 0.186 
2 0.149 
3 0.173 
4 0.131 
Fen 
0.237 
0.180 
0.250 
0.240 
0.194 
0.172 
0.310 
0.300 
0.137 
0.273 
0.241 
0.227 
0.231 
0.204 
0.323 
0.309 
0.251 
0.219 
0.241 
0.237 
0.202 
0.190 
0.237 
0.260 
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Pir Sal ill PIT 
0.187 0.226 0.224 0.214 
0.175 0.178 0.193 0.223 
0.214 0.230 0.211 0.239 
0.213 0.243 0.287 0.241 
0.193 0.216 0.208 0.190 
0.225 0.206 0.175 0.174 
0.186 0.273 0.291 0.184 
0.173 0.253 0.340 0.172 
0.187 0.147 0.156 0.171 
0.184 0.119 0.185 0.164 
0.141 0.174 0.250 0.169 
0.149 0.170 0.312 0.172 
0.207 0.165 0.217 0.158 
0.170 0.166 0.171 0.155 
0.187 0.223 0.298 0.193 
0.170 0.198 0.300 0.153 
0.233 0.246 0.207 0.250 
0.222 0.264 0.255 0.255 
0.239 0.215 0.279 0.232 
0.244 0.244 0.270 0.278 
0.139 0.177 0.187 0.180 
0.165 0.165 0.168 0.171 
0.166 0.188 0.241 0.175 
0.161 0.192 0.230 0.157 
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4.4.3 Alteration in Airway Tone Associated with Inhibition of Cough 
AN OVA Tables 
FEV1 (n = 6) 
Analysis of conductance and FEV 1 without carryover effects 
Log (cond 3 / cond 2) 
Source Of SSg MSg F 
Bet Patients 5 0.0610 0.0122 2.708 NS 
Bet Periods 5 0.0439 0.0088 1.950 NS 
Bet Treatments 5 0.1183 0.0237 5.25 p<0.01 
Oral Effects 1 0.0212 0.0212 4.701 p<0.05 
Orug 2 0.0508 0.0254 5.639 p<0.05 
Interaction 2 0.0463 0.0231 5.133 p<0.05 
Residual 20 0.0901 0.0045 
TOTAL 35 0.3133 
Log (FEV1 3/ FEV121 
SQun~e Of SSg MSg F 
Bet Patients 5 0.0014 0.0003 1.026 NS 
Bet Periods 5 0.0014 0.0003 1.022 NS 
Bet Treatments 5 0.0058 0.0012 4.38 p<O.01 
Oral Effects 1 0.0017 0.0017 6.448 p<0.05 
Orug 2 0.0035 0.0018 6.623 p<0.01 
Interaction 2 0.0005 0.0003 1.088 NS 
Residual 20 0.0053 0.0027 
TOTAL 35 0.0139 
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4.4.3 ANOVA Tables continued 
Analysis of cough without carryover effects 
(square root cough 1) - (square root cough 3) 
SQyrQe Df SSg MSg F 
Bet Patients 5 9.486 1.897 1.873 NS 
Bet Periods 5 3.616 0.723 0.714 NS 
Bet Treatments 5 30.673 6.135 6.056 p<0.01 
Oral 1 6.938 6.938 
Drug 2 10.074 9.537 
Interaction 2 4.661 2.331 
Residual 20 20.252 1.013 
TOTAL 35 64.027 
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4.6.2 (8) Specific L TD4 Antagonist. SK&F 104353 
Raw Data Tables 
LTD4 
Cough frequencies (cough/5 min) 
Subject Placebo 50Ug 400Ug 
13 13 9 1 
14 7 2 0 
15 49 2 19 
16 1 1 0 2 
17 26 15 4 
18 44 41 0 
LTD4 
FEV1 (I) 
Placebo 400"9 
PRE POST 5MIN POST PRE POST 5MIN POST PRE POST 5MIN POST 
CH CH CH 
13 3.50 3.35 3.40 2.70 3.60 3.60 3.60 2.60 3.50 3.55 3.50 3.40 
14 3.70 3.70 3.70 3.15 3.70 3.50 3.55 3.30 3.70 3.60 3.60 3.55 
15 2.85 2.75 2.80 2.10 2.90 2.85 2.80 2.60 2.90 2.80 2.90 2.45 
16 3.75 3.85 3.85 3.05 3.65 3.75 3.75 3.15 3.75 3.70 3.80 3.45 
17 4.05 4.00 4.10 3.20 4.10 4.00 4.00 3.15 4.10 4.10 4.10 3.90 
18 4.10 4.00 4.15 3.40 4.10 4.10 4.10 3.40 4.00 3.90 3.90 3.85 
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4.6.2 (8) Raw Data Tables continued 
LTD4 
Raw (kPaJl/s) 
Su Placebo 50119 400119 
PRE POST 5MIN POST 5MIN PRE POST 5MIN POST 5MIN PRE POST 5MIN POST 5 MIN 
CH POST CH POST CH POST 
13 0.30 0.16 0.30 0.32 0.63 0.27 0.24 0.23 0.32 0.99 0.30 0.19 0.15 0.12 0.19 
14 0.26 0.18 0.23 0.32 0.41 0.17 0.15 0.11 0.15 0.19 0.12 0.06 0.28 0.25 0.21 
15 0.34 0.11 0.14 0.14 0.46 0.29 0.12 0.18 0.18 0.33 0.31 0.30 0.26 0.29 0.82 
16 0.28 0.34 0.22 0.32 0.42 0.33 0.24 0.21 0.25 0.49 0.12 0.14 0.14 0.18 0.19 
17 0.20 0.18 0.17 0.20 1.02 0.12 0.13 0.16 0.21 0.45 0.22 0.19 0.21 0.25 0.29 
18 0.24 0.20 0.18 0.26 0.49 0.27 0.20 0.19 0.37 0.42 0.24 0.18 0.20 0.17 0.22 
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4.6.2 (8) Specific L TD4 Antagonist. SK&F 104353 
ANOVA Tables 
LTD4 
Transformed Cough Freguencies (coughs/min) 
Source of Variation df SSg MSg F 
Between Subjects 5 22.39 4.48 2.69 
Between Periods 2 8.96 4.48 2.69 
Between Treatments 2 25.13 12.56 7.54 p<0.05 
Residual 8 13.33 1.67 
Total 17 69.80 
LTD4 
Transformed FEV 1 
Source of Variation df SSg MSg F 
Between Subjects 5 0.206 0.041 
Between Periods 2 0.0004 0.0002 0.58 
Between Treatments 2 0.0035 0.00177 4.73 p<0.05 
Residual 8 0.003 0.00037 
Between Times 3 0.062 0.0206 80.2 p<0.001 
Residual 15 0.0038 0.00026 
Time x Period 6 0.00148 0.00025 1.12 NS 
Time x Treatment 6 0.0119 0.00198 8.97 p<0.01 
Residual 24 0.0053 0.00022 
TOTAL 71 0.2970 
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4.6.2 (8) ANOVA Tables continued 
LTD4 
Transformed Raw 
Source of Variation df SSg MSg F 
Between Subjects 5 0.21 0.042 
Between Periods 2 0.60 0.300 11.6 p<0.01 
Between Treatments 2 0.20 0.098 3.79 NS 
Residual 8 0.20 0.026 
Between Times 4 1.40 0.350 18.9 p<0.001 
Residual 20 0.37 0.019 
Time x Period 8 0.11 0.014 <1 
Time x Treatment 8 0.17 0.022 1.28 NS 
Residual 32 0.55 0.017 
TOTAL 89 
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4.6.2 (b) Non-Specific Inhibition with Salbutamol 
Raw Data Tables 
FEV1 (I) 
Placebo Salbutamol 
Time 1 2 3 4 1 2 3 4 
3.80 3.75 3.45 3.60 3.65 3.80 3.75 3.65 
4.10 4.20 3.50 3.70 4.25 4.45 4.25 4.25 
2.80 2.80 2.30 2.35 2.85 2.80 2.75 2.65 
3.65 3.65 2.90 3.20 3.65 3.65 3.60 3.80 
2.70 2.70 2.35 2.50 2.75 2.85 2.75 2.70 
sGaw & Cough Frequency (coughs/5min) 
Placebo Salbutamol 
1 2 3 4 Cough 1 2 3 4 Cough 
2.54 2.29 1.84 2.10 0 2.11 2.70 2.29 2.29 0 
1.40 1.40 0.38 0.78 25 1.41 3.31 2.20 2.20 0 
2.51 3.28 0.45 0.92 1 1 2.38 4.57 2.67 2.67 0 
1.83 1.63 0.36 0.65 31 1.67 2.67 2.13 2.55 0 
3.43 3.40 1.07 1.07 10 3.93 4.99 2.37 3.25 3 
Times 1, 2, 3 & 4 correspond to baseline, pre and 5 & 15 m in post challenge 
ANOVA Table 
Transformed Cough Frequencies 
Source of Variation df SSq MSq F 
Between Subjects 4 6.66 1.66 
Between Treatments 1 15.72 15.72 8.46 p<0.05 
Residual 4 7.43 1.86 
TOTAL 9 29.81 
SE = 0.61 
95% CL = 1.69 
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APPENDIX 3 - Antitussive Studies 
Raw Data And Anova Tables 
5.3.1 Opiates 
Raw Data Tables 
UNDW-Induced CouQh 
CouQh Freguencies (coughs/min) 
SubjeQt Placebo Noscapine Noscapine Codeine 
(50mg) (150mg) (60mg) 
1 27 32 21 24 
2 1 1 2 7 1 1 
3 1 1 6 2 4 
4 10 18 10 15 
5 38 39 33 37 
6 27 18 10 15 
7 0 8 6 0 
8 14 23 15 29 
9 33 38 23 36 
10 23 15 19 31 
1 1 34 25 19 25 
12 35 30 39 23 
13 10 6 12 2 
14 4 1 1 9 9 
15 7 0 4 6 
16 10 0 0 13 
17 8 18 13 18 
18 12 4 23 0 
19 30 27 29 35 
20 15 19 1 1 21 
21 25 23 13 23 
22 0 8 3 22 
23 5 10 9 25 
24 23 8 21 2 
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5.3.1 Raw Data Tables continued 
Citric Acid-Induced Cough 
Cough Frequencies (coughs/min) 
Subject Placebo Noscapine Noscapine Codeine 
(50mg) (150mg) (60mg) 
1 32 24 13 16 
2 18 21 1 1 7 
3 5 8 3 2 
4 0 14 10 3 
5 29 35 41 28 
6 17 8 18 10 
7 5 21 9 0 
8 14 23 15 24 
9 34 33 39 27 
10 0 0 4 20 
1 1 1 1 20 18 9 
12 10 5 18 5 
13 9 6 12 2 
14 8 4 6 5 
15 9 4 6 5 
16 1 1 0 2 9 
17 5 21 15 18 
18 17 0 13 0 
19 34 26 32 30 
20 13 1 1 14 8 
21 18 19 10 14 
22 0 9 12 8 
23 9 10 14 25 
24 12 6 20 13 
5.3.1 Opiates 
ANOVA Table 
UNDW- and Citric Acid-Induced Cough 
Transformed cough frequencies 
Source of Variation df SSq 
Between Subjects (S) 23 222.20 
Between Treatments (T) 3 0.53 
Between Challenges (C) 1 6.93 
SxT 69 96.88 
SxC 23 34.53 
TxC 3 3.68 
SxTxC 69 25.61 
TOTAL 191 390.36 
MSq F 
9.66 26.0 p<0.01 
0.18 <1 p>0.05 
6.93 4.62 p<0.05 
1.40 3.78 p<0.01 
1.50 4.04 p<0.01 
1.23 3.31 p<0.05 
0.37 
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5.3.2 Nedocrom il Sodium 
Raw Data Tables 
UNDW-Induced Cough 
Cough Frequencies (coughs/min + divided into 3 consecutive periods) 
Placebo Fenoterol Nedocromil 
21 (11,4,6) 12(8,3,1) 10 (6,3,1) 
46 (20,13,13) 11 (8,3,0) 27 (19,5,3) 
26 (18,2,6) ° (0,0,0) 26 (17,5,4) 
15 (7,4,4) ° (0,0,0) ° (0,0,0) 
28 (12,9,7) 30 (14,8,8) 30 (17,6,7) 
4 (0,0,4) ° (0,0,0) ° (0,0,0) 
17 (10,5,2) 10(4,3,3) 18 (12,2,4) 
22 (10,7,5) 1 (1,0,0) 16 (12,0,4) 
22 (13,6,3) ° (0,0,0) ° (0,0,0) 
° (0,0,0) ° (0,0,0) ° (0,0,0) 
44 (18,18,8) 16 (8,5,3) 30 (15,10,5) 
27 (14,9,4) 4 (4,0,0) 8 (8,0,0) 
7 (1,6,0) 7 (0,0,7) ° (0,0,0) 
9 (7,2,0) 5 (2,3,0) 9 (9,0,0) 
20(11,8,1) 3(2,0,1) 6 (2,2,2) 
12 (3,3,6) 2 (0,2,0) 13 (3,8,2) 
16 (4,8,4) ° (0,0,0) 1 (0,1,0) 
10 (6,3,1) 6 (4,1,1) 4 (4,0,0) 
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5.3.2 Raw Data Tables continued 
Citric Acid-Induced Cough 
Cough Frequencies (coughs/min + divided into 3 consecutive geriods) 
Placebo Fenoterol Nedocromil 
9 (5,4,0) 6 (6,0,0) 14 (10,3,1) 
4 (3,1,0) ° (0,0,0) ° (0,0,0) 
11 (10,0,1) 10 (10,0,0) 19(9,9,1) 
22 (9,6,7) 4 (4,0,0) 16 (6,4,6) 
18 (8,4,6) 35 (13,16,6) 32 (16,13,3) 
6 (4,2,0) ° (0,0,0) ° (0,0,0) 
9 (7,0,2) 14 (7,5,2) 27 (14,8,5) 
20 (14,4,2) 1 (1,0,0) 5 (5,0,0) 
5 (5,0,0) 9 (9,0,0) 5 (5,0,0) 
3 (3,0,0) ° (0,0,0) 3 (3,0,0) 
8 (8,0,0) 7 (5,1,1) 6 (4,2,0) 
6 (6,0,0) 3 (3,0,0) 6 (6,0,0) 
6 (0,6,0) ° (0,0,0) ° (0,0,0) 
6 (6,0,0) 5 (5,0,0) 14 (11,3,0) 
24 (17,7,0) 18 (10,8,0) 24 (12,12,0) 
5 (3,0,2) 6 (2,4,0) 8 (0,4,4) 
9 (4,3,2) 9 (3,3,3) 10 (4,4,2) 
5 (5,0,0) 7 (7,0,0) 9 (7,2,0) 
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5.3.2 Raw Data Tables continued 
Capsaicin-Induced CouQh 
CouQh Frequencies (couQhs/min + divided into 3 consecutive periods) 
Placebo Fenoterol Nedocromil 
17 (10,5,2) 6 (4,2,0) 1 (1,0,0) 
9 (9,0,0) 11 (9,2,0) 7 (7,0,0) 
10 (5,3,2) 8 (5,3,0) 17 (10,7,0) 
21 (10,8,3) 19(11,4,4) 13 (7,4,2) 
25 (12,9,4) 22 (8,6,8) 12 (10,2,0) 
25 (14,7,4) 2 (2,0,0) 2 (2,0,0) 
19 (9,6,4) 27 (12,9,6) 26 (11,8,7) 
30 (13,8,9) 22 (12,7,3) 11 (6,3,2) 
14 (12,1,1) 29 (18,11,0) 20 (9,7,4) 
14 (12,1,1) 33 (20,5,8) o (0,0,0) 
29 (12,8,9) o (0,0,0) 7 (7,0,0) 
23 (8,7,8) 10 (3,3,4) 10 (7,3,0) 
13(0,3,10) 30 (10,14,6) 28 (3,20,5) 
8 (6,0,2) 12 (6,4,2) 15 (13,2,0) 
22 (14,8,0) 25 (5,12,8) 16(8,7,1) 
6 (0,4,2) 12 (2,6,4) 1 (0,1,0) 
10 (2,5,3) 12 (8,4,0) 9 (5,1,3) 
8 (6,0,2) 21 (0,16,5) 3 (0,03) 
5.3.2 Nedocromil Sodium 
ANOVA Table 
Transformed Gough Frequencies 
Source of Variation df SSq MSq 
Between Subjects (S) 17 70.96 4.17 
Between Periods (P) 2 0.64 0.32 
Between Treatments (T) 2 16.68 8.34 
Residual 32 30.83 0.96 
Between Challenges (C) 2 15.50 7.75 
CxT 34 66.01 1.94 
CxP 4 2.06 0.52 
C xT 4 20.11 5.03 
Residual 64 35.24 0.55 
Between Times (20 sec) 2 72.49 36.25 
Times x S 34 38.99 1.15 
Times x P 4 0.39 0.10 
Times x T 4 1.60 0.40 
Residual 64 17.23 0.27 
Times xC 4 2.72 0.68 
Times x C x S 68 24.52 0.36 
Times x C x P 8 4.87 0.61 
Times x C x T 8 3.00 0.38 
Residual 128 31.86 0.25 
TOTAL 465 455·71 
F 
4.33 P<0.01 
<1 NS 
8.66 p<0.01 
14.1 p<0.01 
3.53 p<0.01 
<1 NS 
9.13 p<0.01 
134.6 p<0.01 
4.26 p<0.01 
<1 NS 
1.49 NS 
2.73 p<0.05 
1.45 p<0.05 
2.45 p<0.05 
1.51 NS 
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5.3.3 Diuretics 
Raw Data Tables 
Cough Frequencies (coughs/30 sec) 
Placebo Amiloride Frusemide 
12 7 0 
8 18 13 
30 16 17 
23 9 12 
1 0 0 
0 0 0 
0 0 0 
14 2 0 
FEV1 (I) 
Placebo Amiloride Frusemide 
Time 1 2 3 1 2 3 1 2 3 
2.20 2.10 1.65 2.60 2.40 2.20 2.25 2.20 2.25 
3.80 3.80 3.00 3.50 3.50 3.20 3.90 3.70 3.90 
2.35 2.35 1.80 2.10 2.00 2.00 2.40 2.40 2.40 
2.90 2.80 1.85 2.90 2.75 2.10 2.90 2.90 2.00 
4.85 4.40 3.90 4.95 4.40 3.85 4.60 4.80 4.60 
3.10 3.00 2.55 2.90 2.90 2.50 2.70 2.60 2.60 
2.60 2.60 1.95 2.75 2.65 2.45 2.70 2.70 2.50 
Times 1, 2 & 3 represent baseline, post treatment and post UNDW 
challenge respectively 
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5.3.3 Raw Data Tables continued 
% Fall in FEV 1 at Baseline PD20 
Placebo Amiloride Frusemide 
20 20 0 
25 16 0 
21 9 0 
25 1 1 7 
36 28 31 
18 14 4 
23 5 0 
24 14 5 
ANOVA Table 
Transformed Cough Freguencies 
Source of Variation df 
Between Subjects 7 
Between Treatments 2 
Residual 14 
TOTAL 23 
SE = 0.27; 95% CL = 0.578 
Placebo - Frusemide 
Placebo - Am iloride 
ANOVA Table 
SSg MSg 
43.21 6.17 
3.91 1.95 
8.08 0.58 
55.20 
t = 2.55 P < 0.05 
t = 1.68 NS 
% Fall in FEV 1 at Baseline PD20 
Source of Variation df SSg MSg 
Between Subjects 7 1047.3 149.6 
Between Treatments 2 1314.6 657.3 
Residual 14 283.4 20.2 
TOTAL 2;3 2645.;3 
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F 
10.69 p<0.001 
3.39 P = 0.06 
F 
7.39 p<0.001 
32.47 p<0.001 
APPENDIX 4 - Afferent Lung C-Fibre Stimulants And Cough 
Raw Data Tables 
6.3.2 Adaptation and Cross-Adaptation of Cough 
Cough Frequencies (Total + Divided into 3 equal and consecutive periods) 
Subject Baseline 5 min 3 hrs 
UNDW UNDW UNDW 
1 37 (20,8,9) 9 (6,0,3) 36 (21,6,9) 
2 20 (7,9,4) 3 (3,0,0) 18 (5,8,5) 
3 23 (15,5,3) 6 (6,0,0) 24 (11,9,4) 
4 35 (17,11,7) 12 (5,5,2) 23 (9,8,6) 
5 22 (11,9,2) 14 (9,2,3) 28 (12,9,7) 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
PGE2 PG E2 PGE2 
12 (1,6,5) ° (0,0,0) 8 (0,3,5) 
16 (4,7,5) 2 (2,0,0) 5 (0,3,2) 
25 (13,9,3) 6 (0,3,3) 24 (10,8,6) 
20 (9,7,4) 4 (2,0,2) 12 (8,4,0) 
12 (5,0,7) 5 (0,5,0) 8 (4,4,0) 
CAPSAICIN CAPSAICIN CAPSAICIN 
22 (5,10,7) 24 (8,7,9) 22 (7,9,6) 
15 (2,6,7) 15 (5,7,3) 14 (8,6,0) 
23 (7,8,8) 23 (11,6,6) 28 (13,6,9) 
13 (3,5,5) 13 (4,4,5) 13 (4,5,4) 
10 (0,5,5) 9 (0,5,4) 15 (4,5,6) 
UNDW PGE2 PGE2 
44 (24,12,8) 33 (13,10,10) 17 (8,7,2) 
23 (5,11,7) 12 (5,5,2) 9 (2,4,3) 
22(10,9,3) 27(16,7,4) 23(13,9,1) 
30 (17,8,5) 16 (7,4,5) 15 (8,5,2) 
10(10,0,0) 21 (10,6,5) 27(11,9,7) 
UNDW CAPSAICIN CAPSAICIN 
31 (16,12,3) 9 (1,4,4) 18 (11,3,4) 
16 (8,6,2) 3 (0,3,0) 22 (8,6,8) 
10(8,2,0) 28 (9,13,6) 28 (9,9,10) 
28 (14,12,2) 8 (4,2,2) 15 (6,4,5) 
25 (13,8,4) 8 (0,4,4) 12 (2,6,4) 
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6.3.2 Raw Data Tables continued 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
PGE2 
21 (9,7,5) 
17 (9,3,5) 
22 (12,7,3) 
16 (9,5,2) 
24 (13,6,5) 
UNDW 
° (0,0,0) 
8 (2,2,4) 
9 (6,3,0) 
10(7,3,0) 
8 (3,3,2) 
UNDW 
33 (18,8,7) 
22(4,11,7) 
15(11,2,2) 
24 (13,4,7) 
23 (13,4,6) 
PGE2 CAPSAICIN CAPSAICIN 
12 (4,5,3) 5 (0,3,2) 17 (8,7,2) 
11 (6,5,0) 20 (6,9,5) 23 (13,5,5) 
26 (13,10,3) 6 (4,2,0) 17 (8,6,3) 
20 (10,6,4) 9 (2,2,5) 14 (0,8,6) 
16 (7,4,5) 24 (8,8,8) 22 (7,8,7) 
CAPSAICIN UNDW 
25 (8,14,3) 29 (8,12,9) 
12 (3,3,6) 21 (5,6,10) 
25 (7,6,12) 10 (8,2,0) 
10 (2,6,2) 20 (9,9,2) 
16 (3,6,7) 25 (16,3,6) 
UNDW 
39 (24,10,5) 
22 (9,7,6) 
11 (8,3,0) 
28 (15,7,6) 
29 (19,7,3) 
CAPSAICIN PGE2 PGE2 
16 (2,6,8) 34 (19,10,5) 29 (10,12,7) 
10 (0,3,7) 12 (2,5,5) 14 (2,7,5) 
21 (8,7,6) 28 (15,11,2) 22 (11,8,3) 
10 (1,5,4) 12 (5,5,2) 12 (4,4,4) 
15 (3,6,6) 22 (10,4,8) 24 (12,6,6) 
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6.3.2 Adaptation and Cross-Adaptation of Cough 
ANOVA Tables 
Transformed Total Cough Freguencies 
(Root (x + 1)) 
Source of Variation df SSg MSg F 
Subjects 4 8.75 2.107 
Sequences 8 23.23 2.90 
Subjects x Sequences 32 29.90 0.93 
Periods 2 21.29 10.64 
Subjects x Periods 8 3.33 0.42 
Treatments 
Direct effects 2 4.41 2.20 3.07 NS 
Carryover effects 2 10.59 5.30 7.38 p<0.01 
Residual 76 54.52 0.72 
TOTAL 134 156.00 
SE = 0.379 
3 x Consecutive periods of baseline challenge 
Challenge 2 5.08 2.54 2.07 NS 
Periods 2 7.97 3.99 7.76 p<0.05 
Subjects 4 5.04 1.26 5.4 p<0.001 
Challenge x Periods 4 18.58 2.65 12.96 p<0.01 
Challenge x Subjects 8 9.8 1.23 5.26 p<0.001 
Periods x Subjects 8 4.11 0.51 2.21 p<0.05 
Challenge x Period x 16 5.74 0.36 
1.54 NS 
Subjects 
Residual 90 20.93 
0.23 
TOTAL 134 77.24 
SE = 0.125 
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6.3.2. AN OVA Tables continued 
PGE2 & CaQsaicin onl~ 
Transformed Raw 
Log (During/Pre Challenge) 
Source of Variation df SSg MSg F 
Subjects 4 0.10 0.025 
Challenge 1 0.06 0.061 4.32 NS 
Time of Challenge 2 0.04 0.018 6.10 p<0.05 
Subject x Challenge 4 0.06 0.014 
Subject x Time 8 0.02 0.003 
Challenge x Time 2 0.00 0.002 <1 NS 
Subject x Challenge x Time 8 0.11 0.014 
Residual 60 0.34 0.006 
TOTAL 89 0.73 
SE = 0.034 
6.3.3 The Antitussive Efficacy of Nedocrom il Sodium 
Raw Data Tables 
Cough Frequencies (Total + Divided into 3 consecutive periods) 
ULTRASONIC CHALLENGE 
(+ cough during 5 m in post challenge) 
PG E2 Capsaicin 
Placebo Nedocromil Placebo Nedocromil 
1 15 (15,0,0) 9 15 (13,2,0) 11 16 (7,3,6) ° 31 (21,7,3) 4 
2 2 (2,0,0) 10 6 (3,0,3) 13 15 (8,5,2) ° 13 (5,4,4) 1 
3 15(11,2,2)20 16(5,10,1)15 7 (6,1,0) ° 8 (8,0,0) 2 
4 25(16,8,1)5 19 (14,2,3) 3 18 (9,6,3) ° 11 (9,2,0) ° 
5 18 (13,3,2) 23 15 (15,0,0) 24 7 (2,2,3) 1 13 (4,2,7) 5 
6 8 (8,0,0) 4 11 (11,0,0) 17 27 (16,4,7) 1 26 (21,5,0) 12 
7 19 (12,7,0) 12 11 (11,0,0) 4 23 (9,9,5) 4 32 (9,11,12) 6 
8 7 (7,0,0) 4 7 (7,0,0) 5 18 (9,5,4) ° 32(16,10,6)6 
JET CHALLENGE 
1 10 (4,2,4) 8 (3,3,2) 12 (5,3,4) 5 (0,3,2) 
2 12 (12,0,0) 13 (9,4,0) 8 (3,2,3) 7 (0,1,6) 
3 8 (5,0,3) 6 (3,3,0) 12(6,5,1) 5 (0,3,2) 
4 8 (2,2,4) 10 (5,1,4) 16 (6,5,5) 14 (5,4,5) 
5 24 (15,9,0) 18 (7,9,2) 20 (4,8,8) 24 (7,10,7) 
6 16 (11,5,0) 13 (9,1,3) 19 (6,7,6) 8 (0,5,3) 
7 10 (4,6,0) 11 (5,6,0) 19 (3,5,11) 10(1,4,5) 
8 9 (7,2,0) 6 (4,2,0) 16 (4,7,5) 14 (4,4,6) 
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6.3.3 Raw Data Tables continued 
Jet Challenge 
Raw 
PGEg 
Placebo Nedocromil 
1 2 3 4 1 2 3 4 
1 0.43 0.41 0.55 0.42 0.40 0.44 0.48 0.39 
2 0.27 0.30 0.37 0.28 0.28 0.27 0.39 0.28 
3 0.21 0.19 0.30 0.19 0.20 0.17 0.23 0.22 
4 0.39 0.29 0.29 0.31 0.31 0.24 0.34 0.28 
5 0.25 0.29 0.31 0.24 0.25 0.25 0.32 0.27 
6 0.40 0.30 0.50 0.27 0.36 0.38 0.43 0.34 
7 0.39 0.34 0.34 0.40 0.36 0.35 0.40 0.37 
8 0.20 0.20 0.26 0.24 0.26 0.25 0.27 0.24 
Capsaicin 
Placebo Nedocromil 
1 2 3 4 1 2 J 4 
1 0.40 0.37 0.47 0.43 0.42 0.41 0.42 0.49 
2 0.29 0.33 0.40 0.27 0.29 0.30 0.45 0.29 
3 0.19 0.20 0.25 0.18 0.18 0.21 0.25 0.19 
4 0.26 0.25 0.24 0.25 0.31 0.29 0.40 0.28 
5 0.29 0.33 0.25 0.28 0.27 0.23 0.36 0.23 
6 0.32 0.39 0.55 0.33 0.42 0.41 0.46 0.37 
7 0.41 0.34 0.32 0.36 0.47 0.30 0.44 0.35 
8 0.28 0.17 0.37 0.25 0.24 0.24 0.33 
0.23 
Times 1, 2, 3 & 4 correspond to Baseline, Pre-challenge, During challenge 
and Post-challenge respectively. 
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6.3.3 The Antitussive EfficaQ~ of Nedocromil Sodium 
ANOVA Tables 
Ultrasonic Qhalleng~ 
Transformed <?o.ugh Frequencies (1 min challenge + 5 min post challenge) 
Source of Vanatlon df SSg MSg F 
Between Subjects 7 6.97 0.996 <1 NS 
Between Periods 3 2.34 0.78 <1 NS 
Betwe~n Treatm~nts 
Placebo vs Nedocromil 1 1.95 1.95 1.59 NS 
PGE2 vs Capsaicin 1 3.56 3.56 2.91 NS 
Interaction 1 1.85 1.85 1.51 NS 
Residual 18 22.07 1.27 
Between Time of Challenge 1 33.48 33.48 119.7 p<0.01 
Time x Subjects 7 10.05 1.44 5.13 p<0.01 
Time x Periods 3 0.91 0.30 1.09 NS 
Time x Treatment 3 21.50 7.17 25.6 p<0.01 
Time x Placebo/Nedocromil 1 0.46 0.46 1.65 NS 
Time x PGE2/Capsaicin 1 20.88 20.88 74.6 p<0.01 
Time x Interaction 1 0.156 0.156 <1 NS 
Residual 18 5.04 0.28 
TOTAL 63 109.72 
Jet Challenge 
Transformed Qough Frequencies (1 min challenge + 5 min post challenge) 
Between Subjects 7 7.29 1.04 7.72 
Between Periods 3 1.17 0.39 2.89 
Between Treatments 3 2.62 0.88 6.48 p<0.01 
Placebo vs Nedocrom il 1 1.01 1.01 7.47 p<0.01 
PG E2 vs Capsaicin 1 0.94 0.94 6.94 p<0.01 
Interaction 1 0.68 0.68 
Residual 18 2.43 0.135 
Between times of challenge 2 2.83 1.42 4.04 p<0.05 
Times x Subjects 14 4.45 0.32 <1 NS 
Times x Periods 6 1.10 0.18 <1 NS 
Times x Treatments 6 12.08 2.01 5.75 p<0.01 
Times x Piacebo/Nedocromil2 1.13 0.57 1.62 NS 
Times x PGE2/Capsaicin 2 10.85 5.43 15.5 p<0.01 
Times x interaction 2 0.09 0.04 <1 NS 
Residual 36 12.6 0.35 
TOTAL 9~ 4.66 
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6.3.3 ANOVA Tables continued 
Log Transformed Raw 
Source of Variation df SSg MSg F 
Between Subjects 7 1.24 0.178 70.3 p<0.01 
Between Periods 3 0.007 0.002 <1 NS 
Between Treatments 3 0.0085 0.0028 1.12 NS 
Placebo vs Nedocrom il 1 0.0031 0.0031 1.22 NS 
PG E2 vs Capsaicin 1 0.0014 0.0014 <1 NS 
Interaction 1 0.004 0.004 1.59 NS 
Residual 18 0.0455 0.0025 
Between Times of Challenge 3 0.189 0.063 21.4 p<0.01 
Times x Subjects 21 0.092 0.004 1.48 NS 
Times x Periods 9 0.010 0.001 <1 NS 
Times x Treatments 9 0.007 0.001 <1 NS 
Times x Placebo/Nedocromil 3 0.002 0.001 <1 NS 
Times x PGE2/Capsaicin 3 0.001 0.0003 <1 NS 
Times x Interaction 3 0.004 0.001 <1 NS 
Residual 54 0.159 0.0029 
TOTAL 127 1.761 
SE = 0.0218 
APPENDIX 5 - Cough Associated With Viral Infection 
Raw Data And Anova Tables 
7.4 Effect of Bronchodilator Treatment on Cough Associated with URTI 
Placebo GrouQ 
Baseline - Day 1 Day 10 
FEV1 FVC PEF UNDW FEV1 FVC PEF UNDW 
2.90 3.90 300 34 3.10 3.80 390 37 
5.30 6.30 490 22 5.30 6.20 570 2 
3.00 3.50 390 22 3.00 3.50 420 7 
3.35 3.75 500 6 3.30 3.50 430 1 1 
4.30 5.60 610 0 4.20 5.80 655 0 
3.70 4.20 490 4 3.70 4.20 490 2 
3.70 4.20 490 8 3.80 4.20 510 9 
2.60 3.20 420 61 2.60 3.20 450 38 
4.40 5.00 550 29 4.50 5.10 550 17 
3.30 4.40 410 40 3.40 4.40 460 20 
5.50 6.70 680 37 5.80 7.00 610 8 
3.40 3.95 490 28 3.40 3.90 510 8 
3.90 4.70 510 27 3.90 4.60 500 21 
3.65 4.25 410 41 3.90 4.55 450 12 
4.00 4.15 510 19 3.90 4.15 490 26 
4.80 4.95 545 19 5.00 5.05 580 9 
3.70 4.60 640 8 3.80 4.60 690 14 
3.55 4.2 490 12 3.35 4.15 450 3 
3.70 4.40 415 4 3.80 4.35 440 6 
2.95 3.10 420 9 3.00 3.30 500 10 
3.70 3.95 510 46 3.75 3.90 465 6 
3.85 4.50 495 12 4.00 4.50 530 0 
3.65 4.40 420 10 3.75 4.35 470 31 
2.75 3.30 380 20 2.75 3.40 450 13 
3.75 4.80 500 24 3.85 5.00 540 5 
3.35 4.40 370 37 3.50 4.30 425 17 
3.95 4.35 470 14 3.60 4.20 510 20 
4.50 5.90 600 46 4.80 5.80 590 32 
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7.4 Raw Data Tables continued 
Oxitropium Group 
Baseline - Day 1 Day 10 
FEV1 FVC PEF UNDW FEV1 FVC PEF UNDW 
3.65 3.90 480 38 3.50 3.70 460 32 
2.50 2.80 385 26 2.80 3.10 400 24 
3.90 4.30 550 26 4.20 4.50 570 5 
3.60 4.45 390 41 3.65 4.40 440 34 
4.50 4.90 480 31 4.40 4.90 500 27 
3.20 3.70 420 33 3.60 3.90 430 42 
3.35 3.75 490 0 3.35 3.85 510 0 
3.55 4.00 380 20 3.85 4.10 430 0 
3.85 4.20 550 17 3.70 4.00 500 2 
6.20 7.30 550 21 6.35 7.50 560 1 1 
3.15 4.00 400 21 3.25 4.00 440 2 
5.10 6.10 600 21 5.15 6.20 720 28 
4.20 5.70 580 31 3.90 5.40 560 25 
3.65 3.90 380 31 3.70 4.15 480 29 
3.20 4.90 440 25 2.45 4.20 430 5 
3.05 3.40 360 18 3.05 3.20 410 10 
5.05 5.70 590 3 5.35 5.80 610 2 
4.00 4.40 530 16 3.90 4.55 540 30 
3.00 3.40 410 22 3.40 3.75 420 24 
3.30 3.50 480 58 3.35 3.60 470 24 
3.60 4.20 430 9 3.45 4.10 440 14 
3.50 4.00 400 40 3.60 4.30 490 0 
1.50 1.80 305 16 1.50 1.85 340 7 
3.75 4.35 485 2 3.50 4.10 470 0 
4.65 5.90 560 4 4.60 5.90 570 5 
3.25 3.45 340 35 3.30 3.40 410 15 
7.4 ANOVA Tables 
UNDW-Induced CouQh 
Transformed CouQh Freguencies 
Placebo Group 
SQurce of Variation 
Between Subjects 
Between Visits (Day1 /10) 
Residual 
TOTAL 
SE = 0.18 
95% CL = 0.375 
OxitrQpium Group 
Source of Variation 
Between Subjects 
Between Visits 
Residual 
TOTAL 
SE = 0.21 
95% CL = 0.437 
df 
30 
1 
30 
61 
df 
27 
1 
27 
55 
SSg MSg 
104.44 3.48 
14.85 14.85 
31.57 1.05 
150.86 
SSg MSg 
120.44 4.46 
18.21 18.21 
34.32 1.27 
172.96 
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F 
3.308 p<0.001 
14.12 p<0.001 
F 
3.51 p<0.OO1 
14.32 p<O.001 
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7.4 ANOVA Tables continued 
Diary PEFR (11m in) 
Time EffeQt 
SourQe Qf Variation df SSg MSg F 
Model 56 1006741 17978 53.9 p<0.0001 
Error 102 34048 333.8 
Total 158 1040788 
Between Treatment 1 2488.9 2488.9 7.46 p<0.01 
Between Subjects 51 998185 19572 58.63 p<0.001 
Between Times 2 5963.2 2981.6 8.93 p<0.001 
Treatment x Time 2 104.0 52.02 0.16 NS 
Day x Time Effects 
Source Qf Variation df SSg MSg F 
Model 56 3899.5 69.6 8.34 p<0.001 
Error 102 851.6 8.35 
Total 158 4751.3 
Between Treatment 1 8.98 8.98 1.08 NS 
Between Subjects 51 3865 75.8 9.08 p<0.0001 
Day x Time 2 23.6 11.8 1.41 NS 
Treat xDayxTime 2 1.92 0.96 0.12 NS 
7.4 ANOVA Tables continued 
ANOVA Lung Function. Day 10 - Day1 
Source of Variation df SSg 
FEV1 
Treatment 
Error 
Total 
FVC 
Treatment 
Error 
Total 
PEFR 
Treatment 
Error 
Total 
1 
52 
53 
1 
52 
53 
0.01 
2.07 
2.08 
0.00 
1.80 
1.80 
1 70.10 
52 87487.8 
53 87557.9 
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MSg F 
0.014 0.35 NS 
0.040 
0.000 0.01 NS 
0.035 
70.096 0.04 NS 
1682.5 
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